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TUMOUR BIOLOGY AND PATHOLOGY
1O
DETECTION OF ALK REARRANGED NON-
SMALL CELL LUNG CARCINOMAS BY 
IMMUNOHISTOCHEMISTRY: COMPARISON OF 
DIFFERENT ANTIBODIES (D5F3 AND 5A4), DETECTION 
SYSTEMS AND AUTOMATED IMMUNOSTAINERS
S. Savic1, J. Diebold2, A. Zimmermann3, W. Jochum4, B. Baschiera1, R. 
Epper1, S. Grieshaber1, L. Tornillo1, K. Kerr5, L. Bubendorf1 1Pathology, 
University Hospital Basel, Basel, SWITZERLAND, 2Institute of Pathology, 
Cantonal Hospital Lucerne, Luzern, SWITZERLAND, 3Institute of Surgical 
Pathology, University Hospital Zurich, Zürich, SWITZERLAND, 4Institute 
of Pathology, Cantonal Hospital St.Gallen, St. Gallen, SWITZERLAND, 
5Department of Pathology, Aberdeen Royal Infirmary Anchor Unit, Aberdeen, 
UNITED KINGDOM
Aim: Immunohistochemistry (IHC) has become a promising method for pre-
screening predictive ALK-rearrangements in non-small cell lung carcinomas 
(NSCLC). Various ALK antibodies, enhanced detection systems and auto-
mated immunostainers are available. We therefore aimed to compare the per-
formance of: 1. the D5F3 (Cell Signaling, Ventana) and the 5A4 (Novocastra, 
Leica) monoclonal antibodies (mAb) and 2. the 5A4 mAb on two different 
automated immunostainers (BenchMark, Ventana and BOND-MAX, Leica).
Methods: Sixty-five formalin-fixed and paraffin-embedded non-squamous 
NSCLC with available ALK FISH results were retrospectively analysed. The 
specimens were enriched for ALK FISH-positive NSCLC (24/65, 36.9%). 
IHC was performed with the OptiView Amplification Kit (Ventana) on 
BenchMark using the D5F3 and the 5A4 mAb, respectively. Additionally 
IHC with the 5A4 mAb and the Bond Polymer Refine Detection Kit (Leica) 
on Bond-MAX was performed. For D5F3 any strong IHC-staining (3+) was 
regarded as a positive result, as suggested by the manufacturer. For 5A4 any 
IHC-staining (1+, 2+, 3+) was regarded as a positive result. The IHC results 
of all three protocols were compared to the FISH results. In case of a discrep-
ancy the IHC-stained slide and the FISH signals were reviewed.
Results: Fifty-seven out of 65 NSCLC (87.7%) were evaluable and all 
showed congruent results for all three IHC protocols used. Twenty-three out 
of 24 ALK FISH positive NSCLC (95.8%) were ALK IHC-positive. Only 
one ALK FISH positive NSCLC (3.2%) was false negative by IHC. The sen-
sitivity, specificity and positive and negative predictive values for ALK IHC 
compared to ALK FISH were 96%, 100%, 100% and 97%, respectively, irre-
spective of antibody, detection system and immunostainer used.
Conclusions: D5F3 and 5A4 are equally well suited and BenchMark and 
BNOND-MAX immunostainers can both be used for prescreening ALK-
rearrangements in NSCLC.
Disclosure: All authors have declared no conflicts of interest.
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SIGNIFICANCE OF LEPIDIC GROWTH COMPONENT IN 
THE DISCRIMINATION OF MULTIPLE PRIMARY LUNG 
CANCERS FROM INTRAPULMONARY METASTASES
D. Lin1, W. Sun1, Y. Liu2, X. Liu2, L. Shan2, X. Yang2 1Department of Pathology, 
Cancer Institute and Hospital of the Chinese Academy of Medical Sciences, 
Beijing, CHINA, 2Department of Etiology and Carcinogensis, Peking Union 
Medical College, Cancer Institute and Hospital of the Chinese Academy of 
Medical Sciences, Beijing, CHINA
Aim: The distinction of intrapulmonary metastases from multiple primaru 
tumors is of great clinical importance as it influences staging, prognosis 
and therapeutic strategy. Although Comprehensive Assessment (CHA) was 
recommended by IASLC/ATS/ERS to differentiate multiple lung primary 
non-small cell carcinoma from metastases, the limitaitons of CHA have been 
addressed. Lung adeocarcinoma in situ is characteried by noninasive lep-
idic growth. Whether this histological characterized by noninvasive lepidic 
growth. Whether this histological characteristic could be served for assessing 
primary lung cancer has not been well determined. In this study, we evalu-
ated the applicaion value of CHA and lepidic growth component (LGC) in 
ditinguishing multiple primary lung cancers from intrapulmonary metastass.
Methods: We retropectively analyzed a cohort of 31 patients with 68 multiple 
lung tumors. All of the patients have follow up data. The histological evalu-
ation was performed according to 2011 IASLC/ATS/ERS Classification of 
Lung Adenocarcinoma. The percentage of each tumor subtype in each case 
was recorded. The inrapulmonary metastases and multiple primary tumors 
were differentiated based on CHA and LGC (if applicable).
Results: According to CHA alone, there were 13 and 18 cases diagnosd as 
multiple primary tumors and intrapulmonary metastases, respecively. Disease-
free interval (DFI) of the 13 patients with multiple tumors was ranged from 11 
to 110 months and DFI of the 18 patients with intrapulmonary metastases was 
range from 1 to 93 months. There was no statistically difference between these 
two types of patients (p=0.240). According to CHA with inclusion of LGC, 20 
and 11 cases were diagnosed as multiple primary tumors and intraplumonary 
metastases, respectvely. DFI of the 20 and 11 cases were ranged from 11 to 
110 months and from 1 to 34 months, respectvely. Statistical signifcance was 
detected (P=0.003). These results suggested that CHA combining with LGC 
might have assesssment advantage to distinguish multiple primary tumors 
from intrapulmonary metasases compared to use CHA alone.
Conclusions: The apperence of adenocarcima with LGC might indicate lung 
primaries. Combining with CHA, LGC could potentially improve diagnosis 
to differentiate multiple primary tumors and intrapulmonary metastases.
Disclosure: All authors have declared no conflicts of interest.
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ALK AND MET ARE SYNERGISTIC CO-ACTIVATORS 
OF DOWNSTREAM SIGNALS BY AMPLIFICATION 
IN PULMONARY SARCOMATOID CARCINOMA: 
A POTENTIAL FOR TARGETED THERAPY?
G. Pelosi1, P. Gasparini2, G. Sozzi3, V. Ciravolo3, S. Pupa3, E. Tamborini1, P. 
Scanagatta4, F. De Braud5, U. Pastorino4 1Department of Pathology, Fondazione 
IRCCS Istituto Tumori Milano, Milano, ITALY, 2Department of Pathology 
and Experimental Oncology, Fondazione IRCCS Istituto tumori Milano, 
Milano, ITALY, 3Department of Experimental Oncology, Fondazione IRCCS 
Istituto tumori Milano, Milano, ITALY, 4Department of Thoracic Surgery, 
Fondazione IRCCS Istituto tumori Milano, Milano, ITALY, 5Department 
of Medical Oncology, Fondazione IRCCS Istituto tumori Milano, Milano, 
ITALY
Aim: Genetic alterations suitable for targeted therapy are poorly known issues 
in pulmonary sarcomatoid carcinoma (PSC), an uncommon and life-threaten-
ing family of non-small cell lung cancer (NSCLC). We here investigate the 
role of ALK and MET in this subtype of aggressive NSCLC.
Methods: Eighty-six cases of PSC, all formalin-fixed and paraffin-embedded, 
were assessed for ALK and MET gene status by FISH and relevant protein 
expression by immunohistochemistry (IHC) also taking advantage of phos-
phorylated antibodies for MET. Moreover, ALK and MET mRNA evaluation 
by real-time PCR (qPCR) and biochemistry assay by Western Blotting (WB) 
for downstream activation pathways involving p-MAPK, p-AKT, p-SRC and 
p-FAK were also carried out.
Results: ALK amplification was found in 15/86 (17%) and MET amplifica-
tion in 21/86 (24%) PSC, with ALK-amplified tumors also showing MET 
amplification. A few PSC, however, showed MET amplification without 
any ALK gene alteration. Fifty metastatic lung adenocarcinomas used as 
controls showed ALK or MET amplification in 1 and 1 cases, respectively 
(p=0.1). ALK protein expression was always lacking in PSC, while p-MET 
ABSTRACTS
S8 Copyright © 2014 by the European Lung Cancer Conference organisers, ESMO, and IASLC.
Abstracts Journal of Thoracic Oncology ®  •  Volume 9, Number 4, Supplement 1, April 2014
was limited to the relevant amplified tumors. Increased levels of ALK and 
MET mRNA were instead detected in tumors, especially amplified cases. 
WB assays showed complete activation of downstream signal pathways up to 
p-SRC and p-FAK recruitment in ALK/MET co-amplified tumors, whereas 
isolated MET amplification or coexisting increased gene copy gain of ALK/
MET was limited to activate p-MET, p-MAPK and p-AKT.
Conclusions: ALK and MET genes acted as synergistic, non-random co-acti-
vators of downstream signal when co-amplified in a subset of PSC patients, 
so indicating an oncogene addiction mechanism. These alterations could have 
a potential for targeted therapy by specific inhibitors.
Disclosure: All authors have declared no conflicts of interest.
4PD
THE PROGNOSTIC EFFECT OF IASLC/
ATS/ERS CLASSIFICATION OF LUNG 
ADENOCARCINOMA ON POSTRECURRENCE 
SURVIVAL IN RESECTED ADENOCARCINOMA
J. Hung1, T. Chou2, Y. Wu1, W. Hsu1 1Department of Surgery, Taipei Veterans 
General Hospital, Taipei, TAIWAN, 2Department of Pathology, Taipei 
Veterans General Hospital, Taipei, TAIWAN
Aim: Factors predicting post-recurrence survival (PRS) in resected lung adeno-
carcinoma after recurrence have not been reported. This study aimed to inves-
tigate the prognostic factors of PRS, including the new classification of lung 
adenocarcinoma proposed by the International Association for the Study of 
Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European 
Respiratory Society (ERS), in resected lung adenocarcinoma after recurrence.
Methods: The clinicopathological characteristics of 140 patients with recur-
rence after complete resection of lung adenocarcinoma at Taipei Veterans 
General Hospital were retrospectively reviewed. The prognostic factors of 
PRS were analyzed.
Results: The pattern of recurrence included local only in 22 (17.1%), distant 
only in 40 (31.0%), and both local and distant in 84 (51.9%) of patients. The 
2- and 4-year PRS were 67.2% and 39.1%, respectively. The most common 
organ sites of metastasis were the contralateral lung (40.7%), followed by the 
brain (37.1%) and bone (30.7%). Univariate analysis showed that N2 status 
(vs. N0 and N1) (P = 0.007), stage III (vs. stage I and II) (P = 0.043), micro-
papillary/solid predominant pattern group (P = 0.012), liver metastasis (P = 
0.033), and no treatment for recurrence (P < 0.001) were significant predic-
tors of worse PRS. Multivariate analysis revealed that N2 status (P = 0.036), 
micropapillary/solid predominant pattern group (P = 0.018), and no treatment 
for recurrence (P < 0.001) were still significant predictors of worse PRS.
Conclusions: N2 status, micropapillary/solid predominant pattern group, and 
no treatment for recurrence predict worse PRS in patients with resected lung 
adenocarcinoma. The new classification of lung adenocarcinoma had signifi-
cant impact on PRS.
Disclosure: All authors have declared no conflicts of interest.
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ESTROGEN RECEPTOR BETA OVER EXPRESSION 
IN WOMEN WITH LUNG ADENOCARCINOMA 
IS ASSOCIATED WITH BETTER SURVIVAL
N.J. Lalic Invasive Diagnostic Procedures, Institute of Oncology Vojvodina, 
Sremska Kamenica, SERBIA
Aim: Adenocarcinoma of lung is becoming the most common histologic type 
of lung cancer in both sexes. It is more frequent in females than in males and 
developes more frequently than other histologic types in individuals who have 
never smoked. This evidence suggests that other etilogic factors of lung can-
cer need to be ivestigated, such as sex hormones. Recent studies have shown 
that estrogens promote the growth of lung cancer cells and may potentially be 
responsible for incresed susceptibility to lung cancer in woman. The aim of 
this study was to elucidate the correlation between expression of beta estrogen 
receptor and clinicopathologic factors and prognosis in adenocarcinoma of 
the lung.
Methods: This study evaluated paraffin embedded, histological material wich 
were collected from 200 patients (100 men and 100 women). Histological 
materials collected as specimens wich were taken during bronchoscpy proce-
dures or from operated adenocarcinoma specimens in the period 2006–2008. 
Estrogen receptor beta (ERβ) was immunohistochemically analised. Kaplan-
Meier survival curves were generated to evaluate the significance of ERβ 
expression for the prognosis.
Results: ERβ positivity was demonstrated in 78 (39,0%) of the tumour speci-
mens. There was no statisticaly significant correlation between ERβ expres-
sion and age, gender, stage, smoking status, comorbidity, fertility among 
women, therapeutic aproaches. In multivariate analyses, females were more 
likely to have ERβ-positive tumors but not statistically significant. Hoewer 
females with ERβ-positive tumors had significant reduction in mortality 
compared with men and ERβ-negative tumors women (Breslow: p= 0,037; 
Mantel-Cox: p= 0,112). Females with ERβ-positive tumors had statistically 
significant longer disease free period (n= 42) 23,8 ± 6,8% during two years 
period and 7,1 ± 4,0% during five years period (Mantel-Cox, p= 0,049).
Conclusions: The presence of ERβ in a tumor seems to be a positive prognos-
tic factor for women with lung adenocarcinoma. The finding confirms another 
recent study and suggest that the relations between estrogens and lung cancer 
be investigeted futher especially with evaluation of EGFR mutation because 
cross-talk mechanism between an EGFR mutation and expression or function 
of ERβ.
Disclosure: All authors have declared no conflicts of interest.
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EXPLORING TUMOR-STROMA INTERACTION 
IN LUNG ADENOCARCINOMAS: A GENOME 
WIDE ANALYSIS OF THE RESPONSE TO BMP 
SIGNALING IN HUMAN LUNG FIBROBLASTS
M. Buess1, M. Rajski2 1Medical Oncology, St. Claraspital, Basel, 
SWITZERLAND, 2Institute of Physiology, University of Zürich, Zürich, 
SWITZERLAND
Aim: The BMP signaling system plays a key role in development, morpho-
genesis and cancer. As observed for development, heterotypic cellular inter-
actions also play an essential role in carcinogenesis. The aim of this study was 
to characterize the response of lung stromal fibroblasts to BMPs and their 
antagonists and investigate its potential role in human lung adenocarcinomas.
Methods: We used an ex vivo culture model and measured changes in gene 
expression in human lung fibroblasts after stimulation with BMP2, BMP4, 
or BMP7, as well as their antagonists, gremlin and noggin, using HEEBO 
microarrays. The in vitro data were correlated with in vivo observations by 
comparing the results with published expression datasets of human lung ade-
nocarcinoma biopsies.
Results: In addition to differential expression of several genes that play direct 
roles in the BMP signaling pathway, we observed a fundamental reprogram-
ming of gene expression patterns typical for carcinoma-associated fibroblasts 
and deregulation of genes involved in several other processes such as develop-
ment and angiogenesis. We have systematically analyzed the cellular response 
to BMP2, BMP4 and BMP7, as well as their antagonists, gremlin and noggin, 
to define common and specific gene expression patterns. A BMP2 induced 
gene expression signature was defined, which is specific for the response of 
the stromal fibroblasts. The gene expression data from lung adenocarcinoma 
biopsy specimens were analyzed to determine the prognostic significance of 
the “Fibroblast specific BMP2 induced gene list”. The expression of the genes 
in the “Fibroblast specific BMP2 induced gene list” provided a basis for seg-
regating the patients of different published gene expression datasets. In two 
small datasets (Garber et al. and Lee et al.) there was a strong trend for a 
worse prognosis of patients with adenocarcinomas of all stages over-express-
ing the “Fibroblast speciic BMP2 induced gene list”. In a larger dataset with 
stage I adenocarcinomas (Bhattacharjee et al.) we observed a significantly 
worse recurrence-free (p=0.002) and overall survival (p=0.0002).
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Conclusions: The effects of BMPs and their antagonists are very heteroge-
neous depending on the target cell type. The expression patterns of genes 
induced by BMP2 in primary lung fibroblasts may predict outcomes of 
patients with lung adenocarcinomas.
Disclosure: All authors have declared no conflicts of interest.
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PLASMA CELL-FREE DNA CONCENTRATION 
AND INTEGRITY ANALYSIS IN PATIENTS WITH 
CHEST RADIOLOGICAL FINDINGS: NSCLC 
VERSUS NON-MALIGNANT PATHOLOGIES
A. Szpechcinski1, W. Kupis2, R. Langfort3, J. Zaleska4, K. Maszkowska-
Kopij5, R. Struniawski1, M. Skronski1, T. Orlowski2, K. Roszkowski-Sliz4, J. 
Chorostowska-Wynimko1 1Department of Genetics and Clinical Immunology, 
National Institute of Tuberculosis and Lung Diseases, Warsaw, POLAND, 
2Department of Thoracic Surgery, National Institute of Tuberculosis and 
Lung Diseases, Warsaw, POLAND, 3Department of Pathomorphology, 
National Institute of Tuberculosis and Lung Diseases, Warsaw, POLAND, 
4III Department of Lung Diseases, National Institute of Tuberculosis and 
Lung Diseases, Warsaw, POLAND, 5Outpatient Clinic, National Institute of 
Tuberculosis and Lung Diseases, Warsaw, POLAND
Aim: The quantification of cell-free DNA in plasma (cfDNA) has been 
repeatedly shown to accurately differentiate NSCLC patients from healthy 
individuals and indicate the increased cancer risk. However, to be of clini-
cal value, such quantitative assay should also discriminate between lung 
cancer and non-malignant pathologies presenting similar radiological image. 
Recently, we demonstrated that increased cfDNA levels in NSCLC patients 
result from complicated tumor-host interactions, but not from chronic respi-
ratory inflammation itself. In present study we determine cfDNA levels in 
resectable NSCLC versus non-malignant lung tumors to evaluate the factual 
clinical utility of cfDNA quantification for early NSCLC detection.
Methods: We measured cfDNA levels and integrity index (DII) using real-
time PCR in 66 NSCLC patients (ADC, SQC, NOS, stage I-IIIA), 28 patients 
with benign lung nodules and tumors (hamartoma, granuloma, tuberculoma 
and other) and 40 healthy controls.
Results: Mean cfDNA level of 21,5 ng/ml in NSCLC group was significantly 
higher than 4,5 ng/ml in healthy controls (p=0.000). There were no significant 
associations between cfDNA levels and TNM stages or histological types in 
NSCLC. The cfDNA levels in NSCLC did not differ significantly from val-
ues observed in patients with non-malignant tumors (23,4 ng/ml; p=0,45). 
Similarly, the mean DII in NSCLC (4,0) significantly differed from control val-
ues (1.0; p=0.000), but not from DII observed in non-malignant group (4,0).
Conclusions: Our data suggest that while massive cell death is common for 
benign and malignant lung tumors, more complex mechanisms regulate mas-
sive cfDNA release into the blood circulation of NSCLC patients. The presence 
of a solitary pulmonary nodule or lung tumor, irrespectively to its malignancy 
status, significantly increased the mean cfDNA integrity index with respect to 
healthy controls, thus reflecting the intensified cell death processes.
Disclosure: All authors have declared no conflicts of interest.
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SYSTEMATIC DETERMINATION OF EGFR MUTATION 
(M) AND IMMUNOHISTOCHEMISTRY (IHC) OF ALK 
TRANSLOCATION (T) STATUS IN PATIENTS (P) WITH 
NEWLY NON SMALL CELL LUNG CANCER (NSCLC)
S. Ponce Aix1, J. Zugazagoitia2, M. Blazquez Arroyo1, G. Ruiz Ares1, J.A. 
Nuñez Sobrino1, L.C. Iglesias Docampo1, R.A. Manneh Kopp1, R.M. García 
Martín3, J.L. Rodriguez Peralto3, A.B. Enguita Valls3 1Servicio de Oncologia 
Medica, University Hospital 12 de Octubre Medical oncology, Madrid, 
SPAIN, 2Medical Oncology, Hospital 12 Octubre. Universidad Complutense, 
Madrid, SPAIN, 3Servicio Anatomia Patológica, University Hospital 12 de 
Octubre Medical oncology, Madrid, SPAIN
Aim: Detection of EGFR m. p. is done in a routine way. Also detection of 
ALK t. has become an important issue for therapeutic decision making in 
NSCLC. Which is the best technic to broad test of ALK t. remain unclear. We 
implemented a systematic determination of EGFR m. and ALK t. status to 
asses feasibility and accuracy in a clinical setting.
Methods: We have selected all p. with newly diagnosed NSCLC non squa-
mous or squamous never smokers between May 2013 to November 2013. The 
objective was to evaluate the accuracy of EGFR m. testing, using TheraScreen 
or Cobas EGFR mutation test, and ALK t. testing, using IHC Ventana (D5F3) 
and positive patients checked by FISH (Abbot Vysis Break Apart)
Results: One hundred and one p. were analyzed. Median age was 64.6. 27 
(26.73%) women and 74 (73.26%) men; 100 (99%) caucasians and 1 (1%) 
asiatic; 100 (99%) non squamous (including adenocarcinoma, large cell carci-
noma and others) and 1 (1%) squamous; Current smokers 38 (37.62%), former 
smokers 51 (50.49%), never smokers 6 (5.94%) and unknown 6 (5.94%). The 
tumor sample was paraffin embedded (91.1%) and cytology (8.9%). We per-
formed successfully both determination in 97.02% of the samples, and only 
in 3 p. ALK was not done (2.98%). The median time to results was 5.8 days. 
Only 8 patients with EGFR m. were found (7.92%): del 19 (62.5%), 21 L858R 
(25%) and exon 18 (12.5%). IHC for ALK t. positive for 9 patients (8.9%) 
and confirmation by FISH in 8 p. (88.8%). T. rate in women was 11.11% and 
men 88.88%. Median age was 59.7 (48- 67); 7 adenocarcinoma (77.77%), 1 
squamous (11.11%) and 1 neuroendocrine (11.11%). The only discordance 
between the results of IHC and FISH was in a p. with neuroendocrine subtype.
Conclusions: Systematic determination of EGFR m. and ALK t. in a public 
center is feasible offering an acceptable time to result and with good perfor-
mance. Rate of EGFR m. was minor than reported previously in our center 
due to the small number of patients tested in this series. In other hand ALK 
t. is higher than reported in literature may be due to the same reason. ALK t. 
testing can be done by IHC as screening method in all non squamous NSCLC 
patients and in those squamous never smokers. Special consideration must be 
made in p. with NSCLC with neuroendocrine differentiation.
Disclosure: All authors have declared no conflicts of interest.
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DOWN-REGULATION OF ERCC1 BY 
EGFR-TKI IMPROVES PLATINUM-BASED 
CHEMOTHERAPY EFFICACY FOR NON-
SMALL CELL LUNG CANCER (NSCLC)
H.T. Cheong1, C.W.C. Hui1, F. Xu2, T.S.K. Mok1, C.H. Wong1 1Clinical 
Oncology, State Key Laboratory In Oncology In South China, The Chinese 
University of Hong Kong, Hong Kong, CHINA, 2Medical Oncology, Sun-Yat 
Sen University Cancer Center, Guangzhou, CHINA
Aim: Platinum-based chemotherapy (Chemo) is the standard first line treat-
ment for patients with EGFR wild type while EGFR TKI is the standard for 
patients with the mutation. FASTACT-2 (Wu et al Lancet Oncology 2013) 
compared intercalated Chemo and EGFR-TKI with Chemo, and subgroup 
biomarker studies showed that patients with EGFR wild type and positive 
ERCC1 attained longer progression free survival and overall survival. We 
postulate that EGFR TKI down-regulates ERCC1 expression in wild type 
EGFR NSCLC cells, thus enhances the chemotherapy efficacy.
Methods: In vitro and in vivo studies were designed to study the impact of 
EGFR TKI on ERCC1 expression. H358 and H1993 cells were treated with 
EGFR-TKI for 72 hours and transient siRNA transfection was performed 
for ERCC1 suppression. The cisplatin sensitivity of the transfected cells was 
tested by cell viability assay. H358 and H1993 xenograft tumor model were 
established and animals were treated with 2 weeks of oral erlotinib. ERCC1 
expression was studied by western blot and IHC by Mab clone 8F1.
Results: ERCC1 expression is not directly related to EGFR-TKI sensitivity. 
However, ERCC1 expression progressively reduced over 72-hours of EGFR-
TKI exposure. ERCC1 knock-down increased cells’ sensitivity towards cispla-
tin, the IC
50s
 for H358 and H1993 were reduced from 11.94μM to 0.31μM and 
14.67μM to 0.16μM respectively. On the other hand, TKI showed no effect on 
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tumor volume of these EGFR wild type xenografts but displayed a significant 
reduction in ERCC1 level by IHC staining after treatment with TKI.
Conclusions: These data suggested that EGFR-TKI may reduce ERCC1 
expression and potentially enhance sensitivity to platinum-based 
chemotherapy.
Disclosure: All authors have declared no conflicts of interest.
11P
GENE EXPRESSION OF EPIDERMAL GROWTH FACTOR 
RECEPTOR, MYC-INDUCED NUCLEAR ANTIGEN, 
53KDA AND MECHANISTIC TARGET OF RAPAMYCIN 
IN PULMONARY NEUROENDOCRINE TUMORS
D.M. Marinova1, Y. Slavova2, G. Stancheva3, D. Kachakova3, A. Mitkova3, R. 
Kaneva3 1Pneumology, University Hospital for Pulmonary Diseases, Sofia, 
BULGARIA, 2Pathology, University Hospital for Pulmonary Diseases, Sofia, 
BULGARIA, 3Medical Chemistry and Biochemistry, Medical University - 
Sofia, Sofia, BULGARIA
Aim: To study the gene expression of Epidermal growth factor receptor 
(EGFR), MYC-induced nuclear antigen, 53kDa (MINA53) and Mechanistic 
target of rapamycin (MTOR) in pulmonary neuroendocrine tumors (pNET), 
and their correlations and prognostic significance.
Methods: Surgically resected specimens from 42 patients with pNET were 
studied: 23 carcinoid tumors (CT), 13 small cell lung carcinomas (SCLC), 
6 large cell neuroendocrine carcinomas (LCNEC). The histological subtype, 
pTNM stage, survival and gene expression of EGFR, MINA53 and MTOR 
were evaluated.
Results: Overexpression of EGFR was found in 17% (3 CT, 13%; 4 SCLC/
LCNEC, 21%), of MINA53 – in 38% (5 CT, 22%; 11 SCLC/LCNEC, 58%) 
and of MTOR – in 69% (17 CT, 74%; 12 SCLC/LCNEC, 63%). Decreased 
expression of EGFR was found in 38% (5 CT, 22%; 11 SCLC/LCNEC, 
58%) and of MTOR – in one CT (4.3%). CT were more often with normal 
expression of EGFR (65%), while SCLC/LCNEC were more often with 
decreased expression (58%) (p=0.015), confirmed by regression analysis 
(Odds ratio 8.25; p=0.007). There were no difference in the expression of 
MINA53 (p=1.000) and MTOR (p=0.400) between CT and SCLC/LCNEC. 
The median survival time was significantly longer in cases with normal EGFR 
and MINA53 expression compared to cases with overexpression (p=0.003; 
p=0.042 respectively). Patients with normal MTOR expression survive insig-
nificantly longer (p=0.50). The Cox regression analysis showed survival 
advantage for cases with normal EGFR expression compared to those with 
overexpression (Hazard ratio [HR] 13.31; p=0.021) and a prognostic potential 
for MINA53 (HR 4.5; p=0.063). No prognostic significance of MTOR expres-
sion was found (p=0.505). Positive correlations between EGFR and MINA53 
(r=0.45, p=0.003), EGFR and MTOR (r=0.48, p=0.001) and MINA53 and 
MTOR (r=0.46, p=0.002) were observed.
Conclusions: EGFR and MINA53 overexpressions are negative prognostic 
factors in pNETs. EGFR, MTOR and MINA53 are potential targets for com-
bined therapy – there are positive correlations between their expression levels. 
As EGFR and MTOR are often overexpressed in pNETs and are therapeutic 
targets in lung cancer so in future the patients with tumors that overexpress 
them can be considered for treatment with these drugs.
Disclosure: All authors have declared no conflicts of interest.
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EGFR GENE MUTATION IN ADVANCED NON-
SMALL CELL LUNG CANCER - A CASE SERIES
T. Mehmood Radiation Oncology, Shaukat Khanum Memorial Cancer 
Hospital and Reserch Centre (SKM), Lahore, PAKISTAN
Aim: Molecular targeted therapy based on TKIs, directed at the Epidural 
growth factor receptor (EGFR) is one of the recent options for the manage-
ment of advanced Non-Small Cell Lung Cancer (NSCLCs). EGFR gene 
mutations, exon 19 deletions (LREA deletions) and exon 21 (L858R) are 
most common and good predictions of response to EGFR-TKI treatment. 
EGFR gene mutations are found in approximately 10% of Caucasian patients 
and up to 50% of Asian populations. Recent studies have endorsed these inci-
dences in European and Asian populations. The frequency of EGFR muta-
tion is higher in non-smokers and in women. To objective of this study was 
to determine the frequency of EGFR gene mutations in non–small-cell lung 
cancer patient presenting at our institute.
Methods: Between September 2011 and September 2013, we sent EGFR 
mutation testing for 39 patients with proven histology of TTF-1 positive ade-
nocarcinoma lung. EGFR gene mutations in exons 18, 19, 20 and 21 were 
carried out by National University Hospital Singapore and and at Shaukat 
Khanum Memorial Cancer Hospital Lahore, Pakistan.
Results: 72% of the patients were males and 28% were females. 49% were 
smokers, 41% were non-smokers and this information was missing in 10% of 
the patients. 18.5% of the patients were found to have EGFR gene mutation 
positive; 28.5% on exon 18, 28.5% on exon 19, 14.5% on exon 20 and 28.5% 
on exon 21. Among patients having EGFR gene mutation positive, 57% were 
smokers while 43% were non-smokers.
Conclusions: The frequency of EGFR mutation in our institution was 18.5% 
and all these patients were male, with almost half of the patients being smok-
ers. This trend is not in accordance with published literature. This merits simi-
lar study with a larger number of patients to find out the real trend of EGFR 
gene mutation in our population.
Disclosure: All authors have declared no conflicts of interest.
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LEPDIC AND MICROPAPILLARY GROWTH PATTERN 
AND EXPRESSION OF NAPSIN A CAN STRATIFY 
PATIENTS OF STAGE I LUNG ADENOCARCINOMA 
INTO DIFFERENT PROGNOSTIC SUBGROUP
D. Lin1, Y. Xin2 1Department of Pathology, Cancer Institute and Hospital of 
the Chinese Academy of Medical Sciences, Beijing, CHINA, 2Department of 
Pathology, Cancer Institute, Beijing, CHINA
Aim: Aim of this study was to investigate contribution of histologic catego-
ries and relative growth pattern proposed by IASLC/ATS/ERS classification 
to patients’ clinical outcome in stage I lung adenocarcinoma, and whether 
expression of thyroid transcription factor-1 (TTF1) and napsin A can further 
stratify patients of specific histologic subgroup with respect to prognosis.
Methods: A total of 211 cases were available for histologic analysis. 
Histological subtypes and percentage of lepidic and micropapillary growth 
patterns according to the IASLC/ATS/ERS classiﬁcation were estimated 
with slight modifications. Tissue microarrays were constructed and expres-
sion levels of TTF1 and napsin A were evaluated by immunohistochemistry. 
Kaplan-Meier curves were used to calculate survival rate for each separate his-
topathologic features and immunohistochemistry variant. Univariate and mul-
tivariate analyses were undertaken to control for validated prognostic factors.
Results: In univariate analyses, female sex (p=0.009), lepidic growth 
pattern (P=0.011) and lack of micropapillary pattern (P=0.048) were 
favorable predictor significantly associated with disease-free survival 
(DFS). Lack of mitosis (P=0.044) and napsin A expression (P=0.031) 
were favorable predictors for overall survival (OS). Tumors with a maxi-
mum diameter ≤2cm had both longer DFS (P=0.008) and OS (P=0.020). 
Negative TTF1 expression indicated increased risk of death, but failure in 
statistical significance (P=0.215). After multivariate analysis, histologic 
subtype, tumor size and gender were identiﬁed as independent predictor 
for DFS (RR: 0.343, 3.697, 0.494; P=0.006, 0.029, 0.019), no feature was 
found as an independent predictor for overall survival (P>0.05).
Conclusions: In early-stage lung adenocarcinoma, lepidic growth pattern, 
female sex and tumor size ≤2cm were independent favorable predictors for 
tumor recurrence. Tumors with any percentage of lepidic growth pattern will 
have a better prognosis than absence.
Disclosure: All authors have declared no conflicts of interest.
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CASE-CONTROL STUDY: SMOKING HISTORY 
AFFECTS THE PRODUCTION OF TUMOR ANTIGEN 
SPECIFIC ANTIBODIES IN PATIENTS WITH NSCLC IN 
COMPARISON WITH CANCER DISEASE FREE GROUP
D. Myšíková1, J. Šimonek1, J. Pozniak1, J. Kolařík1, R. Špíšek2, R. Lischke1 
1Thoracic and Lung Transplantation Division, 3rd Department of Surgery, 
First Faculty of Medicine, Charles University in Prague and University 
Hospital Motol, Prague, CZECH REPUBLIC, 2Department of Immunology, 
Second Faculty of Medicine, Charles University in Prague and University 
Hospital Motol, Prague, CZECH REPUBLIC
Aim: We focused on an impact of active smoking in a prospective case-con-
trol study comparing differences in the frequency of tumor antigen specific 
antibodies (TAA) in the serum in the group of NSCLC patients versus benign 
diagnosis group.
Methods: Serum from two comparable groups of patients was analyzed for 
the presence of TAA against 3 tumor antigens HER2 neu, NY-ESO-1 and 
MAGE A4 by ELISA: 57 patients with NSCLC were compared with 57 
benign controls. Serum from 32 healthy volunteers was used for cut-off point 
calculation. Seropositivity was evaluated in three subgroups (smokers, ex-
smokers, non-smokers) of NSCLC patients and similarly in 3 subgroups of 
benign patients.
Results: TAA were detected in NSCLC group - NY-ESO-1 in 28,1 % (16/57), 
HER 2 neu in 10,5% (6/57) and MAGE A4 in 19,3% (11/57) as well as in 
group of benign controls - NY-ESO-1 in 17,5 % (10/57), HER 2 neu in 8,8 
% (5/57) and MAGE A4 in 7,7 % (4/57).However, the highest frequency of 
TAA was observed in NSCLC smokers and declined in the groups of ex- and 
non-smokers. This trend was the most prominent in NY- ESO 1 detection, 
40% (12/30) NSCLC smokers were NY-ESO 1 positive, only 22,2% (4/18) 
ex-smokers were positive and all of 9 non-smokers were NY-ESO 1 nega-
tive. Results were not significant probably due to an uneven distribution of 
patients in subgroups, p=0,052. Similarly, higher not significant frequency 
of HER 2 neu and MAGE A4 was observed in NSCLC smokers.There was 
a significant difference in NY ESO 1 production between group of NSCLC 
patients in comparison with benign controls according to smoking history 
p=0,002. The difference was most evident in subgroup of smokers, 12/30 
NSCLC smokers versus only 4/30 benign controls were positive for NY-ESO 
1.There was no similar significant difference in Her 2 neu and MAGE A4 
frequency.
Conclusions: We show that an active smoking has a profound impact on the 
frequency of TAA in the serum of NSCLC patients in comparison with benign 
controls. Antibody production in smokers might indicate the chronic inflam-
matory state that potentiates the development of tumor specific immune 
response.
Disclosure: All authors have declared no conflicts of interest.
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THE TARGETING OF MTOR PATHWAY BY SPORE-
FORMING BACILLUS FROM CHEONGGUKJANG, 
KOREAN FERMENTED SOYBEAN PASTE 
TO OVERCOME DRUG RESISTANCE IN 
NON-SMALL CELL LUNG CANCER
J.K. Park, M. Yang Department of Microbiology, Chungnam National 
University, School of Medicine, Cancer Research Institute, Daejeon, 
KOREA
Aim: Drug resistance is one of the main problems associated with non-
small cell lung cancer (NSCLC) treatment. Targeting of mTOR pathway 
is an attractive strategy in the development of therapeutic agents against 
resistant NSCLC cells. Recently, we have isolated the Bacillus subtilis (BS) 
as a gram-positive, spore forming, non-pathogenic bacterium isolated from 
Cheonggukjang, Korean traditional fermented food that might have an 
apoptotic effects on NSCLC cells through the inhibition of mTOR pathway. 
In this study, we investigated the growth inhibition effects of BS in NSCLC 
cell lines via molecular mechanism studies of BS induced apoptosis signal-
ing pathway.
Methods: NSCLC cell lines (TKI-sensitive PC9, TKI-resistant H1975), 
HepG2, HCT116, and human dermal fibroblast cell line were exposed with 
BS with MOI of 0.1 or 1 and its cytotoxic effect was evaluated by MTT. 
For further explore of in vitro protein level changes made by the apoptotic 
reagent, western blotting analysis was conducted.
Results: We isolated five Bacillus species from Cheonggukjang. Among 
them, the only strain BS showed 90% of cytotoxicity on all NSCLC cell 
lines (less than 60% by rapamycin). However, the cell viability of BS treated 
HepG2, HCT116, and fibroblast cell were not affected. Treatment of NSCLC 
cell lines with BS activated caspase-9, -3 and increased cleavage form of 
poly (ADP-ribose) polymerase (PARP). However, caspase-8 activity was not 
increased by BS. BS-activated intrinsic pathway via increase of pro-apoptotic 
(Bax) and decrease of anti-apoptotic (Bcl-2) proteins on mitochondria, dis-
ruption of mitochondrial membrane potential, release of cytochrome c from 
mitochondria.
Conclusions: Findings in this study direct us that BS can become a promising 
specific tumor targeting therapeutic agent in NSCLC via intrinsic cell death 
pathways. These results suggest that the combination of molecular targeted 
agents and BS has the potential to be a therapeutic strategy for drug resistant 
NSCLCs.
Disclosure: All authors have declared no conflicts of interest.
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PROGNOSTIC VALUE OF CYCLOOXYGENASE 
2, ENHANCER OF ZESTE HOMOLOG 2 AND 
P53 EVALUATED BY QUANTITATIVE IMAGE 
ANALYSIS IN MALIGNANT NSCLC
K. Hainis1, A.M. Athanasiadou2, E. Haini1, A. Tsipis2, M. Gonidi3, P. 
Athanassiadou2 1Pulmonary, Corfu General Hospital, Corfu, GREECE, 
2Pathology Laboratory, Medical School, University of Athens, Athens, 
GREECE, 3Cytology Lab, Corfu General Hospital, Corfu, GREECE
Aim: Cyclooxygenase 2 (COX-2), Enhancer of Zeste Homolog 2 (EZH-2) 
and p53 overexpression is seen in many malignancies including lung cancer. 
The aim of this study was to investigate the usefulness of the expression of 
COX-2, p53 and EZH-2 in NSCLC using an image analysis system on immu-
nostained specimens with regard to biological behavior of the tumor.
Methods: The samples consisted of FNA material from 80 NSCLC lung 
carcinomas. Twenty specimens with hyperplastic lesion were using as con-
trol group. FNA specimens were collected in Cytolyt solution and Thin 
Prep slides were prepared. Image analysis of the smears stained immu-
nocytochemically with the use of COX-2, p53 and EZH-2 antibodies was 
performed.
Results: The intensity and extent for COX-2 correlated with staining extent 
(p<0,001). Extent of staining for COX-2 correlated with percentage of posi-
tive for EZH-2 (0,001) and p53 nuclei (p<0,001). The intensity of COX-2 
was lower in the carcinoma group (118,57 ± 12,43) than in the hyperplastic 
(127,16 ± 11,71) group. On the contrary the mean value of staining extent 
was greater in the carcinoma cases (15,96 ± 13,03) than in hyperplastic 
cases (4,04 ± 1,94). The percentage of EZH-2 and p53 positive cells cor-
related with histological type of the lesions (p=0,001 and p=0,011 respec-
tivelly). There was also a statistic correlation between the histological type 
of the lesions with the expression of COX-2 (p=0,001), EZH-2 (P=0,010) 
and p53 (p=0,010).
Conclusions: In conclusion our results provide a basis for the concept that 
high expression of EZH-2, COX-2 and p53 as detected by IHC at quantitative 
level may be a predictor for distinguishing histologically benign lesions at 
high risk for malignant progression.
Disclosure: All authors have declared no conflicts of interest.
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CAN SUBTYPING DIAGNOSIS HELP IN OPTIMIZING THE 
MANAGEMENT OF LUNG ADENOCARCINOMA PATIENTS?
T.T. Kondratieva1, N. Velizheva2, M.V. Dardyk3, A. Pavlovskaya4, N. Mazurenko5, 
I. Tsyganova5, S. Subramanian6 1Clinical Cytology Laboratory, Clinical Oncology 
Research Institute, FSBI N. N. Blokhin RCRC RAMS, Moscow, RUSSIAN 
FEDERATION, 2Laboratory of Cell Imunity, Research Institute of Experimental 
Diagnostics and Tumor Therapy, FSBI N. N. Blokhin RCRC RAMS, Moscow, 
RUSSIAN FEDERATION, 3Department of Oncology, Moscow State University 
of Medicine and Dentistry, Moscow, RUSSIAN FEDERATION, 4Human Tumor 
Pathologic Anatomy Department, Clinical Oncology Research Institute, FSBI 
N. N. Blokhin RCRC RAMS, Moscow, RUSSIAN FEDERATION, 5Laboratory 
of Oncogenomics, Research Institute of Carcinogenesis, FSBI N. N. Blokhin 
RCRC RAMS, Moscow, RUSSIAN FEDERATION, 6Eurasian Federation of 
Oncology, Moscow, RUSSIAN FEDERATION
Aim: In the era of targeted therapy of metastatic and locally advanced lung 
cancer (LC) the final verdict already often belongs to genetists. Is it reason-
able to do molecular screening for 80% of LC that are NSCLC? Are the 
advantages worth the price of research? Are there any correlations between 
molecular changes, morphological features of different histological subtypes, 
clinical implications and prognosis of disease? 1. To evaluate the need and 
clinical significance of subtyping lung cancer adenocarcinomas (AC) on 
small biopsies and cytological samples in daily practice 2. To analyze the 
correlation between histologic subtypes of Lung AC, EGFR/KRAS-status and 
efficiency of the treatment in LC patients.
Methods: Cytological and histological samples of 271 (100%) bronchos-
copies conducted in 2012 were analyzed. Simultaneous histological and 
cytological examinations were performed in 162 (60%) cases. In 78 (29%) 
patients EGFR/KRAS-status was analyzed.
Results: 78 (100%) Lung AC was confirmed. Among them: AC with papillary 
patterns – 26 (33%), with the predominance of solid and acinar patterns and pres-
ence of mucus – 23 (29,5%), large cell low differentiated – 16 (21%), AC with 
micropapillary patterns – 9 (11,5%) and mucoepidermoid cancer – 4 (5%). Poor 
clinical course of disease was observed in patients with AC with the presence of 
large, middle and small cells with the severe anaplasia of nuclei. The differential 
feature is presence of multiple metastasis, especially in bones. EGFR-mutations 
were observed in 14 (18%) patients. In this subgroup the following subtypes were 
observed: AC with solid and acinar patterns with clear cells, AC with papillary 
and micropapillary patterns and production of mucus and combined subtypes. 
Presence of mutated KRAS was associated with prominent adenous differentia-
tion of the tumor and the evident presence of mucus production
Conclusions: 1. Accurate subtyping of lung AC within the International 
Classification is essential stage in diagnosis and treating patients. Simultaneous 
usage of histologic and cytological examination helps to solve the problem. 2. 
No evident correlation between genetic mutations and morphological features 
of adenocarcinomas were found. Further data collection and analysis on mor-
phogenetic changes with its clinical implications are needed.
Disclosure: All authors have declared no conflicts of interest.
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PROTEIN TYROSINE KINASE 7 PLAYS A TUMOR 
SUPPRESSOR ROLE BY INHIBITING ERK AND 
AKT PHOSPHORYLATION IN LUNG CANCER
H.W. Lee1, M.C. Kang1, J.H. Kwon1, D.W. Choe2, C.H. Kim3, H.J. Yoo4, J.S. 
Koh5, J.H. Park1 1Thoracic Surgery, Korea Cancer Center Hospital, Seoul, 
KOREA, 2Radiology, Korea Cancer Center Hospital, Seoul, KOREA, 
3Pulmonology, Korea Cancer Center Hospital, Seoul, KOREA, 4Radiation 
Oncology, Korea Cancer Center Hospital, Seoul, KOREA, 5Pathology, Korea 
Cancer Center Hospital, Seoul, KOREA
Aim: Protein tyrosine kinase 7 (PTK7) is a catalytically inactive receptor 
tyrosine kinase that is also known as colon carcinoma kinase-4 (CCK-4). 
Recent reports have shown that PTK7 plays an important role in carcino-
genesis, and it is known to be up-regulated in gastric cancer, colon cancer, 
esophageal cancer, and liposarcoma. However, we found that PTK7 expres-
sion was down-regulated at the mRNA as well as protein levels in human lung 
squamous cell carcinoma (LSCC), unlike in other tumors. In this study, we 
attempted to explore the role of PTK7 in lung cancer.
Methods: We analyzed expression of PTK7 by RT-PCR and western blot 
analysis using tumor and normal lung tissue from 10 LSCC patients. To 
explore the functional role of PTK7, the expression of PTK7 in LSCC cells 
was examined using empty vector and PTK7 gene inserted vector.
Results: We found that PTK7 expression was down-regulated at the mRNA 
as well as protein levels in human lung squamous cell carcinoma (LSCC). 
Upon investigating the functional role of PTK7 in LSCC, we found that over-
expression of PTK7 in LSCC cells resulted in inhibition of cell proliferation, 
invasion, and migration. Further, we confirmed that these phenotypic changes 
are associated with the activation of Akt and ERK.
Conclusions: These observations may indicate a role for PTK7 in cell prolifera-
tion, wound healing and invasion via regulating Akt and Erk activation. Our find-
ings suggest that PTK7 has different oncogenic roles in organs and target tumors.
Disclosure: All authors have declared no conflicts of interest.
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CYTOTOXIC EFFECT OF VENOM FROM SEA ANEMONES  
ON HUMAN NON-SMALL-CELL LUNG CANCER CELL LINE
M. Ramezanpour1, B. Sanderson1, K. Burke da Silva2 1Medical Biotechnology, 
Flinders University, Adelaide, SA, AUSTRALIA, 2School of Biological 
Sciences, Flinders University, Adelaide, SA, AUSTRALIA
Aim: Nature has been instrumental as a source of therapeutics. The major anti-
infective, anticancer, analgesics and immunosuppressive compounds are of nat-
ural origin. Sea anemones are well known for being rich sources of toxins. The 
goal of this study was to determine the susceptibility of human non-small-cell 
lung cancer cell line (A549) to killing by four different sea anemone venoms.
Methods: In this study, the nematocyst venom of four sea anemones (Heteractis 
malu, Heteractis Crispa, Cryptodendrum adhaesivum and Entacmaea quad-
ricolor) were obtained by the milking technique, and the potential of these 
venoms to kill cancer cells was tested on human non-small-cell lung cancer 
(NSCLC) A549 cells. The total protein level in the crude extract was deter-
mined by the bicinchoninic acid (BCA) protein assay. The cytotoxicity on the 
cell line was assayed using the 3-(4, 5-dimethylthiazol-2- yl)-2, 5-diphenyltet-
razolium bromide (MTT) assay which measures survival based on the detec-
tion of mitochondrial activity and by the crystal violet assay, which measures 
survival based on the ability of cells to remain adherent to microplates.
Results: In the MTT assay, C. adhaesivum and H. malu had significant inhibi-
tory effect on A549 cells, although E. quadricolor and H, Crispa showed less 
inhibitory effect on A549 cells. In the crystal violet assay, the toxic effects of 
the extracts were evident for C. adhaesivum and H. malu and E. quadricolor 
at 24 and 72 hours however, H, Crispa did not show any significant effect.
Conclusions: Venom from H. malu, C. adhaesivum and E. quadricolor show 
promising results against human non-small-cell lung cancer (NSCLC) cell line.
Disclosure: All authors have declared no conflicts of interest.
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EVALUATION OF 1H-NMR SPECTROSCOPY 
IN PREDICTING PLATINE-RELATED 
TOXICITIES IN LUNG CANCER PATIENTS
K. Vanhove1, L. Mesotten2, M. Thomeer3, E. Louis1, P. Adriaensens4 
1Faculty of Life Sciences, University of Hasselt, Diepenbeek, BELGIUM, 
2Nuclear Medicine, ZOL, Genk, BELGIUM, 3Respiratory Division, ZOL, 
Genk, BELGIUM, 4Institute for Material Research, University of Hasselt, 
Diepenbeek, BELGIUM
Aim: Lung cancer is the leading cause of cancer mortality worldwide. Despite 
progress in treatment of lung cancer we experience unacceptable toxicities 
without a significant increase in overall survival (OS) and progression free 
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survival (PFS). The goal of this study was to find out whether the metabolic 
profile derived from blood plasma can differentiate between subject groups 
who do and do not develop toxicities.
Methods: This project investigated subjects with a new diagnosis of lung can-
cer (n = 76) independent of stage (IB 1.3 %, IIA, 7.9%, IIB 5.3%, IIIA 31.6%, 
IIIB 18.4% and stage IV 35.5%) and who received chemotherapy. All patients 
received a platinum-based cytotoxic treatment.Participants were asked to pro-
vide a fasted sample of blood. Samples were analysed by 1H-NMR spectroscopy 
using a 400 MHz spectrometer. Slightly T2-weighted spectra were acquired and 
the chemical shifts were referred to TSP at 0.015 ppm. The integration values 
of 110 spectral integration regions (IRs) were analyzed appropriate statistical 
methods followed by an orthogonal partial least squares discriminant analysis 
(OPLS-DA) to investigate whether a discriminating classifier can be constructed.
Results: There were severe adverse events (grade 3 and 4) in both groups: 
thrombopenia (9%), neutropenia (38%), leukopenia (17%) and anemia (8 %). 
There were no cases of severe renal failure. According to the ECOG criteria of 
toxicity subgroups were created. Normal probability plots were constructed and 
a Kolmogorov-Smirnov test was carried out. Analysis of variance (ANOVA) was 
performed if the null hypothesis of the Kolmogorov Smirnov test was accepted. 
In the case of rejection of the null hypothesis Kruskall-Wallis was performed. No 
significant difference was found between the groups with and without toxicities. 
This was true for all the toxicities of interest in this study. Multivariate analysis 
(OPLS-DA) was not able to construct a discriminating classifier.
Conclusions: Lung cancer patients experiencing toxicities could not be dif-
ferentiated from those without toxic effects based on the metabolic profiles 
obtained by 1H-NMR spectroscopy. However, this might be due to the treat-
ment schedule, number of cycles administered, and the rather small and het-
erogeneous group of subjects.
Disclosure: All authors have declared no conflicts of interest
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ALTERATION OF TUMOR SUPPRESSOR GENES 
IN MALIGNANT PLEURAL EFFUSION
J. Chang Respiratory Center, Ewha Womans University, Seoul, KOREA
Aim: Pleural fluid is one of the most important materials for cancer diagnosis. 
Although cytologic examination has been used as a standard method to diag-
nose malignant effusion, its sensitivity is still insufficient. To determine whether 
the genetic analysis of pleural fluid can be used for the diagnosis of malignant 
effusion, mutations of p53 and FHIT, loss of heterozygosity (LOH), and micro-
satellite instability (MA) were investigated in malignant pleural effusion.
Methods: To determine whether gene analysis of pleural fluid can be used for 
the diagnosis of malignant effusion, malignancy-associated pleurisy (ME) were 
enrolled in 40 subjects and tuberculous pleurisy (TB) enrolled in 17 subjects as 
controls. From DNA of Pleural fluid and Blood, mutations of p53 and FHIT gene 
and microsatellite alteration were evaluated. As markers of microsatellite altera-
tion, D3S1234, D3S1285, D9S171, and TP53 were applied for the analysis.
Results: Among 40 malignant associated effusion subjects, 5 subjects (12.5%) 
of p53 mutation and 7 subjects (17.5%) of FHIT mutation were detected. 
Using 4 microsatellite markers, 25 subjects (63%) exhibited LOH and/or MI 
in at least one marker. In 4 of 5 effusion with negative cytopathology and 
negative CEA in pleural fluid, microsatellite alterations were identified.
Positivity of cytopathology, CEA, and microsatellite alteration (MA) in 
malignancy pleural effusion
Pathology Cytopathology (%) CEA a(%) MA b(%) 
Overall 58 68 63 
NSCLC 81 73 58 
Squamous cell 80 60 80 
Adenocarcinoma 81 76 52 
SCLC 29 57 71 
a: > 12ng/ml. b: LOH and/or MI
Conclusions: Diagnostic yield of pleural fluid cytopathology was 58% and 
positivity of analysis using 4 microsatellite markers was 63%. Gene analysis 
of pleural fluid could be used as a diagnostic tool to compromise conventional 
methods.
Disclosure: All authors have declared no conflicts of interest.
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PEGYLATED γ-FE2O3-NANOCRYSTAL FROM 
GOAT RED BLOOD CELLS ENHANCES 
THE NUCLEAR-TARGETED DELIVERY OF 
DOXORUBICIN IN LUNG CANCER THERAPY
V. Sreevani1, K. Shanthi1, S. Kannan2 1Zoology, Bharathiar University, 
Coimbatore, INDIA, 2Zoology, Periyar University, Salem, INDIA




-NC using goat blood as 
a bio-precursor (Molecular approach).
• To exhibit potent cytotoxicity against A549 and iron detection by Prussian 
blue stain.
• To detect apoptosis by Ao/EtBr and nuclear fragmentation by DAPI.
• To study DOX signal detection implies nuclear targeting.
• To observe cellular internalization of nanocrystals.





terized using UV spectroscopy, XRD (X-ray diffraction), HR-TEM (High 
Resolution Transmission Electron Microscope), DLS (Dynamic Light 
Scattering), EDS (Energy Dispersive Spectrometric analysis) techniques, 
and FTIR (Fourier transform infrared). MTT assay determines A549 cell 
viability, intracellular iron detection by Prussian blue stain, morpho-
logical assessment by AO/EtBr and DAPI staining techniques with the 
confocal studies for DOX detection and internalization of nanocrystals 
by TEM.





-NC was found to be highly crystalline with 60–70 nm 
and confirmed the presence of DOX and PEG. The dose dependent cytotox-
icity and morphological changes was observed. Intracellular iron detection 
was also confirmed. Strong DOX signals in the nucleus clearly implies the 





-NC was also observed.
Conclusions: Synthesis was very effective as the protocol developed here 
avoid the use of harsh reaction conditions such as high temperature, corrosive 
reagents, etc., and could be used as promising nanotherapeutic for nuclear-
targeted chemotherapy for non-small cell lung cancer.
Disclosure: All authors have declared no conflicts of interest.
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ESTABLISHMENT OF LUNG CANCER MOUSE 
MODEL INDUCED BY BENZO (A) PYRENE
H.S. Moon1, H.Y. Lee2, I.K. Kim1, C.D. Yeo2, C.H. Kim2, S.H. Lee1 1Department 
of Internal Medicine, St. Paul’s Hospital, The Catholic University of Korea, 
Seoul, KOREA, 2Department of Internal Medicine, The Catholic University 
of Korea, Seoul, KOREA
Aim: Several novel animal models for lung cancer have been developed 
in recent years. Cancer mouse models by exposure to various carcinogens 
are still commonly used tumor mouse models. Benzo(a)pyrene (B[a]P) 
is one of the major environmental pollutants and induces carcinogenesis 
specifically targeting the lung. The aim of this study is to establish a stan-
dard design of mouse models for lung cancer following B[a]P exposure 
method.
Methods: A lung cancer mouse model was developed through repeated 
oral gavage or intratracheal (i.p.) injection of B[a]P, and then the incidence 
of lung tumor in B[a]P treated mice was measured following time course 
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from 20 weeks to 32 weeks. To make precise pathological diagnoses, lung 
tissue sections were hematoxylin and eosin stained and observed under a 
microscope.
Results: B[a]P administration by oral gavage induced slight reductions 
in body weight, while significant reductions in body weight were found 
in B[a]P i.p. injection group steadily through 32 weeks compared with 
the control group (p < 0.001). The tumor multiplicity following treatment 
with B[a]P (oral gavage or i.p) was similar by 28 weeks, while the size of 
lung tumors was significantly increased at 28 weeks. At 32 weeks, the size 
of lung tumors as well as tumor multiplicity significantly increased com-
pared to 28 weeks, especially showing greater increase following treat-
ment with IP injection. In addition, the adenomas and adenocarcinomas 
in B[a]P-treated mice significantly appeared to increase from 20 weeks 
to 32 weeks.
Conclusions: This study presented a standard period and method of car-
cinogen exposure to establish an effective spontaneous lung cancer model. 
Treatment of B(a)P by oral gavage or IP injection showed similar tumor 
multiplicity, however the IP method showed slight more increase in tumor 
formation and is more convenient as the injection is single dose. From 32 
weeks onwards, there is a significant increase in tumor multiplicity and 
size. Therefore we suggest that the results of the B(a)P induced lung can-
cer mouse model should be investigated after 32 weeks to yield effective 
outcomes.
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL UTILITY OF A PLASMA-BASED MICRORNA 
SIGNATURE CLASSIFIER WITHIN COMPUTED 
TOMOGRAPHY LUNG CANCER SCREENING
U. Pastorino1, M. Boeri2, G. Sozzi2 1Thoracic Surgery, Fondazione IRCCS 
Istituto Nazionale dei Tumori, Milan, ITALY, 2Experimental Oncology, 
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY
Aim: Recent screening trial results indicate that low-dose computed tomog-
raphy (LDCT) reduces lung-cancer mortality in high risk subjects. However, 
high false positive rates, costs and potential harms highlight the need for 
complementary biomarkers. MicroRNAs (miRNAs) are tissue and disease 
specific molecules, actively released by cells in the circulatory system, which 
are associated with protein complexes and/or packaged in exosomes and 
microvesicles. Circulating miRNAs are rather stable and easily detectable in 
body fluids suggesting the possibility of using miRNAs as a new promising 
class of biomarkers. We previously reported that miRNA profiling in plasma 
samples of disease-free smokers enrolled in two independent spiral-CT 
screening trials, resulted in the generation of miRNA signatures with strong 
predictive, diagnostic, and prognostic potential (Boeri et al. PNAS 2011).
Methods: The diagnostic performance of a non-invasive plasma microRNA 
signature classifier (MSC) was retrospectively evaluated in samples prospec-
tively collected from smokers within the randomized Multicentre Italian Lung 
Detection (MILD) trial. Plasma samples from 939 subjects including 69 lung 
cancer patients and 870 disease-free individuals (652 LDCT arm; 287 obser-
vation arm) were analyzed using a qRT-PCR based assay for MSC. Diagnostic 
performance of MSC was evaluated in a blinded validation study using pre-
specified risk groups.
Results: The diagnostic performance of MSC for lung cancer detection was 
87% for sensitivity and 81% for specificity across both arms, and 88% and 
80% respectively in the LDCT arm. For all subjects, MSC had a negative 
predictive value of 99% and 99.86% for detection and death-by-disease 
respectively. LDCT had sensitivity of 79% and specificity of 81% with a false 
positive rate of 19.4%. Diagnostic performance of MSC was confirmed by 
time dependency analysis. Combination of both MSC and LDCT resulted in a 
5-fold reduction of LDCT false positive rate to 3.7%. MSC risk groups were 
significantly associated with survival (=49.53, p<0.0001).
Conclusions: This large validation study indicates that MSC has predictive, 
diagnostic and prognostic value and could reduce the false positive rate of 
LDCT improving the efficacy of lung cancer screening.
Disclosure: All authors have declared no conflicts of interest.
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INTERNATIONAL COMPARISON OF TREATMENT 
AND SURVIVAL FOR PLEURAL MESOTHELIOMA, 
COMBINED ANALYSIS OF 9.014 PATIENTS FROM 
BELGIUM, THE NETHERLANDS AND ENGLAND
J.P. van Meerbeeck1, R.A. Damhuis2, A. Khakwani3, H. De Schutter4, 
A. Rich3, S.A. Burgers5 1Thoracic Oncology, U.Z.A. University Hospital 
Antwerp, Edegem, BELGIUM, 2Comprehensive Cancer Centre, Utrecht, 
NETHERLANDS, 3Division of Epidemiology & Public Health, University 
of Nottingham, Nottingham, UNITED KINGDOM, 4None, Belgian Cancer 
Registry, Brussels, BELGIUM, 5Thoracic Oncology, Netherlands Cancer 
Institute, Amsterdam, NETHERLANDS
Aim: Pleural mesothelioma is refractory to treatment and has a poor prog-
nosis. Only chemotherapy was proven effective in randomized trials. Novel 
chemotherapy may increase median survival by several months and was 
gradually introduced in the period 2003–2006. Little is known about con-
temporary treatment practice in Europe. To determine patterns of care and 
current survival rates, three large population-based registries were queried in 
a uniform manner.
Methods: Data from the Belgian Cancer Registry, the Netherlands Cancer 
Registry and the UK National Lung Cancer Audit were analyzed for patients 
diagnosed with pleural mesothelioma as of 2007. Treatment patterns and sur-
vival rates were compared between countries.
Results: The study comprised 900, 2.306 and 5.808 patients from Belgium, 
Netherlands and England, respectively. Fifty-nine percent of patients were 70 
years or older and 84% were men. Surgery and radiotherapy patterns varied 
between countries but comparisons were hampered due to variation in coding 
practice. Chemotherapy rates decreased with advancing age and chemother-
apy was more often applied in Belgium (53%) than in the Netherlands (41%) 
and England (37%). Median survival was 10,6 months in Belgium versus 
9,5 months for England and 9,2 months for the Netherlands. Survival rates 
decreased with advancing age. After stratification for age and chemotherapy, 
survival was comparable for the three countries.
Conclusions: Combined analysis of data from three countries with high 
mesothelioma rates demonstrates that chemotherapy has become standard 
treatment for younger patients. Less toxic treatment options will be required 
to improve the prospects for elderly mesothelioma patients.
Disclosure: All authors have declared no conflicts of interest.
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AN INNOVATIVE TECHNOLOGY FOR IN VIVO 
ISOLATION OF CIRCULATING TUMOR CELLS IN NON-
SMALL CELL LUNG CANCER (NSCLC) PATIENTS AND 
IMMUNOFLUORESCENT DETECTION OF ALK PROTEIN
B. Dlugaszewska1, L. Gasiorowski2, S. Herold1, B. Nowack3, G. Dworacki4, 
K. Luecke5, W. Dyszkiewicz2 1KS, GILUPI GmbH, Potsdam, GERMANY, 
2Department of Thoracic Surgery, University of Medical Sciences, Poznan, 
POLAND, 3R&D, GILUPI GmbH, Potsdam, GERMANY, 4Department of 
Clinical Immunology, University of Medical Sciences, Poznan, POLAND, 
5GM, GILUPI GmbH, Potsdam, GERMANY
Aim: Circulating tumor cells (CTCs) in lung cancer patients can provide 
additional information on patient prognosis and treatment efficacy. Currently, 
CTCs are isolated in vitro from limited volumes of patient blood samples. 
To overcome this limitation, an innovative device, Detektor CANCER01 
(DC01), was used to isolate CTCs in vivo, directly from the bloodstream of 
lung cancer patients.
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Methods: 48 NSCLC patients (stages I-IIIB) and 12 non-cancer patients 
were enrolled in this study. The DC01 was inserted into a cubital vein 
through a standard cannula for 30 minutes. The interaction of target CTCs 
with the device was mediated by an antibody directed against the epi-
thelial cell adhesion molecule (EpCAM). CTC binding was confirmed 
by immunocytochemistry (ICC) with EpCAM and/or cytokeratines as 
positive markers, and CD45 for negative cell selection. Enumeration 
data were available for 34 NSCLC patients and 8 non cancer patients. 
For 34 patients, blood samples were tested with a reference method 
(CellSearch).
Results: Using the DC01, we successfully isolated EpCAM-positive tumor 
cells from the peripheral blood of NSCLC patients. DC01 sensitivity for in 
vivo CTC isolation was 94% (similar for early and late stage NSCLC patients) 
compared to the in vitro detection rate of 5.8% (CellSearch). In all matched 
pairs, the DC01 detected the same number or more CTCs then the CellSearch 
method. In non-cancer patients, no CTCs were detected (100% specificity of 
the DC01). Furthermore, the anaplastic lymphoma kinase protein (ALK) was 
identified by ICC in cell lines captured on DC01.
Conclusions: Due to a high CTC detection rate (>90%), the DC01 may 
overcome present limitations in the enrichment of CTCs. Its implemen-
tation into clinical practice may improve early detection, prognosis and 
therapy monitoring in NSCLC patients. Tumor cells captured by the 
DC01 can be subsequently analyzed by immunofluorescence or molecular 
techniques. This opens the possibility of establishing personalized thera-
pies, e.g. based on the identification of ALK rearrangements or EGFR 
mutations.
Disclosure: B. Dlugaszewska: GILUPI employee S. Herold: Stock-ownership 
in GILUPI B. Nowack: GILUPI employee K. Luecke: Stock ownership in 
GILUPI All other authors have declared no conflicts of interest.
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LUNG CANCER DETECTION WITH CHEST 
DIGITAL TOMOSYNTHESIS: RESULTS FROM 
THE SOS OBSERVATIONAL STUDY
L. Bertolaccini1, A. Viti1, C. Tavella2, R. Priotto2, D. Ghirardo2, G. 
Giovinazzo2, C. Vinay2, M. Grosso2, A. Terzi1 1Division of Thoracic Surgery, 
Azienda Ospedaliera St. Croce e Carle, Cuneo, ITALY, 2Radiology, Azienda 
Ospedaliera St. Croce e Carle, Cuneo, ITALY
Aim: Low-Dose Computed Tomography (LDCT) screening for Lung Cancer 
(LC) is currently suggested (grade of recommendation = 2B); nevertheless, 
radiation exposure and costs are still a problem. In Baseline results of SOS 
study, single-arm observational study of chest Digital Tomosynthesis (DT) 
in a LC at-risk population, we have shown a LC detection rate comparable 
to LDCT (0.98%), low effective radiation dose (0.13 mSv), and 1/6 cost of 
LDCT. DT is limited angle tomography that allows reconstruction of multiple 
image planes and provides high-resolution images in coronal planes. We pres-
ent the results of the SOS study.
Methods: Sample size of 2,000 subjects (current or former smoker >20 pack-
years; age 45 – 75 years; no previous cancer in 5 years before study) was 
planned on basis of incidence and mortality data reported in Piedmont Cancer 
Registry. DT was performed one-year later in negative Baseline subjects. In 
subjects with uncertain nodule >5 mm or with multiple nodules, first-line 
LDCT was warranted.
Results: 1,703 candidates (mean age = 60 years, range = 49 – 73) under-
went First Round DT (92% of baseline, drop out = 0.4%). Lung nodules 
>5 mm were detected in 13 (0.7%) subjects; none had any nodules at 
Baseline DT. There was one false positive at CT; 2 subjects had follow-
up schedule. Surgery was performed in 10. Histology revealed organiz-
ing pneumonia = 2, tuberculosis nodule = 1, intrapulmonary lymph node 
increased in size = 1, and lung metastasis from biliary tree adenocarcinoma 
(operated more than 10 years before) = 1. LC was diagnosed and resected 
by VATS lobectomy in 5 subjects (Table). LC detection rate at First Round 
was 0.3% (5/1703).
Table. Tumor stage and histology in LC diagnosed by chest DT at 
Baseline and First Round.
No. of Subjects














Conclusions: First Round results on DT in early detection of LC are as good 
as for baseline. LC detection rate is comparable to LDCT and achieved at 
far lower costs and radiation dose. DT is a possible first-line LC screening 
tool and is effective in high-risk subjects follow-up. Nevertheless, studies on 
larger number of subjects are needed to confirm these results.
Disclosure: All authors have declared no conflicts of interest.
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MEASURING THE POPULATION IMPACT 
OF INTRODUCING STEREOTACTIC 
ABLATIVE RADIOTHERAPY (SABR) 
FOR STAGE I NSCLC IN CANADA
A.V. Louie1, G.B. Rodrigues2, D.A. Palma2, S. Senan1 1Radiation Oncology, 
VU University Medical Center, Amsterdam, NETHERLANDS, 2Radiation 
Oncology, London Regional Cancer Program, London, CANADA
Aim: SABR achieves long-term local control rates of up to 90% in stage I 
NSCLC. We used the Cancer Risk Management Model (CRMM) to estimate 
the health and economic impact of introducing SABR for stage I NSCLC in 
Canada.
Methods: The CRMM employs Monte Carlo microsimulation of all 
Canadians from birth to death. The lung cancer module outputs were previ-
ously validated internally using Health Canada census data, and externally 
with Canadian Cancer Registry data. We updated costs using the Ontario 
schedule of fees and benefits, or consumer price index (Bank of Canada) 
to calculate 2013 Canadian dollars, discounted at a 3% rate. Our baseline 
model assumed that for stage I NSCLC, 75% of patients undergo surgery 
(lobectomy, sublobar resection, or pneumonectomy), 12.5% radiotherapy 
(RT), and 12.5% best supportive care (BSC). SABR was introduced in 2008 
as an alternative to sublobar resection, RT, and BSC at rates reflective of the 
current literature. Incremental cost effectiveness ratios (ICER) were calcu-
lated; a willingness to pay threshold of $100,000 per QALY was used from 
the healthcare payer perspective.
Results: The total cost for 25,085 new cases of lung cancer in 2013 was 
calculated to be $608,002,599. Median upfront costs for the 4,318 stage 
I cases were: RT ($7,646.98), SABR ($8815.55), sublobar resection 
($12,161.17), lobectomy ($16,266.12), pneumonectomy ($22,940.59), 
and BSC ($14.582.87). SABR dominated (higher QALY, lower cost) RT, 
sublobar resection, and BSC (Table 1). RT had lower initial costs than 
SABR, which were offset by subsequent costs associated with recur-
rence. Lobectomy was cost-effective when compared to SABR, with an 
ICER of $55,909.
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Table: Cost-effectiveness of SABR
Scenario 






RT -5,187,816 1693 Dominated




Lobectomy -164,370,264 -294 55909
Conclusions: The use of SABR for stage I NSCLC is projected to result 
in significant cost savings and survival gains in Canada. In this model, 
SABR dominated most alternative treatments, but lobectomy was the 
most cost-effective treatment option and should be employed where 
appropriate.
Disclosure: A.V. Louie: Dr. Louie was the recipient of the 2013 Canadian 
Association of Radiation Oncologists’ Elekta Research Fellowship. The 
VUMC has a has a departmental master research agreement with Varian 
Medical Systems Inc. D.A. Palma: Dr. Palma was the recipient of the 
2009 Canadian Association of Radiation Oncologists’ Elekta Research 
Fellowship. S. Senan: Dr Senan has received research funding from 
Sanofi-Aventis and speaking honoraria from Varian Medical Systems 
Inc. The VUMC has a departmental master research agreement with 
Varian Medical Systems Inc. All other authors have declared no conflicts 
of interest.
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ASSOCIATION OF POLYMORPHISMS IN THE MICRORNA 
TARGET SITES AND SURVIVAL OF PATIENTS IN 
EARLY-STAGE NON-SMALL-CELL LUNG CANCER
J.E. Choi1, M.J. Hong1, J. Jang1, H. Jeon1, Y.Y. Choi1, J.Y. Park2 1Department 
of Biochemistry and Cell Biology, School of Medicine, Kyungpook National 
University, Daegu, KOREA, 2Internal Medicine, Kyungpook National 
University School of Medicine, Daegu, KOREA
Aim: MicroRNAs (miRNAs) have a key role in carcinogenesis through the 
negative regulation of their target genes. This study was conducted to inves-
tigate the associations between single-nucleotide polymorphisms (SNP) 
located in the microRNA target sites (poly-miRTSs) and survival of patients 
with early-stage non–small cell lung cancer (NSCLC), and to identify the 
lung cancer prognosis-specific poly-miRTS.
Methods: In the discovery cohort, 392 poly-miRTSs were investigated in 
357 patients using a Sequenom mass spectrometry-based genotype assay. A 
replication study was performed on an independent patient population (n = 
479). Luciferase assays were conducted to examine functional relevance of a 
potentially functional poly-miRTSs.
Results: Of the 392 SNPs, 289 poly-miRTSs were excluded (failed geno-
type, genotype call rate < 90%, minor allele frequency (MAF) < 10% or 
Hardy-Weinberg equilibrium Equation P value < 0.05) from further analysis. 
14 SNPs were significantly associated with survival outcomes in a discov-
ery study. Among the fourteen miRTSs, one miRTS (KRT81 rs3660) were 
found to be associated with survival outcomes in a validation cohort. In 
combined analysis, Patients with the rs3660 CC genotype had a significantly 
decreased overall survival (OS) compared with patients with GG+GC geno-
type (adjusted hazard ratio [aHR] for OS, 0.65; 95% Confidence Interval [CI] 
0.50–0.85; P= .001). An increased expression of the reporter gene for the C 
allele of rs3660 was observed then compared with the common G allele by 
luciferase assay.
Conclusions: The rs3660G>C affects KRT81 expression and thus influences 
survival in early-stage NSCLC. The analysis of the rs3660G>C polymor-
phism can be useful to identify patients at high risk of a poor disease outcome.
Disclosure: All authors have declared no conflicts of interest.
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EVALUATION OF EPIDERMAL GROWTH FACTOR 
RECEPTOR MUTATIONS IN BULGARIAN PATIENTS 
WITH NON-SMALL CELL LUNG CANCER
S. Bichev1, D.M. Marinova2, Y. Slavova2, A. Savov1 1National Genetic 
Laboratory, University Hospital of Obstetrics and Gynecology “Maichin 
Dom”, Sofia, BULGARIA, 2Pulmonology, University Hospital for Pulmonary 
Diseases “St. Sofia”, Sofia, BULGARIA
Aim: The aim of the present study is to determine the prevalence of EGFR 
mutations in non-small cell lung carcinomas (NSCLCs) in the East European 
Bulgarian population in different histological subtypes, in cytological vs. his-
tological samples and in primary lung carcinomas vs. metastatic locations.
Methods: Our cohort consisted of 1427 tissue specimens from patients with 
NSCLC. DNA was extracted from eighter paraffin embedded tissues or cytol-
ogy slides and analyzed for TKI activating mutations in EGFR gene by real-
time PCR technique.
Results: EGFR mutations were significantly more often in: female (n=355,69 
positive) than in male (n=1072,58 positive) patients (19.4% vs. 5.4%, 
p<0.001); adenocarcinomas (n=576,72 positive) than in squamous cell car-
cinomas (n=676,42 positive) or other types (n=118,9 positive) (12.5%, 6.2%, 
and 7.6% respectively, p=0.009); in never smokers (n=192,44 positive) com-
pared to ex-smokers (n=434,37 positive) and current smokers (n=662,28 
positive) (22.9% vs. 8.5% vs. 4.9% respectively, p<0.001). There wasn’t any 
significant difference between the frequency of EGFR mutations in primary 
tumors (n=1083) compared to metastases (n=269) (7.9% vs. 11.2%,p=0.092); 
or in histological samples (n=1365, 95.7%) compared to cytological samples 
(62,4.3%) (8.9% vs. 8.1%, p=0.813). From patients with TKI activating muta-
tions 66 had deletions in 19th exon (52%), 54 - L858R point mutation in 
21st exon (42.5%), 3 - L861Q point mutation in 21st exon (2.4%), 3 - S768I 
point mutation in 21st exon (2.4%), and 1 - G719X point mutation in 18th 
exon (0.8%). Also, 26 (TKI resistant) T790M point mutations in exon 20 were 
detected, none in combination with another (activating) EGFR mutation – 
1.8% of all cases.
Conclusions: Overall frequency of EGFR mutations in lung adenocarcino-
mas in the studied East European cohort is within the frequency range of 
North American and West European populations, whereas EGFR mutation 
frequency in SCC is higher than in any population described to date. All 
materials are suitable for EGFR molecular testing, even cytological samples, 
regardless of origin – primary or metastatic.
Disclosure: All authors have declared no conflicts of interest.
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SERUM TUMOR MARKERS CEA, CYFRA 21-1 AND 
ANTI-P53 IN PATIENTS WITH LUNG CANCER
F. Lumachi1, F. Mazza2, A. Del Conte3, G.B. Chiara4, S.M.M. Basso4 
1Department of Surgery, Oncology & Gastroenterology, University of Padua, 
School of Medicine, Padova, ITALY, 2Pneumology, S. Maria degli Angeli 
Hospital, Pordenone, ITALY, 3Medical Oncology, S. Maria degli Angeli 
Hospital, Pordenone, ITALY, 4Surgery 1, S. Maria degli Angeli Hospital, 
Pordenone, ITALY
Aim: Lung cancer is one of the most common neoplasms throughout the 
world, and the most devasting cause of cancer-related death. The 5-year sur-
vival rate is very low, accounting for approximately 15%, and it has changed 
minimally over the past 25 years (1). The poor survival is attrubutable to 
the fact that the majority of cases are diagnosed when the disease is already 
metastatic. At this stage, the therapeutic options are restricted to palliative 
systemic chemotherapy or radiation therapy. Only for patients diagnosed and 
treated at early stage (Stage I) the 5-year survival is relatively good, ranging 
between 50% and 80% (2). Several serum tumor markers have been tested in 
patients with lung cancer, including carcinoembryonic antigen (CEA), cyto-
keratin 19 fragments (CYFRA 21-1), squamous cell carcinoma antigen, neu-
ron-specific enolase (NSE), and more recently anti-p53 antibody circulating 
S17Copyright © 2014 by the European Lung Cancer Conference organisers, ESMO, and IASLC.
Journal of Thoracic Oncology ®  •  Volume 9, Number 4, Supplement 1, April 2014 Abstracts
markers. The aim of this study was to evaluate the usefulness of serum CEA, 
CYFRA 21-1, and anti-p53 assay in patents with lung cancer.
Methods: Data regarding a group of 42 patients (27 men, 15 women, median 
age 62 years, range 51–78 years) with confirmed Stage I lung cancer, and 
a group of 45 sex- and age-matched smokers patients with benign chronic 
pulmunary diseases underwent serum CEA, CYFRA 21-1, and anti p53 
measement.
Results: The sensitivity, specificity, positive predicting vaule, negative pre-
dicting value, and accuracy were the followings: 47.6%, 80.0%, 68.9%, 
62.1%, and 64.0% for CEA (chi-squared 0.0006); 40.5%, 92.8%, 85.0%, 
60.9%, 67.0% for CYFRA 21-1 (chi squared 0.00031); 30.9%, 95.2%, 86.7%, 
57.9%, 63.0% for anti-p53 (chi squared 0.00017), respectively.
Conclusions: All the tested serum markers had low sensitivity (from 30.9% 
to 47.6%) in detectiing cancer, but good specificity, ranging between 95.2% 
and 80.0%. However, the accuracy ranged from 63% to 67%, and thus they 
were not useful for early diagnosis of lung cancer. References: 1. Kumar S 
et al. Plasma nucleosome leves might predict response to therapy in patients 
with advanced non-small.cll lung cancer. Clin Lung Cancer 2010; 11 36-40. 
2. Park Y et al. Usefulness of serum anti-53 antibody assay for lung cancer 
diagnosis. Ach Patol Lab Med 201; 135: 1570–1575.
Disclosure: All authors have declared no conflicts of interest.
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RADIOGRAPHIC SCREENING FOR LUNG CANCER IN 
VARESE, ITALY: COST-EFFECTIVENESS ANALYSIS
A. Imperatori1, P. Pertile2, A. Poli3, N. Rotolo1, M. Castiglioni1, D. Di Natale1, 
W. Mantovani3, M. Paolucci4, A. Paddeu5, L. Dominioni1 1Center for Thoracic 
Surgery, University of Insubria, Varese, ITALY, 2Department of Economics, 
University of Verona, Verona, ITALY, 3Department of Public Health, 
University of Verona, Verona, ITALY, 4Department of Radiology, Ospedale S. 
Antonio Abate, Gallarate, ITALY, 5Respiratory Care Unit, Ospedale S. Anna, 
San Fermo della Battaglia, Como, ITALY
Aim: Screening for lung cancer (LC) has recently been shown to reduce LC 
mortality, however the cost-effectiveness of LC screening in the community 
is uncertain. In the PREDICA project (ISRCTN90639073), an observational 
population-based chest X-ray (CXR) screening that compared the screen-
ing invitees (PREDICA Cohort) to the local reference population receiving 
National Health Service (NHS) usual care (Control Group), we showed that 
screening reduced LC mortality by 18%. The present study analyzes in the 
PREDICA Cohort the cost-effectiveness of CXR screening for LC.
Methods: In the PREDICA project, all smokers of >10 pack-years, 45–75 
years old, resident in 50 communities of the Varese Province, screening-eligi-
ble, in 1997 were invited by their general practitioner to a programme of five 
annual CXR screenings. The entire invitation-to-screen cohort (n=5,815 sub-
jects) received NHS usual care, with the addition of CXR exams in volunteer 
participants (1,244 subjects, 21% of invitees). All invitees (participants and 
nonparticipants) were followed up through December 2006. For each of the 
245 LCs diagnosed in the invitees during the 9.5-year follow-up, and for all 
156 Control Group LCs, survival was divided into 5 periods with specific qual-
ity of life (QoL) indexes obtained from the literature. Cost of all LC-related 
events and interventions was obtained from NHS tariff (year 2012) whenever 
possible, or analytically estimated. Costs and utilities were discounted on a 
monthly basis. Correction for censoring of individuals alive at the end of fol-
low-up was based on the median of non-censored individuals, conditioning on 
the length of survival. Correction for lead time bias was included.
Results: The cost-effectiveness of CXR screening was respectively: 21,588 € 
per Quality-Adjusted Life Year (QALY) for participants vs. controls; 23,865 
€ per QALY for all invitees (participants and nonparticipants) vs. controls. 
These estimates were robust to various assumptions on QoL indexes avail-
able. A probabilistic sensitivity analysis based on Monte-Carlo simulations 
is under way.
Conclusions: The results show that a programme of CXR screening for LC 
should be seriously considered as a potentially cost-effective strategy.
Disclosure: All authors have declared no conflicts of interest.
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THE DESCRIPTIVE EPIDEMIOLOGY OF LUNG 
CANCER: AN INTERNATIONAL COMPARISON 
OF INCIDENCE AND MORTALITY
Z. Zaidi, A. Mahnane, S. Laouamri, M. Hamdicherif Epidemiology, 
University hospital of Setif, Setif, ALGERIA
Aim: The global burden of cancer continues to increase largely because of the 
aging and growth of the world population alongside an increasing adoption of 
cancer-causing behaviors, particularly smoking, in economically developing 
countries. Lung cancer is the leading cancer site in males, comprising 17% of 
the total new cancer cases and 23% of the total cancer deaths. The link between 
tobacco and lung cancer was established more than sixty years ago, smoking 
prevalence is higher in men than women in most countries worldwide. This 
communication presents the latest international descriptive epidemiological 
data for lung cancer, including incidence and mortality in the worldwide.
Methods: Incidence and mortality rates (number of cases or deaths per 
100,000 persons per year) were estimated in GLOBOCAN database (version 
1.2), which presents estimates by country, using the most recently available 
data collected at the International Agency for Research on Cancer IARC for 
2008 and presented on may 2011.
Results: Lung cancer was the most commonly diagnosed cancer as well as 
the leading cause of cancer death in males in 2008 globally. Among females, 
it was the fourth most commonly diagnosed cancer and the second leading 
cause of cancer death.It accounts for 13% (1.6 million) of the total cases and 
18% (1.4 million) of the deaths in 2008. *In males, the highest lung can-
cer incidence rates are in Eastern and Southern Europe, North America, 
Micronesia and Polynesia, and Eastern Asia, while rates are low in sub-
Saharan Africa. *In females, the highest incidence rates are found in North 
America, Northern Europe, and Australia/New Zealand. Despite their lower 
prevalence of smoking (less than 4% adult smokers), Chinese females have 
higher lung cancer rates (21.3 cases per 100,000 females) than those in certain 
European countries such as Germany (16.4) and Italy (11.4), with an adult 
smoking prevalence of about 20%. Very low rates are still estimated in Middle 
and Western Africa (2.8 and 3.1 per 100,000 respectively).
Conclusions: Most lung cancers could be prevented by reducing smoking 
initiation among adolescents and increasing smoking cessation among adults. 
This requires a comprehensive tobacco control program includes raising the 
price of tobacco products through excise taxes, banning smoking in public 
places, restricting tobacco advertising and promotion.
Disclosure: All authors have declared no conflicts of interest.
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THE RISK LEVEL OF CANCER AMONGST 
MEN WHO WERE EXPOSED TO SECOND-
HAND SMOKE AT CHILDHOOD
M.O. Tagbarha Epidemiology, University of Abuja, Abuja, NIGERIA
Aim: To ascertain the level of risk of cancer amongst men severely exposed 
to environmental tobacco smoke at child hood.
Methods: We conducted this study among 1,520 men who were diagnosed 
for lung cancer for a period of 6 years from 2006–2012. We checked hospital 
records at childhood for frequent hospitalization related to tobacco effects 
like middle ear infections, pneumonia, bronchitis and worsened asthma 
conditions.
Results: We were able to show the relationship between exposure to environ-
mental tobacco smoke during childhood and cancer risk. Out of the total num-
ber of participants, 2.5% percent (31 men) had been exposed to environmental 
tobacco smoke (ETS) at childhood. We found that the overall cancer risk was 
greater for individuals with exposures to environmental tobacco smoke dur-
ing both childhood and adulthood than for individuals with exposure dur-
ing only one period. When specific cancer sites or types were considered, it 
was found that leukemia and lymphoma among these men were significantly 
related to exposure to maternal passive smoke before 10 years of age.
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Conclusions: Results of epidemiologic studies including this one provide 
evidence that exposure of children to environmental tobacco smoke is associ-
ated with increased rates of lower respiratory illness and increased rates of 
middle ear effusion, asthma, and sudden infant death syndrome. Exposure 
during childhood to environmental tobacco smoke may also be associated 
with development of cancer during adulthood.
Disclosure: All authors have declared no conflicts of interest.
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EVALUATION OF A TOBACCO CESSATION CLINIC 
IN SOUTH INDIA - WHERE DO WE STAND?
B. Sivanesan1, P. Alagappan2, T. Balaji3 1Medical Oncology, G Kuppuswamy 
Naidu Memorial Hospital, Coimbatore, INDIA, 2Counselling, Coimbatore 
Cancer Foundation, Coimbatore, INDIA, 3Oncology, G Kuppuswamy Naidu 
Memorial Hospital, Coimbatore, INDIA
Aim: India is the second largest consumer of tobacco in the world with an 
estimated 120 million smokers and 75 million smokeless tobacco users. In 
India, the annual deaths from smoking are expected to rise from the present 
930,000 to 1 million during 2010’s. In the west, the effectiveness of smoking 
cessation programmes are well established. Smoking cessation programmes 
are few and far in India. We evaluated a pilot tobacco cessation clinic at a 
tertiary Cancer Care Centre in South India.
Methods: The Tobacco Cessation Clinic was started in November 2009 and 
functions 5 days a week from 9.00AM to 4.00PM. A trained counselor provided 
individual counseling and the medical management was done by a Thoracic 
Medical Oncologist. The programme was evaluated in terms of outcome.
Results: From November 2009 to November 2012, 2906 tobacco users 
attended the Clinic. Out of these, 84% were Cardiac patients, 8% were 
Cardio-thoracic patients, 3% were Pulmonology patients, 2% were Oncology 
patients and 3% were from general population. The Average Fagerstrom 
Addiction Score was 7.5/11. Majority of the tobacco users (93%) were man-
aged by counselling. 5% were treated with Nicotine Chewing gum. Another 
1% with Nicotine patch. 2% were treated with Vermicline. 1960 tobacco 
users were followed up for 6 months. The 7 day point prevalence quit rate 
was 33%. 40% had reduced their level of tobacco use. 26% had relapsed or 
had no change in their habit. The quit rate among the general population was 
only 11%.
Conclusions: Tobacco Cessation Clinic definitely was successful in reducing 
or quitting the tobacco usage. The high quit rates is essentially due to the fact 
that majority of these tobacco users were hospital based and suffered some 
form of morbidity due to tobacco use and were more willing to quit tobacco. 
The quit rate among the general population tobacco users was only11%. We 
plan to increase our coverage of general population by low cost advertise-
ments and improve Quit rates in the general population by more aggressive 
follow up.
Disclosure: All authors have declared no conflicts of interest.
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LEVEL OF AWARENESS OF LUNG CANCER RISK 
FACTORS, SIGNS, SYMPTOMS AND SAFE PRACTICES 
AMONG COLLEGE TEACHERS OF DIFFERENT STATES 
IN INDIA: DO AWARENESS PROGRAMMES HAVE 
AN IMPACT ON ADOPTION OF SAFE PRACTICES?
A. Shankar, G.K. Rath, R. Bhandari, P.K. Julka, K. Kishor Radiation 
Oncology, All India Institute of Medical Sciences, New Delhi, INDIA
Aim: The aim of this study was to determine the impact of awareness pro-
grammes on change in adoption of safe practices in prevention and early 
detection.
Methods: This assessment was part of pink chain campaign on cancer aware-
ness. During the events in 2011- 2013 at various womens colleges in various 
states in India, Pre test was followed by awareness program consisting of 
lectures on preventive aspects of lung cancer with special note of tobacco 
and smoking and an interactive session. Post test using the same question-
naire was conducted at the end of the interactive session. Literatures related 
to cancer awareness were sent regularly for one year to email ids provided. 
After 6 months and 1 year, the same questionnaires were mailed to the par-
ticipants to see the changes in practice. Data were collected and analyzed by 
using statistical software STATA 10.1. P values less than 0.05 were taken as 
significant.
Results: A total of 1257 out of 1346 teachers participated in the study 
(93.38%). The same questionnaire was answered by 1109 and 795 teach-
ers at the end of 6 and 12 months, respectively. Mean age was 42.46 years 
(28–59 yrs). Among teachers, 31.42% were smokers and 35.73% were alco-
holic. Correct risk factors mostly indicated by teachers were smoking (89%), 
Secondhand smoke (37%), and tuberculosis (36%). Lung cancer symptoms 
known to teachers were Persistent cough (24%), hemoptysis (36%), chest pain 
(12%), and voice change (12%). Magazines and newspapers were sources for 
knowledge in 60%, and 30% of teachers were educated by doctors. There was 
a significant increase in knowledge regarding lung cancer at 6 months and 
this was sustained at 1 year with significant changes in smoking and alcohol 
habits. Major reasons not going for checkup were ignorance (50%), lethargic 
attitude (44.87%) and lack of time (34.61%). 3.81% teachers contacted us 
within 1 year for chest complaints. Three teachers (0.23%) were found to be 
positive for cancer, and one for lung cancer.
Conclusions: Knowledge of lung cancer was very low among teachers. 
Though there was significant change in addiction habits, there was not much 
improvement in people undergoing regular check ups. To inculcate safe prac-
tices in the lifestyle of people, awareness programmes such as the pink chain 
campaign should be conducted more widely and frequently. Further, creat-
ing awareness among health care providers is another issue which has to be 
looked into.
Disclosure: All authors have declared no conflicts of interest.
TRANSLATIONAL RESEARCH
38O
PD-L1 AND PD-1 EXPRESSION IN 
MOLECULARLY SELECTED NON-SMALL-
CELL LUNG CANCER (NSCLC) PATIENTS
A. D’Incecco1, M. Andreozzi2, V. Ludovini3, E. Rossi4, L. Landi1, G. Minuti1, 
G. Fontanini5, L. Crinò3, L. Terracciano2, F. Cappuzzo1 1Istituto Toscano 
Tumori, Oncologia Medica, Ospedale Civile, Livorno, ITALY, 2Department 
of Pathology, Basel Hospital University, Basel, SWITZERLAND, 3S.C. 
Oncologia Medica, Ospedale S. Maria della Misericordia, Perugia, ITALY, 
4Oncologia Medica, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy, 
Livorno, ITALY, 5Anatomia Patologica, Azienda Ospedaliera Universitaria 
Pisana, Pisa, ITALY
Aim: The programmed death 1 (PD-1) receptor is an inhibitory T-cell recep-
tor with two known ligands, PD-L1 and PD-L2 (programmed death-ligand 1 
and 2). Aim of the present study was to evaluate PD-L1 and PD-1 expression 
in a cohort of molecularly selected NSCLC patients.
Methods: The study was conducted in a cohort of 125 NSCLC patients, 
including 56 (44.8%) EGFR mutated, 29 (23.2%) KRAS mutated, 10 (8.0%) 
ALK translocated and 30 (24.0%) EGFR/KRAS/ALK wild-type (wt), defined 
as triple negative. PD-L1 and PD-1 expression was assessed by immunohis-
tochemistry (IHC), considering as positive a staining intensity ≥ 2 in more 
than 5% of cells.
Results: PD-L1 was successfully evaluated in 123 specimens and PD-L1 
positive expression was observed in 68 (54.4%) cases. PD-L1 positivity was 
significantly associated with presence of EGFR mutations (p<0.0001), while 
no association was observed with other biomarkers. PD-1 was assessed in 
122 specimens and PD-1 expression was demonstrated in 43 (34.4%) cases. 
PD-1 positive expression was significantly associated with KRAS mutated 
status (p=0.005), while no association was observed with other biomarkers. 
Among the 95 patients treated with gefitinib or erlotinib and evaluable for 
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response, PD-L1 positive (N=49, 51.6%) patients had significantly higher RR 
(61.2% versus 34.8%, p=0.010), significant longer TTP (11.7 months ver-
sus 5.7 months, p<0.0001) and longer OS (21.9 months versus 12.5 months, 
p=0.087) than PD-L1 negative (N=46, 48.4%) patients. In the subset of EGFR 
mutated patients treated with EGFR-TKIs and evaluable for response (N=55), 
PD-L1 positive (N=39, 70.9%) cases showed a longer TTP (13.0 months ver-
sus 8.5 months, p=0.011) and a trend of better OS (29.5 months versus 21.0 
months, p=0.752) than PD-L1 negative (N=16, 29.1%) patients. No differ-
ences in terms of RR, TTP and OS were identified in PD-1 positive versus 
PD-1 negative patients.
Conclusions: Our results suggest a strong correlation between PD-L1 expres-
sion and EGFR mutation and between PD-1 expression and KRAS mutations, 
supporting further investigation of anti-PD-L1 or anti-PD-1 agents in combi-
nation with targeted therapies.
Disclosure: All authors have declared no conflicts of interest.
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ULTRA-DEEP SEQUENCING OF CIRCULATING 
FREE DNA TO IDENTIFY PREDICTIVE, MUTATED 
HSP90 CLIENTS IN GALAXY-1 (NCT01348126), A 
RANDOMIZED PHASE 2B STUDY OF GANETESPIB 
PLUS DOCETAXEL VERSUS DOCETAXEL 
ALONE IN 2ND LINE ADVANCED NSCLC
D. Fennell1, J. Shaw2, I. El-Hariry3, V.M. Vukovic3, V. Reichert4, L.M. 
Martins5 1Thoracic Medical Oncology, University Hospitals of Leicester 
Leicester Royal Infirmary, Leicester, UNITED KINGDOM, 2Cancer Studies 
and Molecular Medicine, University of Leicester, Leicester, UNITED 
KINGDOM, 3Clinical, Synta Pharmaceuticals, Lexington, UNITED STATES 
OF AMERICA, 4Translational Research, Synta Pharmaceuticals, Lexington, 
UNITED STATES OF AMERICA, 5Cell Death Regulation Laboratory, MRC 
Toxicology Unit, Leicester, UNITED KINGDOM
Aim: Inhibition of Hsp90, a key molecular chaperone required for activa-
tion of many oncoproteins critical to NSCLC growth and aggressiveness, can 
lead to cancer cell death. Ganetespib (G) is a 2nd generation Hsp90 inhibi-
tor (Hsp90i) that has shown single agent clinical activity in patients with 
tumors harboring ALK, KRAS, HER2, and BRAF mutations. Circulating 
free DNA (cfDNA) is present at low levels in plasma of healthy individuals 
allowing detection of somatic mutations by deep sequencing. The aim of this 
work was to determine the mutational spectrum of patients enrolled into the 
GALAXY-1 trial using this liquid biopsy strategy.
Methods: Prospective exploratory analysis was performed to identify 
plasma-borne somatic mutations as predictors of clinical outcome with G in 
GALAXY-1. Plasma samples were collected from approximately 318 patients 
with adenocarcinoma at baseline prior to initiation of treatment, during cycles 
1 and 2, and end of treatment. cfDNA samples were evaluated using the Ion 
AmpliSeq™ Cancer Panel on the Ion Torrent |PGM platform to survey 739 
amplicons in 46 cancer genes at up to 6000x depth.
Results: CfDNA targeted sequence analysis reached the quality control 
(QC) threshold in 94% of samples. Analysis of the first 105 patients revealed 
multiple concurrent mutations in HSP90 client proteins. Sequencing of 
DNA from a larger cohort is underway. Longitudinal sampling of plasma 
has been conducted to monitor temporal evolution of the penetrance of 
mutations.
Conclusions: Ultra-deep re-sequencing of multiple somatic mutations in 
circulating cfDNA is feasible, and can be used to identify biomarkers of 
response to G. This represents a new approach to biomarker discovery in the 
context of phase 2 trials. Results of analysis of cfDNA from the large cohort 
enrolled in GALAXY-1 will be presented.
Disclosure: I. El-Hariry: Full-time employee of Synta Pharmaceuticals and 
stock ownership in this company V.M. Vukovic: Synta pharmaceuticals: stock 
ownership and full-time employee V. Reichert: Synta Pharmaceuticals: full-
time employee, stock ownership All other authors have declared no conflicts 
of interest.
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CLINICAL IMPLICATIONS OF RE-BIOPSY IN 
PATIENTS WITH NSCLC HARBOURING EGFR 
MUTATIONS WITH ACQUIRED RESISTANCE 
TO EGFR TYROSINE KINASE INHIBITORS
A. Passaro1, B. Gori2, A. Leone3, P. Graziano3, F. de Marinis1 1Division of 
Thoracic Oncology, European Institute of Oncology, Milan, ITALY, 21st Pneumo-
oncological Unit, Azienda Ospedaliera S.Camillo Forlanini, Rome, ITALY, 
3Pathology Unit, Azienda Ospedaliera S.Camillo Forlanini, Rome, ITALY
Aim: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
(TKIs) are the gold standard for the treatment of patients with advanced or 
metastatic NSCLC harbouring EGFR mutations. Since aquired resistance 
occurs at disease progression (PD), increasing efforts have led to the discov-
ery of counter mutations in EGFR exon 20 and C-MET amplification related 
to molecular resistance. We evaluated the incidence of these mutations in an 
Italian cohort of EGFR mutated NSCLC patients who had a progression dis-
ease after an oral EGFR TKI treatment.
Methods: We evaluated 17 pts, 12 women and 5 men, 15 with adenocarci-
noma and 2 with squamous cell carcinoma. 12 pts had an EGFR exon 19 
deletion and 5 pts a L858R mutation in exon 21. At first progression disease, 
after a TKI therapy, after previous written informed consent, a second biopsy 
was performed on the PD site to reassess the EGFR mutational status and 
c-MET amplification. Exon 20 T790M mutation analysis was performed on 
14 pre-treatment and all post-treatment specimens by direct sequencing while 
c-MET was studied by FISH on 13 rebiopsies. 10 pts received oral TKIs as 
first line treatment, while the other 7 pts in second line.
Results: In the second biopsy specimen the T790M mutation was detected in 
8 pts (47%), while a c-MET specific amplification was identified in 4 of 13 
evaluated pts (31%). In one patient, T790M mutation and c-MET amplifica-
tion were present in a concomitant fashion while 3 pts exhibited a c-MET 
amplification without any T790M alteration. Therefore clinical resistance 
was explained in the present cohort by novel EGFR T790M and/or c-MET 
molecular alterations in 11 assessed patients (65%). In 2 cases the original 
EGFR TKI-sensitive mutation found in the first diagnostic specimen evalu-
ated was not detected on the site of disease progression. We had 1/5 pre-
treatment EGFR T790M mutations defined by Real Time PCR and one of 
the others by direct sequencing. We did not observe any change in histotype.
Conclusions: EGFR T790M mutations and c-MET amplifications are com-
mon in Italian patients treated with oral TKIs that eventually develop drug 
resistance. Since new generation drugs are currently being developed against 
EGFR (irreversible TKIs) or c-MET, a “molecular follow-up” will allow the 
identification of pts eligible for future treatment options.
Disclosure: All authors have declared no conflicts of interest.
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CIRCULATING TUMOR CELLS AS PREDICTOR 
OF RESPONSE TO PLATINUM AND PEMETREXED 
CHEMOTHERAPY IN PATIENTS WITH 
ADVANCED ADENOCARCINOMA OF THE LUNG 
– AN UPDATE ON AN ONGOING STUDY
F. Grossi1, E. Rijavec1, G. Barletta1, C. Sini1, A. Truini1, A. Alama1, M.G. Dal 
Bello1, S. Coco1, M. Truini2, C. Genova1 1Lung Cancer Unit, IRCCS AOU San 
Martino IST - Istituto Nazionale per la Ricerca sul Cancro, Genova, ITALY, 
2Department of Pathology, IRCCS AOU San Martino IST - Istituto Nazionale 
per la Ricerca sul Cancro, Genova, ITALY
Background: Circulating Tumor Cells (CTC) are cells spread from the pri-
mary tumor into the bloodstream; CTC are involved in the development of 
distant metastases and are associated with aggressive disease.The aim of this 
study is to evaluate the correlation between the numeric variation of CTC in 
the blood of patients (pts) with advanced adenocarcinoma (ADK) of the lung 
during chemotherapy (CHT) and the radiological response to explore their 
potential role as early predictor of treatment response.
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Methods: Blood samples and CT-scans were obtained at baseline from pts 
with ADK candidate for first-line CHT with carboplatin or cisplatin and 
pemetrexed. Blood samples and CT-scans were repeated after 2 cycles. 
Radiologic responses were assessed with RECIST 1.1. CTC were collected 
from blood through a filtration-based device (ScreenCell®, Sarcelles France) 
able to isolate and sort CTC by size. CTC were enumerated and characterized 
through H&E stain and immunofluorescence (IF). Radiological variations in 
tumor size were compared with variations in CTC count.
Results: Baseline CTC and CT-scans were obtained from 45 pts; male/
female:28/17, median age:67 years (range:45–81); to date, 20 pts underwent 
evaluation after 2 cycles, while 6 pts died before assessment, and 1 retired 
consent; 18 pts are expected to be assessed within the following weeks. H&E 
revealed that CTC were morphologically compatible with tumor cells and 
they were present in all pts at baseline (range 1–67 CTC/ml); IF showed CK7 
positivity. Two pts achieved partial response (PR), 5 pts showed progres-
sive disease (PD), and 13 pts achieved stable disease (SD) as best response. 
Variation of CTC count was concordant with variation of tumor size in 14/20 
(70%); in particular, reduction in CTC count was observed in 8 pts out of 11 
(73%) with reduced tumor size, while increase in CTC count was observed in 
6 pts out of 9 (67%) with increased tumor size.
Conclusions: This study demonstrates the feasibility of isolating CTC in all 
advanced ADK pts using a size-based low cost technique. The concordance 
between CTC counts and CT-scans suggests that CTC may represent a predic-
tive factor of treatment outcome.
Disclosure: All authors have declared no conflicts of interest.
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GEMCITABINE (GEM) SENSITIVITY-
RELATED GENE MRNA EXPRESSION AND 
CLINICAL OUTCOME IN ADVANCED NON-
SMALL CELL LUNG CANCER (ANSCLC)
G. Ioannidis1, C. Papadaki2, E. Lagoudaki3, E. Tsakalaki2, M. Trypaki2, E. 
Stathopoulos3, D. Mavroudis4, V. Georgoulias4, J. Souglakos4 1Department 
of Oncology, Nicosia General Hospital of Cyprus and Laboratory of Tumor 
Cell Biology, School of Medicine, University of Crete, Heraklion, GREECE, 
2Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, 
Heraklion, GREECE, 3Department of Pathology, University General Hospital 
of Heraklion, Heraklion, GREECE, 4Department of Medical Oncology, 
University General Hospital of Heraklion and Laboratory of Tumor Cell 
Biology, School of Medicine, University of Crete, Heraklion, GREECE
Aim: Gem remains a viable first-line treatment option for aNSCLC, either 
as monotherapy or within combination regimens. We report the updated total 
results of an exploratory study on the potential predictive value of tumor mRNA 
levels of six chemosensitivity-related genes for clinical outcome in this setting.
Methods: By real-time quantitative polymerase-chain reaction, we retro-
spectively analyzed mRNA expression of the human equilibrative nucleo-
side transporter-1, deoxycytidine kinase, cytidine deaminase (CDA), breast 
cancer 1, early-onset, ribonucleotide reductase M1 (RRM1) and M2 (RRM2) 
genes in microdissected, formalin-fixed, paraffin-embedded primary tumor 
specimens from 152 chemonaïve, stage wet-IIIB and IV (UICC 6th TNM edi-
tion) NSCLC patients treated with Gem, either as monotherapy (G) or com-
bined with platinums (GC/Cb), taxanes (GD/P), or vinorelbine (GV) in the 
context of Hellenic Oncology Research Group clinical trials. Relative gene 
expression was quantified by the 2-ΔΔCt method and normalised to β-actin. 
Individual and combined gene-transcription patterns were statistically evalu-
ated for association with clinicopathological features and outcome endpoints.
Results: Patient, tumour, and therapy characteristics were as follows: median age, 
64 years; males, 87%; ECOG performance status 0–1, 89%; stage IV, 71%; ade-
nocarcinomas, 56% and squamous-cell carcinomas, 30%; GC/Cb: 20%, GD/P 
and GV: 71%. Patients with samples successfully amplified for the potentially 
unfavorable genes RRM1, RRM2 and CDA were classified into high- (17%), 
low- (20%) and mixed- (62%) coexpression groups defined by the corresponding 
median mRNA levels. Overall response and disease control rates (DCR) were 
significantly higher for the low- compared to the high coexpression group [48% 
versus (vs) 13%, P=0.003; and 59% vs 33%, P=0.04, respectively]. Likewise, 
median time to progression (TTP) and overall survival (OS) were significantly 
longer for patients in the low coexpression group [6 vs 2.5 months, P=0.03; and 
14.5 vs 5 months, P=0.01, respectively]. mRNA coexpression of the three unfa-
vorable genes was a multivariate independent predictor for DCR, TTP and OS.
Conclusions: Tumor mRNA coexpression profile of RRM1, RRM2 and CDA 
is a potential biomarker for guiding first-line Gem-based therapy in aNSCLC. 
Independent validation is pending.
Disclosure: All authors have declared no conflicts of interest.
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ARE TUMOURAL MICRORNA (MIR) A RELIABLE 
TOOL IN PREDICTING CHEMOSENSITIVITY AND 
PROGNOSIS IN ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)? A PROSPECTIVE STUDY FROM THE 
EUROPEAN LUNG CANCER WORKING PARTY (ELCWP)
T. Berghmans1, L. Ameye2, M. Paesmans2, J. Lafitte3, A. Meert1, A. 
Scherpereel3, I. CsToth1, T. Dernies1, N. Leclercq1, J. Sculier1 1Intensive 
Care and Oncological Emergencies & Thoracic Oncology, Institut Jules 
Bordet, Brussels, BELGIUM, 2Data Centre, Institut Jules Bordet, Brussels, 
BELGIUM, 3Pneumology, CHU Calmette, Lille, FRANCE
Aim: The activity of cisplatin chemotherapy for NSCLC is not individually 
predictable. In a prospective study (Berghmans et al, Lung Cancer 2013), we 
found two signatures predicting either chemosensitivity (predictive, 2 miR) 
either survival (prognostic, 4 miR), in a group of 38 patients treated with 
cisplatin-vinorelbine. We are presenting the results of a validation study.
Methods: We used the same methodology than in the derivation set. The 
biopsy from the primary tumour was lysed into Tripure Isolation Reagent 
(Roche Diagnostics) on ice, snap frozen and stored at -80°C. The expres-
sion of the 6 miR was individually assessed using the same probes and the 
same protocol than with the TaqMan Low Density Arrays (Life Technologies, 
Applied Biosystems) and normalized using the delta delta CT method to 
RNU48 (SNORD48) CT value for every sample. Survival was measured from 
registration date and response by WHO criteria.
Results: Biopsies for miR analysis were obtained from 22 consecutive patients: 
median age 62 years, male/female 17/5, 80–100 Karnofsky PS 17, stage IV 15, 
adenocarcinoma 8. When comparing derivation and validation sets, no statisti-
cally significant differences were observed according to these clinical character-
istics and for response rate (43% vs 41%) or survival (median 25 vs 29 months). 
The difference between responders and non-responders, in mean expression of 
the two-miR from the predictive signature, was not statistically significant (miR-
149, p=0.07 and miR-375, p=0.11). Sensitivity, specificity, positive and negative 
predictive values of the signature were 33%, 77%, 50% and 63%. Among the 
4 miR included in the prognostic signature, only miR424 retained a borderline 
statistical significance for survival (HR 0.66, p=0.05). The 4-miR signature did 
not anymore distinguish patients with poor and good prognosis.
Conclusions: In this prospective study with advanced NSCLC treated with cispla-
tin-vinorelbine, we were not able to reproduce our results in an independent valida-
tion set. The role of miR as predictive or prognostic factor remains questionable.
Disclosure: All authors have declared no conflicts of interest.
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THE IDENTIFICATION OF CIRCULATING MICRO-
RNAS (MIRNA) TO MONITOR TUMOUR BURDEN 
(TB) IN SMALL CELL LUNG CANCER (SCLC)
A. Greystoke1, M. Ayub1, N. Smith1, C. Hodgkinson1, D. Morris1, R. Metcalf1, 
L. Carter1, F. Blackhall2, C. Dive1, G. Brady1 1Clinical and Experimental 
Pharmacology, CRUK Manchester Institute, Manchester, UNITED KINGDOM, 
2Medical Oncology, Christie NHS Trust, Manchester, UNITED KINGDOM
Aim: SCLC is characterized by high metastatic burden, poor prognosis 
and emergence of treatment resistance. Sensitive circulating biomarkers 
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of TB have potential to inform on progression prior to onset of symptoms, 
to aid in identifying novel treatment targets and as pharmacodynamic bio-
markers in early clinical trials. We evaluated miRNA profiling of plasma 
from SCLC patients in order to identify potential biomarkers of TB. Using 
explants derived from patient circulating tumour cells (CTCs) we evalu-
ated the relationship between levels of identified miRNA in the circulation 
and TB.
Methods: miRNAs were extracted from 200μl of plasma from SCLC 
patients (n=16) and healthy volunteers (n=11) and from 10μl of plasma from 
mice bearing xenografts (4 derived from CTCs from SCLC patients and 3 
SCLC cell-lines (H526, H1048, COR-L103)). 754 miRNAs were assessed 
using Taqman Low Density Arrays. Significant miRNAs were identified by 
LIMMA analysis using MEVsoftware.
Results: 43 miRNAs were significantly elevated in patients with SCLC cf to 
healthy controls (28 in a stage specific manner; with extensive stage patients 
having significantly higher levels that patients with limited disease). 30 of 
these miRNAs had not previously been identified as potential biomarkers in 
SCLC. The identified miRNAs were significantly elevated in the circulation of 
mice bearing xenografts compared to non-tumour bearing mice (P<0.0001). 
Serial sampling showed that exemplar miRNAs were detectable in the circula-
tion of mice at an estimated implant size of only 10mm3 and levels mirrored 
the subsequent implant growth curves.
Conclusions: The combination of miRNA profiling of plasma from patients 
and xenograft-bearing mice can identify novel sensitive biomarkers of tumour 
burden in SCLC.
Disclosure: All authors have declared no conflicts of interest.
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DEBIO 1143, AN ORAL ANTAGONIST OF INHIBITOR 
OF APOPTOSIS PROTEINS, ACTIVATES APOPTOSIS 
AND ENHANCES RADIOSENSITISATION OF NON-
SMALL CELL LUNG CANCER CELLS IN VITRO
B. Lu Rad Onc, Thomas Jefferson University, Philadelphia, PA, UNITED 
STATES OF AMERICA
Aim: Resistance to radiotherapy-induced apoptosis is a hallmark of cancer. 
Inhibitors of apoptosis proteins (IAPs) limit the effectiveness of radiation in 
non-small cell lung cancer (NSCLC). Debio 1143 (a.k.a AT-406) is an oral 
antagonist of multiple IAPs (cIAP1/2 and XIAP) currently in early clinical 
development. The purpose of this study was to investigate the potential of 
Debio 1143 as a radiosensitiser in NSCLC.
Methods: HCC193 and H460 NSCLC cell lines were treated with Debio 
1143 to determine the effects of the compound on cell proliferation, apop-
tosis, drug target inhibition, and radiosensitivity. The extent of apoptotic cell 
death was characterised by Western blot for cleaved caspase 3 and 8. TNF-α 
release was determined by ELISA.
Results: HCC193 cells were more sensitive to Debio 1143-induced apop-
tosis than H460 cells with an IC50 of 1 μM and > 20 μM, respectively. 
HCC193 and H460 cells both demonstrated noticeable time-dependent 
cleavage of caspase-3 and -8, and a decrease in IAP levels, the former at 
2.5 μM Debio 1143 and the latter at 10 μM. In HCC193 cells, but not in 
H460 cells, apoptosis occurred via the extrinsic apoptotic pathway, as evi-
denced by dose-dependent TNF-α release. Combining infliximab, an anti-
TNF-α antibody, with 10 μM Debio 1143 increased HCC193 cell viability 
by nearly 3-fold (23% vs. 64% viability). Finally, Debio 1143 significantly 
sensitised both cell lines to radiation, but a higher concentration was neces-
sary for H460 cells.
Conclusions: Debio 1143 significantly enhanced the radiosensitisation of 
HCC193 and H460 cells in vitro. The sensitisation was mediated by TNF-α. 
More research is warranted to understand the mechanism of action of Debio 
1143 and assess its potential in the clinical setting.
Disclosure: B. Lu: This study was supported by Debiopharm.
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ACTIVITY OF IAP ANTAGONIST DEBIO 1143 AS 
A MONOTHERAPY AND IN COMBINATION WITH 
STANDARD OF CARE AGENTS IN MODELS OF HUMAN 
LUNG CANCER OF DIFFERENT HISTOTYPES
N. Wiedemann1, C.G. Langdon2, M.A. Held2, J.T. Platt2, C. Zanna3, M. Sorensen4, 
S. Wang5, M.W. Bosenberg2, D.F. Stern2, G. Vuagniaux1 1Pharmacology & 
Screening, Debiopharm International S.A., Lausanne, SWITZERLAND, 
2School of Medicine, Yale University, New Haven, UNITED STATES OF 
AMERICA, 3Medical Affairs, Debiopharm International S.A., Lausanne, 
SWITZERLAND, 4R&D, Ascenta Therapeutics, Malvern, UNITED STATES 
OF AMERICA, 5Internal Medicine and Pharmacology, Medicinal Chemistry, 
Michigan University, Ann Arbor, UNITED STATES OF AMERICA
Aim: Drug resistance is a major problem in cancer therapy and response to ther-
apy varies between histotypes and within the same histotype. Resistance may be 
overcome by the combination of drugs simultaneously targeting multiple criti-
cal nodes of the signalling networks controlling growth and survival of cancer 
cells. The members of the Inhibitor of apoptosis protein (IAP) family are fre-
quently overexpressed in most cancer types contributing to tumour cell survival 
and resistance to cancer therapy. The oral monovalent IAP inhibitor Debio 1143/
AT-406 is currently in clinical development for cancer treatment. The aim of the 
study was to evaluate the activity of Debio 1143 as a single agent and in drug 
combinations in in vitro and in vivo lung cancer models of different histotypes.
Methods: Drug sensitivity was assessed on 3-D cultures of lung cancer 
patient-derived xenografts (PDX) in clonogenic assays and on human lung 
adenocarcinoma cell lines in cell viability assays. Synergy of drug combina-
tions was assessed using AUC-based analysis or the Chou-Talalay method 
and selected combinations were studied in tumor xenograft mouse models.
Results: As a single agent Debio 1143 showed selective anti-proliferative 
activity in vitro in a majority of PDX of small, large and squamous histology, 
whereas adenocarcinoma-derived PDX and cell lines were less responsive. 
Furthermore, when combined with NSCLC standard of care (SOC) com-
pounds Debio 1143 displayed synergy on human lung adenocarcinoma cell 
lines. Synergy of Debio 1143 combined with docetaxel was further confirmed 
in vivo on mouse xenografts of human adenocarcinoma cell lines where a 
marked anti-tumor activity was observed.
Conclusions: The IAP inhibitor Debio 1143 displays a differential antipro-
liferative activity across 3-D PDX lung cancer models, as well as strong anti-
tumor activity on NSCLC tumor xenografts in mice. These findings provide 
a rationale for the combination of the IAP inhibitor Debio 1143 with SOC 
compounds in different lung cancer histotypes and are the basis for ongoing 
clinical trials in several cancer types.
Disclosure: N. Wiedemann: I am an employee of Debiopharm International 
S.A. C.G. Langdon: This study was sponsored by Debiopharm Internatioinal 
S.A. M.A. Held: This study was sponsored by Debiopharm International S.A. 
J.T. Platt: This study was sponsored by Debiopharm International S.A. C. Zanna: 
Employed by Debiopharm International S.A. M. Sorensen: Employed by 
Ascenta Therapeutics. This study was sponsored by Debiopharm International 
S.A. S. Wang: This study was sponsored by Debiopharm International S.A. 
M.W. Bosenberg: This study was sponsored by Debiopharm International S.A. 
D.F. Stern: This study was sponsored by Debiopharm International S.A. G. 
Vuagniaux: Employed by Debiopharm International S.A.
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ETHNIC DIFFERENCES IN COPPER 
TRANSPORTER CTR1 EXPRESSION AND TISSUE 
PLATINUM CONCENTRATION IN NSCLC
E.S. Kim1, X. Tang2, C. Chow3, J. Fujimoto4, N. Kalhor3, S.G. Swisher5, D.J. 
Stewart6, I. Wistuba2, Z.H. Siddik7 1Wilmot Cancer Center, University of 
Rochester, NY, UNITED STATES OF AMERICA, 2Translational Molecular 
Pathology, MD Anderson Cancer Center, Houston, TX, UNITED STATES 
OF AMERICA, 3Pathology, MD Anderson Cancer Center, Houston, TX, 
UNITED STATES OF AMERICA, 4Thoracic and HN Oncology, MD 
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Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA, 
5Thoracic Surgery, MD Anderson Cancer Center, Houston, TX, UNITED 
STATES OF AMERICA, 6The Ottawa Hospital Cancer Center, The University 
of Ottawa, Ottawa, CANADA, 7Experimental Therapeutics, MD Anderson 
Cancer Center, Houston, TX, UNITED STATES OF AMERICA
Aim: African Americans (AAs) have lower lung cancer survival rates com-
pared to Caucasian Americans (CAs). A recent study using ethnically-defined 
lymphoblastoid cell lines demonstrated that CAs were significantly more 
sensitive to cisplatin compared with AAs. Furthermore, African-American 
ethnicity was independently prognostic of poor tumor response to cisplatin 
in patients with advanced cervical cancer. We previously demonstrated that 
low tissue platinum (Pt) concentration and undetectable CTR1 (a Pt uptake 
transporter) level in NSCLC tumor specimens were significantly associated 
with reduced tumor response following Pt-based therapy. We hypothesized 
that NSCLC specimens from CAs would have higher CTR1 expression level 
and intratumoral Pt concentrations.
Methods: We identified paraffin-embedded NSCLC tissue blocks of known 
intratumoral tissue Pt concentrations from 30 patients who underwent neoad-
juvant Pt-based chemotherapy at MD Anderson Cancer Center. There were 
23 CAs, 6 AAs and 1 Hispanic patient. Expression of CTR1 was determined 
by immunohistochemistry with adequate controls; 0 = undetectable; 1+ = 
barely detectable staining; 2+ = readily appreciable staining; and 3+ = dark 
brown staining. Tissue Pt concentration, CTR1 expression scores and tumor 
response were compared between AAs and CAs.
Results: Intratumoral Pt concentration significantly correlated with tumor 
response in 30 patients who received neoadjuvant Pt-based chemotherapy 
(P<0.0001). CAs had significantly higher CTR1 expression scores (P=0.0002) 
and intratumoral tissue Pt concentrations (P=0.004) compared to AAs. 
Furthermore, CAs had a significantly greater tumor shrinkage compared to 
AAs following neoadjuvant Pt-based chemotherapy (P=0.021).
Conclusions: We report a novel finding that CAs had a significantly higher 
level of CTR1 expression compared to AAs which corresponded with higher 
tumor Pt concentrations and greater tumor response in CAs. Differential 
CTR1 expression may be a contributing factor to ethnic differences in 
response to Pt therapy. A larger study is warranted.
Disclosure: All authors have declared no conflicts of interest.
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CURCUMIN INDUCES CELL CYCLE ARREST AND 
APOPTOSIS BY UPREGULATING P53-INDUCIBLE 
MIR-192-5P/215 IN HUMAN LUNG CANCER
J. Zhang, M. Ye Department of Pulmonary Medicine, Xijing Hospital, Fourth 
Military Medical University, Xian, CHINA
Aim: Non-small cell lung cancer is one of the leading causes of cancer-
related mortality world wide. The overall survival of lung cancer is far from 
satisfactory and it is urgent to explore more efficient and well-tolerated regi-
mens. The medical herb Curcuma longa derived phytomedicine, curcumin, 
has attracted increasing interest as an anti-cancer drug. The mechanisms of 
action for curcumin involve multiple signaling associated with cancer. The 
present study highlighted curcumin can act as an epigenetic agent for miR-
NAs in human lung cancers.
Methods: miRNAs microarray, qPCR, RT-PCR, luciferase reporter gene assay, 
siRNA, transient transfection, flow cytometry, bioinformatics approach and Western 
blot were applied to investigate expressions and functions of indicated miRNAs.
Results: Curcumin exerts cytotoxic effects on H460 and H661 lung cancer 
cells in vitro and in vivo. miRNAs microarray and qPCR indicated miR-
192-5p and miR-215 were the most upregulated miRNAs upon curcumin 
treatment. miR-192-5p/215 exerted anti-cancer effects in terms of cell cycle 
arrest and apoptosis. Antagonizing miR-192-5p/215 abrogated curcumin’s 
efficiency. Curcumin promoted p53 accumulation in H460 and H661 cells. 
p53 knockdown in both cell lines attenuated miR-192-5p/215 upregulation by 
curcumin treatment. Similarly, in the p53 proficient A549 cells, curcumin was 
able to upregulate miR-192-5p/215 expressions. While in H1299 cells, a p53 
deficient lung cancer cell line, curcumin failed to modulate miR-192-5p/215 
expressions. By bioinformatics methods, luciferase reporter assay, RT-PCR 
and Western blot, XIAP was proved to be a target for miR-192-5p/215. 
Curcumin upregulated XIAP in p53-expressing H460, H661 and A549 cells, 
rather than in p53-nonexpressing H1299 cells.
Conclusions: The p53-inducible miR-192-5p/215 acts as crucial mediators 
of curcumin efficiency. The p53-miR-192-5p/215-XIAP axis is an important 
pathway that contributes to curcumin’s anti-cancer activities in lung cancer.
Disclosure: All authors have declared no conflicts of interest.
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SRC INHIBITORS ACT THROUGH DIFFERENT 
MECHANISMS TO COOPERATE WITH EGFR 
OR MEK INHIBITORS IN NSCLC MODELS 
SENSITIVE OR RESISTANT TO ERLOTINIB
L. Raimondo, L. Formisano, R. Rosa, L. Nappi, A. Servetto, R. Marciano, 
V. D’Amato, C. D’Amato, C. Di Mauro, R. Bianco Medicina Clinica e 
Chirurgia, Università degli studi di Napoli Federico II, Naples, ITALY
Aim: The EGFR TKIs gefitinib and erlotinib are the first-line therapy for 
NSCLCs with EGFR-activating mutations. The intrinsic resistance to these 
agents and the onset of acquired resistance in the responders is a relevant 
clinical issue. Although Src TK has been involved in such resistance in pre-
clinical models, clinical development of these agents has been so far limited
Methods: We used human NSCLC cell lines with these characteristics: 
PC9 and HCC827 (EGFR-activating mutation; highly sensitive to erlotinib), 
Calu3 (EGFR/Ras wild-type, wt; moderately sensitive), Calu3-ER (acquired 
resistant), H1299 and A549 (Ras mutant; resistant), H1975 (EGFR T790M 
mutant; resistant). In these cells, we tested three different Src inhibitors (sara-
catinib, dasatinib and bosutinib), both in vitro and in vivo.
Results: NSCLC cell lines showed different activation of EGFR- and Src-dependent 
pathways and variable sensitivity to Src inhibitors. A kinase assay demonstrated that all 
the compounds are able to directly inhibit not only Src, but also EGFR TK variants. 
However, in cell lysates only saracatinib and bosutinib efficiently reduced EGFR activa-
tion, while dasatinib was the more effective agent in inhibiting Src TK. Consistently, 
in EGFR-activating mutant, erlotinib sensitive cells, saracatinib and bosutinib showed 
anti-proliferative effects related to simultaneous EGFR/Src inhibition. In EGFR wt/Ras 
mutant cells Src inhibition by dasatinib interfered with cell proliferation and signal trans-
duction. Since Src inhibitors had only moderate effects as single agents, both in vitro 
and in vivo, we tested the combination of saracatinib with EGFR inhibitors (erlotinib 
or cetuximab) in EGFR-addicted cells, and of dasatanib with MEK inhibitors (selu-
metinib) in Ras mutant, erlotinib resistant models. These combinations were effective 
both in vitro and in nude mice, inhibiting tumor growth, prolonging mice survival and 
interfering with signal transduction. Importantly, the combination of saracatanib and 
cetuximab was effective also in the erlotinib resistant, EGFR T790M mutant model.
Conclusions: Src inhibitors may act with different mechanisms in NSCLC 
cell lines, depending on EGFR/Ras mutational profile. Integration of anti-Src 
agents with EGFR or MEK inhibitors could represent effective therapeutic 
options for different cohorts of NSCLC patients.
Disclosure: All authors have declared no conflicts of interest.
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UTILITY OF THE FOLATE RECEPTOR-SPECIFIC 
IMAGING AGENT 99MTC-ETARFOLATIDE 
IN PREDICTING VINTAFOLIDE THERAPY 
RESPONSE IN VITRO AND IN VIVO
C. Leamon1, J. Reddy2, P. Klein3, I. Vlahov4, M. Vetzel2, A. Bloomfield2, R. 
Dorton2, M. Nelson2 1Research & Development, Endocyte Inc., West Lafayette, 
IN, UNITED STATES OF AMERICA, 2Biology, Endocyte Inc., West Lafayette, 
IN, UNITED STATES OF AMERICA, 3Discovery Biology, Endocyte Inc., 
West Lafayette, IN, UNITED STATES OF AMERICA, 4Discovery Chemistry, 
Endocyte Inc., West Lafayette, IN, UNITED STATES OF AMERICA
Aim: Many epithelial cancers express the folate receptor (FR) – a biomarker 
target for drug development. Vintafolide, a potent folate-targeted vinca 
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alkaloid conjugate, is currently being evaluated in a phase 3 trial in platinum-
resistant ovarian cancer patients and in a phase 2 study for advanced non-
small-cell lung cancer patients. 99mTc-etarfolatide is a folate-based companion 
imaging agent which can non-invasively identify the location of functionally 
active and anatomically accessible FRs in real-time. (Pre)clinical studies have 
demonstrated that response to vintafolide is associated with FR expression; 
therefore real-time screening for FR-positive disease is of high value. The aim 
of these studies was to determine if 99mTc-etarfolatide could predict response 
to vintafolide therapy.
Methods: The pharmacological properties of 99mTc-etarfolatide were evalu-
ated in vitro (cell lines) and in vivo (mouse xenograft models). 99mTc-etar-
folatide’s relative FR binding affinity in tumor cells was determined using 
increasing competitor concentrations of folic acid or vintafolide. BALB/c 
mice bearing subcutaneously inoculated tumor cells were used to examine 
99mTcetarfolatide’s ability to target tumors.
Results: 99mTc-etarfolatide and vintafolide bind the FR with high affinity (K
d
 
~3 nM) in an FR expression-dependent, cell type-independent saturable man-
ner. 99mTc-etarfolatide’s in vivo specificity was demonstrated by i) correla-
tion of 99mTc-etarfolatide’s binding to cells and its accumulation within solid 
tumors to FR expression, and ii) competitively blocking 99mTc-etarfolatide’s 
cell/tissue binding with excess folic acid or vintafolide. Cellular 99mTc-etarfo-
latide uptake correlated to the cytotoxic effect of vintafolide, which could also 
be blocked by excess un-labeled etarfolatide.
Conclusions: These data suggest vintafolide and 99mTc-etarfolatide are dis-
tributed similarly in vivo, FR mediates 99mTc-etarfolatide tissue binding, and 
99mTc-etarfolatide can identify tumors that may respond to vintafolide. This 
novel predictive medicine approach may enable the identification of patients 
likely to benefit from FR-targeted treatment.
Disclosure: C. Leamon: Dr. Leamon owns Endocyte Inc. stock J. Reddy: Dr. 
Reddy owns Endocyte Inc. stock I. Vlahov: Dr. Vlahov owns Endocyte Inc. 
stock M. Vetzel: Dr Vetzel owns Endocyte Inc. stock All other authors have 
declared no conflicts of interest.
51P
GENERATION OF IMMUNOGENIC KILLED 
TUMOR CELLS FOR DENDRITIC CELL-BASED 
LUNG CANCER IMMUNOTHERAPY
I. Adkins, N. Hradilova, L. Sadilkova, I. Truxova, I. Vancurova, L. Sojka, J. 
Palich Fucikova, R. Spisek Research Department, Sotio a.s., Prague, CZECH 
REPUBLIC
Aim: High hydrostatic pressure (HHP) was shown to induce immunogenic 
tumor cell death, which is now believed to be crucial for an effective anti-
tumor response. HHP as a physical cell-inducing modality can be suitable for 
the preparation of immunotherapeutic cancer vaccines
Methods: We tested if HHP induces immunogenic cell death in NSCLC cell lines 
H520 and H522 by measuring cell surface levels of HSP70, HSP90 and calreticu-
lin as well as by detecting the release of HMGB1 and ATP from the dying cells. 
Monocyte-derived DCs were generated in vitro for 3 days in cGMP-compliant media 
X-VIVO 15. DCs were incubated with a mixture of HHP- or UVB light-killed tumor 
cells for 4h and subsequently with or without poly(I:C) for 24h and their capacity to 
mature, migrate and stimulate T cell responses in vitro was compared.
Results: DCs incubated with a mixture of HHP- or UVB light-killed tumor 
cells displayed similar capacity to migrate and express co-stimulatory mole-
cules. However, HHP-treated cancer cells were phagocytosed more efficiently 
and induced higher levels of pro-inflammatory cytokine production in DCs 
than UVB light-treated cells. Even though the low number of T regulatory 
cells in DC-T cell co-cultures was similar, DC+HHP-treated cells induced a 
higher number of IFN-γ-producing T cells than DC+UVB-treated cells sug-
gesting a higher immunogenicity of HHP-treated cells. The immunogenic cell 
death induced by HHP was confirmed by the surface exposure of immuno-
genic markers, HMGB1 and ATP release.
Conclusions: These results showed that HHP, but not UVB light induces 
immunogenic cell death in tested NSCLC cell lines. Furthermore, DC gener-
ated short-term in serum free media are capable of processing HHP-killed 
tumor cells and stimulate T cell responses. This optimized protocol might be 
used for the development of a DC-based immunotherapy for NSCLC.
Disclosure: All authors have declared that “The research is performed at and 
sponsored by Sotio a.s, in cooperation with the University Hospital Motol, 
2nd Medical Faculty, Charles University, Prague. All the co-authors are 
employees of Sotio a.s.”
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GENETIC VARIATION OF BCL3 IS ASSOCIATED 
WITH FIVE-YEAR SURVIVAL OF NSCLC PATIENTS
F.D. Dimitrakopoulos1, A.G. Antonacopoulou1, A.E. Kottorou1, D. Dougenis2, 
C. Scopa3, H. Papadaki4, H. Kalofonos1 1Molecular Oncology Laboratory, 
Division of Oncology, Department of Internal Medicine, Medical School, 
University of Patras, Patras, GREECE, 2Department of Cardiothoracic 
Surgery, Medical School, University of Patras, Patras, GREECE, 3Department 
of Pathology, Medical School, University of Patras, Patras, GREECE, 
4Department of Anatomy, Medical School, University of Patras, Patras, 
GREECE
Aim: BCL3 is an atypical member of the IκB family and it has been found to be 
overexpressed in hematological malignancies and in some solid tumors, playing a 
pivotal role in tumor initiation and progression. A tag single nucleotide polymor-
phism of BCL3 (SNP; rs8100239, T>A) has been identified recently but there are 
no data relating to its role in non-small cell lung cancer (NSCLC) development.
Methods: To investigate the role of BCL3 in NSCLC, we genotyped the 
rs8100239 in 281 patients and 279 controls and we retrospectively assessed 
BCL3 expression in 112 NSCLC specimens by immunohistochemistry.
Results: NSCLC patients with AA genotype were observed to have significantly 
worse prognosis compared with T allele carriers (p<0.001) and to have higher 
nuclear BCL3 protein levels (p=0.042). In addition, BCL3 was found to be over-
expressed in tumour tissue compared with normal tissue (p<0.001). Furthermore, 
BCL3 expression was associated with the grade (p=0.013), the relapse rate (p=0.05) 
and tumor’s primary location (p=0.045) and maximum diameter (p=0.012).
Conclusions: The present study represents the first quantitative evaluation of 
BCL3 expression in NSCLC and the first report which relates genetic varia-
tion of BCL3 with survival outcome in cancer patients. Our data suggest 
rs8100239 may be a novel prognostic indicator. Also, our results demonstrate 
the deregulation of BCL3 protein in NSCLC, implicating this central mol-
ecule in pathogenesis of NSCLC.
This research has been co-financed by the European Union (European Social 
Fund – ESF) and Greek national funds through the Operational Program 
“Education and Lifelong Learning” of the National Strategic Reference 
Framework (NSRF) - Research Funding Program: Heracleitus II. Investing in 
knowledge society through the European Social Fund.
Disclosure: All authors have declared no conflicts of interest.
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TARGETING ER-GOLGI HOMEOSTASIS IS AN 
ADVANTAGEOUS THERAPEUTIC STRATEGY IN LUNG 
CANCER: SYNERGISTIC INTERACTION OF HSP90 
ANTAGONIST AND PROTEASOME INHIBITOR
M. Gottfried1, L. Drucker2, V. Zismanov3 1Oncology, Meir Medical Center, 
Kfar Saba, ISRAEL, 2Oncogenetic Laboratory, Meir Medical Center, Kfar 
Saba, ISRAEL, 3Lung Cancer Research Laboratory, Meir Medical Center, 
Kfar Saba, ISRAEL
Aim: Lung cancer remains the most common cause of cancer-related death 
worldwide. This malignancy is a complex disease, and it is important to 
identify potential biological targets, the blockade of which would affect 
multiple downstream signaling cascades. A growing number of reports rec-
ognize novel therapeutic targets in the protein homeostasis network. These 
include the heat shock protein 90 (Hsp90) essential to posttranslational fold-
ing and maturation of multiple oncogenic kinases, and the proteasome that 
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orchestrates the turnover of innumerable cellular proteins. Previous studies 
demonstrate that targeting Hsp90 or the proteasome separately has anti-
non small cell lung cancer (NSCLC) activity. Here, we explored whether 
combined administration of Hsp90 and proteasome inhibitors promotes the 
anti-NSCLC activity of the drugs by augmenting disruption of ER-Golgi 
homeostasis.
Methods: NSCLC cell lines (A549, H1299, H460) were treated with 
17-DMAG (Hsp90 inhibitor), Velcade (proteasome inhibitor) and both drugs 
simultaneously for 24 hours. Cells were harvested and analyzed for ER stress 
markers (Immunoblot), viability (WST1 assay), motility (Scratch assay), and 
death (Flow cytometer).
Results: Our results demonstrate that co-administration of 17-DMAG and 
Velcade induced significantly elevated ER stress (BiP: <160%, CHOP: 
<900%, pJNK: <125%, ATF-6: <70%). The anti-NSCLC activity of the drug 
combination was also evident in decreased lung cancer cell lines motility (85–
100%, p<0.05), viability (20–40%, p<0.05), cell count (50–60%, p<0.05), 
and synergistically increased apoptotic cell death (7–28%, p<0.05).
Conclusions: Our findings provide proof-of-concept that targeting several 
facets of ER-Golgi homeostasis concurrently is therapeutically beneficial in 
lung cancer cell lines.
Disclosure: All authors have declared no conflicts of interest.
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TELOMERE LENGTH, TELOMERASE ACTIVITY 
AND DAPK1 EXPRESSION, NEW MARKERS FOR 
PROGNOSIS IN NON-SMALL CELL LUNG CANCER
T. Fernández1, I. Pascua1, C. de Juan1, J. Head1, A. Gómez2, J.R. Jarabo2, 
E. Fernández3, M. Benito4, P. Iniesta1, F. Hernando2 1Biochemistry and 
Molecular Biology II, Faculty of Pharmacy, Complutense University and 
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IDISSC), 
Madrid, SPAIN, 2Servicios de Cirugía General y Torácica and Instituto de 
Investigación Sanitaria del Hospital Clínico San Carlos (IDISSC), Hospital 
Clínico San Carlos, Madrid, SPAIN, 3Thoracic Surgery, Hospital Clínico San 
Carlos, Madrid, SPAIN, 4Biochemistry and Molecular Biology II, Faculty of 
Pharmacy, Complutense University and Instituto de Investigación Sanitaria 
del Hospital Clínico San Carlos (IDISSC), Madrid, SPAIN
Aim: The essential role that telomeres and telomerase play in cancer makes 
them an important objective in the field of molecular oncology. Our aim in this 
work consists of analysing the prognostic role of telomere length and telom-
erase activity in non-small cell lung cancers (NSCLCs). Moreover, consider-
ing previous results[1] and its potential as an important downstream target of 
Src kinase inhibitors (bosutinib, dasatinib)[2], we evaluated the expression of 
death-associated protein kinase 1 (DAPK1), in relation to telomere status. [1] 
Oncology 82, (2012). [2] FEBS Journal 277, (2010).
Methods: We analyzed 203 NSCLCs, and their corresponding control sam-
ples, obtained from patients submitted to surgery at San Carlos Hospital, 
Madrid. Survival analyses were performed by the Kaplan-Meier method and 
differences were evaluated with the Log-Rank test. The primary outcome 
used was Disease-Free Survival. Telomerase activity and telomere length 
were established in cancer tissues and control samples. The ratio of telomere 
length in cancer to control tissue was defined as T/N ratio. DAPK1 expression 
was determined by real time quantitative PCR and Western-blot. SPSS 19 was 
used for statistical analyses, and Cutoff Finder web application to determine 
optimal cut-off values.
Results: Regarding survival analysis, patients whose tumours showed a telo-
mere length < 7.29 or T/N ratio < 0.97 had a significantly poor clinical evolu-
tion (P = 0.034 and 0.040, respectively, Log-Rank). In multivariate analysis, 
both parameters proved to be independent prognostic markers. Kaplan-Meier 
curves showed that telomerase activity resulted in a predictor of poor clinical 
outcome (P = 0.028, Log-Rank). A significant association was found between 
telomere status and DAPK1 expression (P = 0.048; Mann-Whitney): tumours 
with the shortest telomeres exhibited a significantly diminished expression of 
DAPK1 mRNA. DAPK1 protein expression correlated with mRNA levels, as 
we confirmed by Western-blot.
Conclusions: Telomere length and telomerase activity represent prognostic 
markers in NSCLC. DAPK1 may be a new target in NSCLC therapy, in rela-
tion to telomere status.
Disclosure: All authors have declared no conflicts of interest.
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MED12 AND STAT3 INFLUENCE OUTCOME 
TO PLATINUM-BASED CHEMOTHERAPY 
IN PATIENTS (P) WITH ADVANCED NON-
SMALL-CELL LUNG CANCER (NSCLC)
D. Morales-Espinosa1, N. Karachaliou2, C. Costa2, M.Á. Molina3, A. Gimenez-
Capitán2, J.J. Sánchez4, B. Massuti5, L. Bonanno6, M. Majem7, R. Rosell8 
1Translational Research Laboratory, Institut Catalá d’Oncologia, Badalona, 
SPAIN, 2Translational Research, RNA Unit, Pangaea Biotech, Barcelona, SPAIN, 
3Translational Research, Pangaea Biotech, Barcelona, SPAIN, 4Department of 
Preventive Medicine, Facultad de Medicina,, Universidad Autónoma de Madrid, 
Madrid, SPAIN, 5Departamento de Oncología, Hospital General Universitario de 
Alicante, Alicante, SPAIN, 6Second Medical Oncology Unit, Istituto Oncologico 
Veneto IRCCS, Padova, ITALY, 7Oncología Médica, Hospital de la Santa Creu 
i Sant Pau, Barcelona, SPAIN, 8Medical Oncology Service, Catalan Institute of 
Oncology, Hospital Germans Trias i Pujol, Badalona, SPAIN
Aim: To examine MED12 – a negative regulator of the TGF-b receptor signaling 
-, IDO, IL6, RelA (NFkB), BIM and the JAK2/STAT3 pathway and KRAS in 
NSCLC tumor samples and correlate results with progression-free survival (PFS).
Methods: The mRNA expression of MED12, IDO, JAK2, STAT3, RelA and 
BIM was examined in microdissected tumor samples from p with stage IV 
NSCLC. mRNA levels were assessed by RT-PCR and categorized by terciles 
(high vs low/intermediate). KRAS mutations were assessed by high resolu-
tion melting.
Results: A total of 55 p with performance status (PS) 0–1, treated with platinum 
plus either gemcitabine or pemetrexed: median age, 62 years; 27.6% females; 
84.2% smokers; 66% adenocarcinoma; 16% with KRAS mutations. There was 
no correlation between gene expression levels and KRAS mutation status. In the 
multivariate analysis, including gene expression levels, histology and PS, only 
MED12 and STAT3 were associated with PFS (low MED12: HR=11.6, P=0.005; 
high STAT3: HR=6.5, P=0.01). HR for low BIM expression was 2.4 (P=0.16). 
None of the markers were associated with overall survival.
Conclusions: To the best of our knowledge, this is the first time that low expres-
sion of MED12 with significantly shorter PFS in NSCLC p receiving platinum-
based chemotherapy. MED12 could be a new biomarker of chemoresistance and 
inhibition of TGF-bR signaling can restore chemotherapy response in patients 
with low MED12.
Disclosure: All authors have declared no conflicts of interest.
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ENHANCED EFFECT OF CYTOTOXIC DRUGS IN 
THE TREATMENT OF LUNG CELLS CANCER
A.R. Rama Ballesteros, P.J. Alvarez, R. Luque, J.R. Delgado, J.C. Prados, C. 
Melguizo, R. Maddedu, A. Aranega Biomedicine Regenerative, Institute of 
Biopathology and Regenerative Medicine (IBIMER), Granada, SPAIN
Aim: The potential use of combined gene therapy is under intensive study to 
improve the effectiveness of these cytotoxic agents and reduce their adverse 
effects. In this context, the association of the cytotoxic drugs with killer 
genes could enhance their antiproliferative effect. The gene E from ΦX174 
encodes for a membrane protein with a toxic domain which causes cell lysis. 
To improve the antitumoral effect of some classical citotoxic agents we inves-
tigated a combined suicide gene therapy on A-549 cells (lung cancer).
Methods: The gene E was cloned into the plasmid pcDNA3.1 (pcDNA3.1-E) 
and the lung carcinoma cell line A-549 were grown in monolayer. Experiments 
were performed in two groups:
- Gene E alone: A-549 transfected (pcDNA3.1-E).
S25Copyright © 2014 by the European Lung Cancer Conference organisers, ESMO, and IASLC.
Journal of Thoracic Oncology ®  •  Volume 9, Number 4, Supplement 1, April 2014 Abstracts
- Combined gene therapy: A-549 transfected and non-transfected cells were 
exposed to Paclitaxel (Pac), Carboplatin (Car) and Gemcitabine (Gem), all of 
them to 100, 50 and 1 μM concentration.
We evaluated the effect of gene E and its combination with the cytotoxic 
drugs by several techniques.
Results: Our results showed that the E expression in A-549 cells carried to 
ultrastructural changes, including dilated mitochondria. These findings were 
corroborated with a significant decrease in mitochondrial transmembrane 
potential (p<0.05).
On the other hand, assays with combined therapy showed that effect of the 
drugs at all different concentration was enhanced by gene E expression. Pac 
induces the greater inhibition of the proliferation, showing at the average con-
centration and transfecting 3 times 85% of growth inhibition, just as the ther-
apy only with Pac to the maximum concentration. Parental and cancer cells 
treated with combined therapy or with citotoxic or gene E separately were 
analysed by FACscan after anexin-PI staining. The results indicated the ability 
of gene E to stimulate apoptosis in A-549 treated with their respective drugs.
Conclusions: In conclusion, gene E has a killer effect in A-549 lung cancer 
cells which enhances growth inhibition cell when used with citotoxic drugs. 
That suggests a possibility to reduce the dose of cytotoxic agents applied 
in the tumours. These results indicate that this combined therapy may be of 
potential therapeutic value in lung cancer.
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MUCIN 1 (MUC1) EXPRESSION IN PATIENTS (PTS) 
WITH EARLY STAGE NON-SMALL CELL LUNG 
CANCER (NSCLC): RELATIONSHIP BETWEEN 
IMMUNOHISTOCHEMISTRY (IHC) IN PRIMARY 
TUMOUR AND PLASMA SOLUBLE MUC1 (SMUC1) LEVEL
P.L.R. Mitchell1, K. Asadi2, T. John1, C. Murone3, S. Knight4 1Ludwig Medical 
Oncology Unit, Olivia Newton-John Cancer and Wellness Centre, Austin 
Health, Melbourne, AUSTRALIA, 2Anatomical Pathology, Austin Health, 
Melbourne, AUSTRALIA, 3Anatomical Pathology, Austin Health and 
Ludwig Institute for Cancer Research, Melbourne, AUSTRALIA, 4Thoracic 
Surgery, Austin Health, Melbourne, AUSTRALIA
Aim: MUC1, a glycoprotein highly expressed in many malignancies, is 
being explored as an antigen for immunotherapy. Although MUC1 expres-
sion on IHC is very frequent In NSCLC (Mitchell et al. Proc ASCO 2013, 
abs 3011) and circulating sMUC1 may be elevated, the relationship has 
been poorly studied. This study explored the relationship between MUC1 
IHC and plasma sMUC1 in patients undergoing lobectomy or pneumonec-
tomy for NSCLC.
Methods: Tissue Micro Arrays (TMAs) were constructed using triplicate 
1mm cores of FFPE primary tumour and stained with 214D4 (recognises pro-
tein core) anti-MUC1 antibody. TMAs were assessed for polarisation, both 
cytoplasmic and membranous staining intensity (scored 0–3) and proportion 
cells +ve (0–100%; scored 0 – 5), averaged for multiple cores. A composite 
score (intensity x cells +ve) was derived, ranging from 0 – 15 (3+ in >75% 
cells). Plasma obtained prior to surgery was analysed for sMUC1 (CA15-3) 
using the Cobas kit.
Results: Of 39 pts analysed. most were adenocarcinoma (26) with 8 squamous 
and 5 other. There were 21 stage 1, 10 stage 2, 7 stage 3 and 1 stage 4 (brain 
metastasis). Tumours from 36 pts (92%) stained with 214D4 with a mean com-
posite score of 9.25 and median 10. Of tumours staining, 20 (56%) were depolar-
ised and 16 (44%) polarised. sMUC1 ranged from 5.9 – 60.7 KU/L, with 9 cases 
(23%) elevated (> 25 KU/L). The mean and median IHC scores for those with 
elevated sMUC1 were 9.3 and 10.0, compared with 9.23 and 10.5 respectively 
for those without elevated sMUC1. There was no clear relationship between 
elevated sMUC1 and histology, stage or primary tumour diameter. However 8/9 
(89%) of those with elevated sMUC1 had depolarised IHC staining compared 
with 12/27 (44%) without elevated sMUC1 (p=0.026, Fisher’s exact test).
Conclusions: Of 39 surgical resection cases, 92% stained for MUC1 while 
9 had elevated plasma sMUC1 levels. No relationship was seen between 
elevated sMUC1 and the presence or degree of MUC1 IHC staining. However 
cases with depolarised MUC1 IHC were significantly more likely to have ele-
vated sMUC1. A depolarised pattern of expression has been previously shown 
to be associated with poor survival in adenocarcinoma (Mitchell 2013). In this 
ongoing study, data on additional cases will be presented along with survival 
analysis.
Disclosure: All authors have declared no conflicts of interest.
58P
LUNG CANCER ABLATION BY USING LUNG 
FLOODING AND THERAPEUTIC ULTRASOUND- 
A NEW PARENCHYMA SPARING APPROACH
F. Wolfram, T. Lesser Thoracic and Vascular Surgery, SRH Waldklinikum 
Gera, Gera, GERMANY
Aim: For inoperable patients alternative thermal interventions (RF) have 
been explored. Those require invasive applicator insertion with a consid-
erable complication rate and are applied for palliation only. Treatment 
of lung cancers and metastases would benefit from minimal-invasive, 
no-touch ablative principles. Unilateral lung flooding enables intra-oper-
ative ultrasound guidance while the non-flooded lung maintain ventila-
tion (TLV). Our work showed it’s safety and stability of surfactant levels. 
Therapeutic Ultrasound (HIFU) as a non invasive ablation technique heat 
embedded cancer without damaging the overlying parenchyma. Recently 
our work showed that ultrasound guidance and the physical conditions in 
flooded lung are superior for HIFU ablation of NSCLC. This data’s dem-
onstrate the usability of minimal-invasive NSCLC ablation on human ex 
vivo and in vivo large animal models.
Methods: Human lung lobes containing NSCLC were flooded with saline 
following intra-surgical atelectasis. Ex-vivo ultrasound images were 
acquired. HIFU was applied into centrally located cancer tissue under 
temperature monitoring. Ablated lung cancer tissue were histological 
analyzed (HE, NADPH). Unilateral lung flooding was performed on pigs 
(“Deutsches Landschwein” 28-33Kg) with permission of the federal eth-
ics committee (TLLV). HIFU was applied trans-thoracic into central tissue 
mimicking targets. Vital parameters (HR, SO2, pCO2) and lesion tem-
perature was monitored. Flooding was maintained for 90 minutes before 
re-ventilation.
Results: In all animals, lung flooding was performed without remaining gas 
content. Vital parameters stayed inside physiological range (HR 45–91 bpm / 
SO2 (85–100%)/ pCO2 (30-63mmHg)). Temperature rose up to 60°C in cen-
tral lung lesion. NSCLC could be visualized and disciminated from flooded 
parenchyma by ultrasound. In targeted cancer temperature reached 80–85°C, 
in parenchyma only 40–45°C. HE stain show areas of thermal necrosis while 
NADPH stain confirmed loss of vitality in targeted NSCLC.
Conclusions: NSCLC can be radically ablated by therapeutic Ultrasound 
without applicator insertion and loss of functional parenchyma. HIFU abla-
tion under flooded lung is feasible and could lead to a potential treatment 
option for inoperable patients and demands further research.
Disclosure: All authors have declared no conflicts of interest.
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ALTERNATIVE METHODS OF PET-CT 
INTERPRETATION: CAN WE IMPROVE MEDIASTINAL 
NODAL STAGING IN LUNG CANCER PATIENTS?
M. Evison1, P. Crosbie2, J. Martin1, P. Barber1, R. Booton2 1North West 
Lung Centre, University Hospital South Manchester, Manchester, UNITED 
KINGDOM, 2University of Manchester, Institute of Inflammation and Repair, 
Manchester, UNITED KINGDOM
Aim: In the absence of distant metastases, lymph node staging becomes the 
pivotal factor in determining treatment and prognosis for lung cancer patients. 
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The sensitivity of PET-CT for nodal staging remains sub-optimal. Using a dif-
ferent SUV ‘cut-off’ value to define a positive lymph node (traditionally 2.5) 
or using the ratio of the lymph node SUV compared to the primary tumour 
SUV may provide more clinically relevant information.
Methods: This prospective observational study included all lung cancer 
patients referred to the University Hospital South Manchester Hospital for 
EBUS-TBNA nodal staging, whom also underwent PET-CT during their stag-
ing work-up. Lymph node SUV (LN-SUV), the ratio of lymph node SUV 
to primary tumour SUV (LN:PT-SUV) and the final lymph node diagnosis 
(benign versus malignant) was recorded for every lymph node sampled. ROC 
curves were produced and used to define the most appropriate ‘cut-off’ values 
for LN-SUV and LN:PT-SUV.
Results: 354 patients with primary lung cancer underwent EBUS-TBNA 
nodal staging and PET-CT imaging in the study period. The mean age was 
69.9 (SD +/-9.4). In total, 566 lymph nodes were sampled. 62.5% (354/566) 
of lymph nodes were ultimately proven to be malignant. The mean LN-SUV 
for benign lymph nodes was 3.0 (SD +/-1.3) compared to 10.4 (SD +/-6.1) 
for malignant nodes. The area under the curve was 0.941. Using a LN-SUV 
‘cut-off value’ of >4.0 to indicate nodal metastases, the specificity was 88.2%, 
sensitivity 90.9%, PPV 92.7% and NPV 84.2%. The mean LN:PT-SUV for 
benign lymph nodes was 26.4% (SD +/-19.2%) compared to 93.6% (SD 
+/-54.8%) for malignant nodes. The area under the curve was 0.933. Using 
a LN:PT-SUV ‘cut-off’ of >40% to indicate nodal metastases the specificity 
was 86.3%, sensitivity 91.0%, PPV 91.7% and NPV 85.1%.
Conclusions: In lung cancer patients, LN-SUV and LN:PT-SUV are highly 
effective at predicting lymph node metastases using a cut-off of >4.0 and 
>40% respectively to indicate malignancy. This should not, however, replace 
pathological nodal staging as approximately 10% and 15% of patients would 
be over-staged and under-staged respectively. The most clinically relevant 
use of these alternative PET-CT interpretation methods may be in classify-
ing which patients need further surgical nodal staging following a negative 
EBUS-TBNA.
Disclosure: All authors have declared no conflicts of interest.
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EVALUATING THE POTENTIAL OF 99MTC-
ETARFOLATIDE TO SELECT NSCLC PATIENTS LIKELY 
TO BENEFIT FROM VINTAFOLIDE TREATMENT
W. Harb1, P. Bonomi2, J. Symanowski3, B. Nguyen4, M. Edelman5 1Horizon 
Oncology Research Inc., Lafayette, IN, UNITED STATES OF AMERICA, 
2Hematology/oncology, Rush University Medical Center, Chicago, IL, 
UNITED STATES OF AMERICA, 3Cancer Biostatistics, Levine Cancer 
Institute, Carolinas Healthcare System, Charlotte, NC, UNITED STATES OF 
AMERICA, 4Medical Affairs, Endocyte Inc., West Lafayette, IN, UNITED 
STATES OF AMERICA, 5Cancer Center, University of New Mexico Cancer 
Center, Albuquerque, NM, UNITED STATES OF AMERICA
Aim: Folate receptor (FR) is expressed in non-small cell lung cancer (NSCLC) 
tumors, making it potentially useful as a biomarker and a therapeutic target. 
Vintafolide is a potent drug conjugate of folic acid and the vinca alkaloid 
desacetylvinblastine hydrazide. 99mTc-etarfolatide, a technetium bound folate 
molecule, allows for full body, real-time, SPECT imaging of FR. These two 
companion agents are being co-developed. This study aimed to evaluate the 
ability of 99mTc-etarfolatide imaging to identify FR expression in NSCLC 
patients’ tumors and to correlate this with response to vintafolide.
Methods: In a phase 2 study (NCT00511485), FR expression in NSCLC tar-
get lesions was assessed by 99mTc-etarfolatide uptake. Patients were catego-
rized as FR(100%) (all target lesions FR positive, n=14) and FR(10−90%) 
(≥10%, but ≤90%, target lesions FR positive, n=14). Patients received vin-
tafolide (IV bolus) in an induction phase (1.0 mg, days 1−5/8−12/15−19 of 
4-week cycles, 2 cycles), followed by a maintenance phase (2.5 mg, days 
1/3/5/15/17/19 of 4-week cycles). Up to 8 cycles of therapy could be received. 
Patients with tumor shrinkage could continue treatment until clinical benefit 
ceased (defined as 2 sequential scans with stable disease).
Results: Median progression-free survival was 31.1 weeks in FR(100%) vs 
7.3 weeks in FR(10–90%) patients (hazard ratio [HR] = 0.326; p = 0.014). 
Median overall survival was longer in FR(100%) patients (47.2 vs 14.9 weeks; 
HR = 0.539; p = 0.101). Tumor response and stabilization were also greater 
in FR(100%) patients (response rate 7.1% vs 0%; disease control rate 57.1% 
vs 14.3%). Both agents were generally safe and well tolerated. Drug related 
adverse events were reported in 3.3% of 99mTc-etarfolatide-treated patients 
(all grade 1/2) and 83.7% of vintafolide-treated patients (14.0% grade 3, no 
grade 4), most commonly fatigue, constipation, nausea, and anorexia.
Conclusions: These data support the potential utility of 99mTc-etarfolatide 
in identifying patients most likely to benefit from vintafolide. An ongoing 
randomized phase 2 study (TARGET) will determine the predictive versus 
prognostic value of this approach
Disclosure: P. Bonomi: Dr Bonomi has received support from Endocyte Inc 
to perform the clinical trial. J. Symanowski: Dr Symanowski has been a con-
sultant for Endocyte Inc. B. Nguyen: Dr Nguyen owns Endocyte Inc. stock M. 
Edelman: Dr Edelman has been a member of an advisory board for Endocyte 
Inc. and has performed research sponsored by Endocyte Inc. All other authors 
have declared no conflicts of interest.
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THE PROVISION OF EBUS-TBNA SERVICES ACROSS 
A UK LUNG CANCER NETWORK; A REPORT FROM 
THE GREATER MANCHESTER AND CHESHIRE 
LUNG CANCER NETWORK EBUS SUB-GROUP
M. Evison1, P. Crosbie1, J. Martin1, P. Barber1, R. Booton2 1North West 
Lung Centre, University Hospital South Manchester, Manchester, UNITED 
KINGDOM, 2Institute of Inflammation and Repair, University of Manchester, 
Manchester, UNITED KINGDOM
Aim: Given the variability in lung cancer outcomes across the UK and the 
explosion of EBUS-TBNA services in recent years, there is a need to ensure 
timely and equitable access to quality assured EBUS-TBNA services for lung 
cancer patients. This report describes how a large cancer network in England 
is taking steps towards achieving this aim.
Methods: The Greater Manchester and Cheshire Cancer Network (GMCCN) 
is made up of eleven NHS trusts. In 2012 the number of EBUS-TBNA ser-
vices increased from one to four. This prompted the formation of a GMCCN 
EBUS sub-group committee and subsequently an EBUS service specification. 
This mandated the collection of pre-defined data for every EBUS-TBNA pro-
cedure performed. This data collection then allows patient pathways, compli-
cations and performance data to be analysed at both a network and individual 
service level.
Results: From the 1st January 2012 to 30th September 2013 756 patients with 
lung cancer underwent EBUS-TBNA. 56.2% (425/756) of procedures were 
for nodal staging with the remainder being performed for pathological diag-
nosis. The average time from referral to procedure was 7.4 days (SD +/-4.9) 
and 75.2% of patients wait 9 calendar days or less. There were 6 major com-
plications from EBUS-TBNA (0.7%) and 45 minor complications (5.9%). 
From 1st January 2012 to 30th April 2013 (to allow 6 months of follow-up) a 
total of 894 lymph nodes were sampled by EBUS-TBNA, from 406 patients, 
at three centres. One centre did not submit any lymph node outcome data. 
Overall, 5.5% (49/894) of lymph nodes were sampled inadequately, 494 
lymph nodes were proven malignant and 321 were deemed negative. 47/321 
were subsequently proven to be false negatives. The overall sensitivity (when 
inadequate samples are classified as false negative) and NPV of EBUS-TBNA 
was 83.7% and 85.4% respectively.
Conclusions: There is clearly work to be done in improving both the com-
pleteness of data submission and the outcome measures across this cancer 
network. Furthermore, the number of patients undergoing pathological nodal 
staging with EBUS-TBNA appears low and requires more detailed investiga-
tion. However, this represents a step in the right direction and ongoing mea-
surement and publication of performance should help to drive improvements 
in these outcomes.
Disclosure: All authors have declared no conflicts of interest.
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PERCUTANEOUS CT-GUIDED BIOPSY FOR 
DIAGNOSIS OF LUNG AND MEDIASTINAL LESIONS
Y. Ragulin, V. Usachev Thoracic, Medical Radiological Research Center, 
Obninsk, RUSSIAN FEDERATION
Aim: The aim of study is the determination of the diagnostic value of trans-
thoracic biopsy under the computer tomography. To compare the diagnostic 
efficacy of percutaneous aspiration and core biopsy intrathoracic lesions.
Methods: From 2007 to 2012 transthoracic needle biopsy under CT con-
trol in 107 patients were performed. Lesions size was 10 x 10 mm to 200 
x 87 mm (mean 49.6 x 38.7 mm). To fine-needle aspiration biopsy (FNAB) 
used needle diameter 20G. Core needle biopsy was performed, representing a 
trocar, which is held inside a stiletto with a split end, allowing you to capture a 
piece of tissue is sufficient for histological examination (diameter 14G, length 
100 mm). This technique allows to obtain material for cytology.
Results: In 4 cases a puncture failed. The diagnosis of malignant lung tumor 
delivered in 80 pts out of 107. FNAB made 34 pts. Final diagnosis: cancer - in 
24 pts, non-neoplastic process - in 10. Of the 24 pts with a diagnosis of lung 
cancer - in 18 could correctly identify the pathology. In 6 cases received false-
negative findings. Sensitivity FNAB for verification of malignancy was 75%. 
Of the 10 pts with non-tumor formations in 7 verified correctly diagnosed. 
The sensitivity was 70%. FNAB accuracy is 0.74. Complications in the form 
of a pneumothorax is not accompanied by clinical symptoms were observed 
in 5 (14.7%) pts. Core biopsies were performed in 69 pts. Malignant process 
was in 56 cases, 13 - non-tumor formation. In 56 pts with a cancer - in 53 
cases correctly verified pathology (83.9% - histologically, 76.8% - cytology). 
False-negative results were obtained in 3 cases. The sensitivity was 94.6%. Of 
the 13 pts with non-tumor formations in 12 verified correctly diagnosed. The 
sensitivity was 92.3%. Core biopsy accuracy was 0.94. Complications have 
been observed in 10 cases (14.5%) patients. Pneumothorax - in 8, hemoptysis 
- in 2. Clinically significant complications were observed in 2 pts (drainage 
of the pleural cavity, hemostatic therapy). According to histological material 
obtained in 5 pts we have EGFR mutations.
Conclusions: Core biopsy of intrathoracic nodules has greater diagnostic value 
in verifying the volume processes in the lung and mediastinum. Method is sim-
ple to use and is not accompanied by serious complications. Obtaining the tissue 
allows the molecular genetic studies and individualized treatment of patients.
Disclosure: All authors have declared no conflicts of interest.
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OUTCOMES OF CT-GUIDED LUNG BIOPSIES FOR 
SUSPECTED LUNG MALIGNANCY - SINGLE CENTRE 
DISTRICT GENERAL HOSPITAL EXPERIENCE
M.A. Abbasi, J. Bhosle, V. Varney, S. Paramothayan, V. Kahr, M. Lapsley, 
A. Witwit Radiology, Respiratory Medicine & Histopathology, St Helier 
University Hospital NHS Trust, Surrey, UNITED KINGDOM
Aim: An audit of CT-guided lung biopsies performed in our institution against 
standards provided by British Thoracic Society guidelines for radiologically-
guided lung biopsy (2003), National Institute for Health and Care Excellence 
(NICE) Lung Cancer guidance (2011) and QS17 Quality Standards (2012).
Methods: All patients undergoing CT-guided biopsy performed between 
March 2012 to March 2013, (12 months and 13 days) were included. The 
complication rate, adequacy of samples as defined by BTS guidelines, false 
negative and positive rates, sensitivity (lesions >2cm) and the success of 
tumour sub-typing and analysis of predictive markers were assessed,
Results: Fifty patients (males 22, females 28, mean age= 67 years) were iden-
tified. Adequate samples for diagnosis were obtained in 47 patients (94%). 
Six patients (12%) had pneumothorax, of which 1 patient (2%) required chest 
drainage. Haemoptysis was observed in 4 patients (8%), of which 1 patient 
required medical management (2%). There were no fatalities. The false posi-
tive rate was 0% and the sensitivity (lesions >2cm) was 94%. Adenocarcinoma 
was diagnosed in 23 patients (46%), NSCLC NOS - 4 (8%), squamous cell 
carcinoma - 4 (8%), small cell carcinoma - 1 (2%), carcinoid - 1 (2%), 
metastases - 1 (2%), tuberculosis - 1 (2%). Three patients (6%) had insuf-
ficient samples; 2 (4%) were subsequently diagnosed with adenocarcinoma 
and no malignancy was seen in 1 patient (2%). Twelve patients (24%) had 
no malignant disease on the initial sample; 4 (8%) were subsequently diag-
nosed with adenocarcinoma by alternative methods, giving a false negative 
rate of 33%. 20/37 (54%) of cases underwent subsequent EGFR-TK analysis. 
3 samples (8%) were unsuitable due to inadequate material. 1 sample (3%) 
was positive for mutant EGFR-TK (exon 19 deletion).
Conclusions: CT –guided biopsies in our institution are largely within stan-
dards set by BTS guidelines. However, there is scope for improvement to meet 
NICE Quality standards for the analysis of predictive molecular markers.
Disclosure: All authors have declared no conflicts of interest.
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THE ROLE OF ENDOBRONCHIAL ULTRASOUND 
IN THE MANAGEMENT OF PATIENTS 
PREVIOUSLY TREATED FOR LUNG CANCER
M. Evison1, P. Crosbie2, R. Califano3, Y. Summers3, J. Martin2, P. Barber2, 
R. Booton4 1Institute of Inflammation and Repair, University of Manchester, 
Manchester, UNITED KINGDOM, 2North West Lung Centre, University 
Hospital South Manchester, Manchester, UNITED KINGDOM, 3Department 
of Medical Oncology, University Hospital South Manchester, Manchester, 
UNITED KINGDOM, 4University of Manchester, Institute of Inflammation 
and Repair, Manchester, UNITED KINGDOM
Aim: Safe and effective pathological sampling methods are pivotal in the 
management of lung cancer patients that have previously undergone either 
curative intent or palliative treatment. Early diagnosis of localised disease 
recurrence may facilitate further curative treatment and re-biopsy in disease 
progression after palliative treatment can inform further management. This 
study assessed the safety and effectiveness of bronchoscopy with radial and 
linear endobronchial ultrasound (EBUS) in patients with suspected lung can-
cer recurrence or progression following treatment.
Methods: Prospective data was collected on all patients with suspected recur-
rence/progression of previously treated primary lung cancer having EBUS at 
the University Hospital South Manchester from August 2010 to June 2013. 
Patient characteristics, complications, pathological results from EBUS and 
6 months of clinical-radiological follow up were recorded for each patient.
Results: 64 patients (58 with suspected recurrence and 6 with suspected pro-
gression) underwent EBUS in the study period. A total of 76 lymph nodes and 
14 intra-pulmonary lesions were sampled. The mean age was 67.2 (SD +/-9.4) 
and 61% (39/64) were male. Of the 58 patients with suspected recurrence, 36 
were ultimately confirmed to have recurrence, 20 were proven to have benign 
pathology, one was diagnosed with metastatic bladder cancer and one with a 
new small cell lung cancer. EBUS correctly diagnosed 95% (55/58) of patients 
(sensitivity 92.1%, NPV 87%). Of the 6 patients with suspected progression, 
80% (4/6) were confirmed pathologically by EBUS. In 100% (16/16) of patients 
requiring molecular testing EBUS guided sampling provided adequate tissue. 
The major and minor complication rate was 0% and 3.1% (2/64) respectively.
Conclusions: Bronchoscopy with endobronchial ultrasound is a safe and 
highly effective diagnostic procedure in suspected lung cancer recurrence/
progression. All physicians, oncologists and surgeons involved in the follow-
up and surveillance of lung cancer patients require rapid and reliable access 
to endobronchial ultrasound services.
Disclosure: All authors have declared no conflicts of interest.
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SYNCHRONOUS LUNG AND THYROID TUMORS: 
A STAGING DILEMMA IN THE PET-CT ERA
M. Moskovitz1, D. Levy Faber2, M. Lapidot2, M. Wollner1, M. Orlovsky2, L.A. 
Best2, R. Kremer2 1Oncology, Rambam Health Care Campus, Haifa, ISRAEL, 
2General Thoracic Surgery, Rambam, Haifa, ISRAEL
Aim: Lung cancer is the second most common non-skin malignancy. In a 
PET-CT-based staging of lung cancer, positive metabolic neck avidity may be 
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considered a metastasis; however, other interpretations may be synchronous 
tumor or non-malignant avidity. We present nine cases of synchronous lung 
and thyroid cancer, which do not share common characteristics, and whose 
concurrent detection affects the patients’ treatment and prognosis
Methods: A retrospective analysis of patients admitted to our department of 
General Thoracic Surgery between January 1, 2004, to January 1, 2013, iden-
tified nine patients with synchronous lung and thyroid malignancies. Data 
collection was of demographics, disease characteristics, diagnosis, surgical 
and oncological treatment, and clinical outcomes.
Results: Nine patients had synchronous thyroid and lung cancer upon 
diagnosis, substantiated by FDG-PET scans with pathological SUV 
uptakes. Lung cancer: All eight operable patients underwent anatomi-
cal lobectomies. Thyroid cancer: Six patients had total resection of the 
thyroid; one patient passed away presurgery; one patient is still recover-
ing from lung malignancy treatment; one thyroidectomy was postponed 
due to lung cancer associated oncological treatments. One patient passed 
away due to intestinal perforation before the thyroidectomy. Four patients 
had typical complications of lung surgery. Three patients had oncological 
treatment complications. Six patients completed their preplanned treat-
ment course of both malignancies.
Conclusions: A high index of suspicion should be given to a PET-CT scan 
demonstrating a pathological lung and neck metabolic avidity, presented dur-
ing the process of lung cancer evaluation; in such case, further evaluation is 
warranted to accurately conclude the patient’s clinical staging.
Disclosure: All authors have declared no conflicts of interest.
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OUTCOMES OF PLATINUM-SENSITIVE SMALL CELL 
LUNG CANCER (SCLC) PATIENTS TREATED WITH 
PLATINUM-BASED CHEMOTHERAPY RECHALLENGE: 
A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS
G. Genestreti1, G. Metro2, H. Kenmotsu3, F. Carloni4, M.A. Burgio5, C. 
Casanova6, M. Tiseo7, E. Scarpi8, T. Korkmaz9, R. Califano10 1Department 
of Medical Oncology, AUSL Rimini, Cervesi Hospital, Cattolica, ITALY, 
2Oncologia Medica, Azienda Ospedaliera di Perugia S. Maria della 
Misericordia, Perugia, ITALY, 3Division of Thoracic Oncology, Shizouka 
Cancer Center, Shizouka, JAPAN, 4Department of Medical Oncology, 
AUSL Rimini, “Cervesi” Hospital, Cattolica, ITALY, 5Department of 
Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio 
e la Cura dei Tumori (I.R.S.T.), Meldola, ITALY, 6Oncology Hematology, 
Ospedale Sta Maria delle Croci, Ravenna, ITALY, 7Oncologia Medica, 
Azienda Ospedaliera di Parma, Parma, ITALY, 8Unit of Biostatistics and 
Clinical Trials, IRCCS Istituto Scientifico Romagnolo per lo Studio e 
la Cura dei Tumori (I.R.S.T.), Meldola, ITALY, 9Medical Oncology, Dr. 
Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, TURKEY, 
10Department of Medical Oncology, The Christie NHS Foundation Trust, 
Manchester, UNITED KINGDOM
Aim: Patients with small-cell lung cancer (SCLC) that progress after first-
line (FL) chemotherapy have a poor prognosis and second-line (SL) chemo-
therapy has limited efficacy. Patients relapsing/ progressing > 90 days after 
completion of FL platinum-based treatment are considered platinum sensitive 
and could be rechallenged with same treatment. We conducted a multicenter 
retrospective analysis to evaluate outcomes of SCLC patients who received 
platinum/etoposide rechallenge as SL.
Methods: The endpoints were: overall survival (OS) from diagnosis and 
rechallenge chemotherapy, and response rate (RR) and progression-free 
survival (PFS) after rechallenge. Survival curves were calculated using the 
Kaplan-Meier method.
Results: We reviewed 2000 SCLC patients treated in 8 institutions between 
January 2007 and December 2011. Patients with sensitive SCLC treated with 
SL platinum/etoposide rechallenge were 112 (5.6%). 64% were males with 
a median age of 64 years (range 40–83). At diagnosis, 49 (44%) patients 
had limited disease. Eastern Cooperative Oncology Group performance sta-
tus (ECOG-PS) was 0–1 and 2 in 87% and 13% of patients, respectively. 
Response to FL chemotherapy: complete response (CR) 14%, partial 
response (PR) 84% and stable disease (SD) 2%. Median time-to-progression 
from completion of FL chemotherapy was 240 days (range 90–1200). Mean 
number of cycles of chemotherapy was 3.6 (range 1–7). Carboplatin and cis-
platin were administered in 96 (86%) and 16 (14%) patients, respectively. 
Median OS from diagnosis and rechallenge chemotherapy was 21.4 months 
(95% CI 19.8–24.1) and 7.9 months (95% CI 6.9–9.7), respectively. Median 
PFS from rechallenge was 5.5 months (95% CI 4.4–6.3). Response to rechal-
lenge chemotherapy: CR 3%, PR 42%, SD 19%, progressive disease 27% and 
not evaluable 9%. Forty patients (36%) received further chemotherapy: CAV 
(cyclophosphamide, adriamycin and vincristine) (12%), topotecan (9%), plat-
inum/etoposide (6%) and other regimen (9%). There was no difference in OS 
from diagnosis, OS and PFS from rechallenge according to stage at diagnosis, 
PS or type of platinum drug administered.
Conclusions: The outcome for SL chemotherapy for SCLC is poor. 
Platinum sensitive disease may be rechallenged with platinum-based treat-
ment. Stage, PS and platinum drug administered do not seem to be inde-
pendent prognostic factors.
Disclosure: All authors have declared no conflicts of interest.
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CABAZITAXEL (CBZ) VS TOPOTECAN (TPT) IN 
PATIENTS (PTS) WITH SMALL CELL LUNG CANCER 
(SCLC) WITH PROGRESSIVE DISEASE DURING/
AFTER FIRST-LINE (1L) TREATMENT WITH 
PLATINUM-BASED CHEMOTHERAPY (CTX)
T. Evans1, B.C. Cho2, K. Udud3, J.R. Fischer4, F.A. Shepherd5, P. Martinez6, 
R. Ramlau7, K.N. Syrigos8, M. Chadjaa9, M. Wolf10 1Perelman Center for 
Advanced Medicine, University of Pennsylvania, Philadelphia, PA, UNITED 
STATES OF AMERICA, 2Yonsei Cancer Center, Yonsei University Health 
System, Seoul, KOREA, 3Korányi National Institute of Pulmonology, 
Budapest, HUNGARY, 4Klinikum Loewenstein, Loewenstein, GERMANY, 
5Princess Margaret Cancer Centre, Toronto, CANADA, 6Vall d’Hebron 
University Hospital, Barcelona, SPAIN, 7Poznan University of Medical 
Sciences, Poznan, POLAND, 8Oncology Unit, 3rd Department of Medicine, 
Athens University School of Medicine, Sotiria General Hospital, Athens, 
GREECE, 9Sanofi, Vitry-sur-Seine, FRANCE, 10Division of Haematology 
and Oncology, Klinikum Kassel, Kassel, GERMANY
Aim: Platinum-based ctx is the 1L standard of care for SCLC, but despite high 
response rates, most SCLC pts experience rapid relapse and die from systemic 
metastases (mets). Therefore, more effective second-line (2L) treatments are 
needed. Taxanes are active 2L in SCLC, and Cbz is effective in 2L in other solid 
tumors. We compared Cbz vs Tpt in a randomized open-label Phase II trial in 
pts with SCLC who had progressed during/after 1L ctx (NCT01500720).
Methods: Pts with locally advanced or metastatic SCLC who had progressed 
during/after 1L platinum-based ctx, ECOG PS ≤1, ≤1 prior ctx and no prior 
taxane/Tpt treatment were enrolled. Pts received IV Cbz 25 mg/m2 (Day 1 
Q3W) or IV Tpt 1.5 mg/m2 (Days 1–5 Q3W) (1:1 ratio). Pts were split into 
ctx-sensitive and ctx-refractory subgroups and stratified by brain mets (yes 
vs no) and lactate dehydrogenase (LDH) plasma concentration (≤ vs > upper 
limit of normal). Endpoints included progression-free survival (PFS; primary 
endpoint), overall survival (OS), safety and health-related quality of life.
Results: 179 pts (Cbz 90; Tpt 89) were randomized. Median age was 61 yrs. 
Baseline characteristics were balanced between treatment arms; approxi-
mately 50% of pts in each arm were ctx-refractory. Median number of cycles 
received was 2 (Cbz) and 4 (Tpt). Median PFS was 1.4 months (mo) (Cbz) 
and 3.0 mo (Tpt). The primary endpoint of improvement in PFS for Cbz vs 
Tpt was not met (log-rank test, 2-sided p<0.0001; HR=2.169, 95% CI 1.563, 
3.010, 90% CI 1.648, 2.856). Similar results were observed in the ctx-sen-
sitive and ctx-refractory subgroups. Cbz was less favorable than Tpt for OS 
(median: 5.2 mo Cbz, 6.8 mo Tpt; log rank test, 2-sided p=0.0125; HR=1.574, 
95% CI 1.099, 2.253, 90% CI 1.165, 2.127). All-grade adverse events (AEs) 
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were more frequent with Tpt (94.3%) vs Cbz (88.8%), as were grade 3–4 AEs 
(Tpt 71.6%, Cbz 58.4%). Febrile neutropenia (Tpt 15.9%, Cbz 11.2%), neu-
tropenic infection (Tpt 6.8%, Cbz 4.5%) and neutropenic sepsis (Tpt 1.1%, 
Cbz 3.4%) were similar across arms.
Conclusions: Cbz failed to meet the primary endpoint of superior PFS and 
showed less favorable median OS vs Tpt in pts with SCLC who had pro-
gressed during/after 1L ctx. No new safety concerns were identified.
Disclosure: T. Evans: Receipt of honoraria or consultation fees:Lilly, 
Genentech. Husband on speakers bureau for Genentech B.C. Cho: Receipt of 
grants/research supports: Novartis Receipt of honoraria or consultation fees: 
Novartis, AstraZeneca and GSK M. Chadjaa: I am a stock shareholder and 
a Sanofi employee All other authors have declared no conflicts of interest.
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PACLITAXEL PLUS BEVACIZUMAB IN PATIENTS 
WITH CHEMORESISTANT RELAPSED SMALL 
CELL LUNG CANCER AS SALVAGE TREATMENT: 
A PHASE II MULTICENTER STUDY OF THE 
HELLENIC ONCOLOGY RESEARCH GROUP
G. Mountzios1, C. Emmanouilidis2, N. Vardakis2, E. Kontopodis2, D. 
Hatzidaki2, E. Popis2, N. Karachaliou2, A. Kotsakis2, M. Agelidou2, V. 
Georgoulias2 1Medical Oncology, 251 Airforce General Hopsital, Athens, 
GREECE, 2Medical Oncology, University of Crete School of Medicine, 
Herakleion, GREECE
Aim: Therapeutic options for patients with relapsed, chemo-resistant small-
cell lung cancer (SCLC) are limited. Since paclitaxel has demonstrated sin-
gle-agent activity in the second-line setting of SCLC and angiogenesis seems 
to play an important role in the pathogenesis of the disease, a phase II trial was 
conducted in order to evaluate the efficacy and the tolerance of their combina-
tion in patients with relapsed, chemo-resistant SCLC.
Methods: Patients with an Eastern Cooperative Oncology Group (ECOG) 
Performance Status of 0 to 2 who experienced relapse within 3 months after 
completion of 1st line chemotherapy for SCLC were eligible. Patients were 
treated with paclitaxel (90 mg/m2, days 1, 8 and 15) along with bevacizumab 
(10 mg per kgr of body weight, days 1 and 15) in cycles of 28 days.
Results: Thirty patients (male/female: 27/3) with a median age of 64 years and 
ECOG Performance Status 0/1/2: 2/25/3 were enrolled. Nineteen patients (63.3%) 
had received at least two lines of prior treatment, 17 (56.7%) had undergone prior 
radiotherapy and nine (30%) had brain metastases at the time of study entry. The 
overall objective response rate was 20% (95% CI: 5.69%-34.31%), including one 
complete remission, whereas the disease control rate was 36.7%. The median 
duration of response was 2.5 months (range, 1.5–5.7), the median progression-free 
survival 2.7 months (range, 0.5 – 9.2) and the median overall survival 6.3 months 
(range 0.5 – 17.9). Grade 3 and 4 toxicities were limited in neutropenia, diarrhea 
and fatigue. There was one case of non-fatal pulmonary embolism.
Conclusions: The combination of paclitaxel with bevacizumab was feasible 
and active in this poor prognosis and heavily pretreated population of patients 
with advanced, chemoresistant SCLC, representing a valid therapeutic alter-
native which merits further evaluation.
Disclosure: All authors have declared no conflicts of interest.
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MONOTHERAPY WITH SINGLE-AGENT TOPOTECAN 
SHOWS SIMILAR EFFICACY AND LESS TOXICITY 
COMPARED TO A COMBINATION TREATMENT 
WITH ADRIAMYCIN, CYCLOPHOSPHAMIDE AND 
VINCRISTINE (ACO) – A SINGLE CENTER EXPERIENCE
R. Hagmann, A. Zippelius, S. Rothschild Medical Oncology, University 
Hospital Basel, Basel, SWITZERLAND
Aim: Small-cell lung cancer (SCLC) accounts for about 10–15% of all lung 
cancer cases and has a dismal prognosis. Randomized trials established 
topotecan and the combination of adriamycin, cyclophosphamide and vincris-
tine (ACO) as options for second-line therapy. In this study we evaluated the 
outcome of patients with SCLC with a special focus on patients undergoing a 
second-line chemotherapy at our institution.
Methods: 92 patients (67.4% male, mean age 63 years) with a histopathologi-
cal diagnosis of SCLC between January 2000 and December 2010 at our insti-
tution were identified. Patients’ characteristics, treatment delivery, response, 
outcome, toxicity and established prognostic parameters were evaluated. 85 
patients (92.4%) were evaluable for outcome data.
Results: From the 22 patients (23.9%) diagnosed with limited disease (LD) 
SCLC 16 patients (72.7%) received platinum-based combined radio-chemo-
therapy (RCT) as first-line treatment. All patients received platinum-based 
chemotherapy as first treatment. 69 (98.5%) of the 70 patients diagnosed with 
extensive disease (ED) SCLC received first-line palliative chemotherapy. In the 
whole cohort, the median overall survival (OS) was 12.7 months (22.7 months 
for LD-SCLC and 10.2 months for ED-SCLC). 42 patients (46.1%) received 
a second-line therapy after having relapsed. The most frequently used regimen 
was ACO in 47.6% of patients. 31.0% of patients received intravenous topote-
can. 8 patients (19.1%) were rechallenged with a platinum and etoposide. The 
treatment decision (ACO vs. topotecan) was not significantly related to any 
clinical parameter. Compared to topotecan ACO had a higher ORR (44.4% 
vs. 30.0%). Neither PFS (3.2 month vs. 3.2 month) nor OS (6.3 month vs. 6.6 
months) did differ significantly. Patients treated with ACO showed more toxic-
ity leading to inpatient care (51.2 vs. 39.2 days).
Conclusions: In this retrospective analysis including all patients with SCLC 
treated at our department between 2000 and 2010 we showed similar out-
comes as reported in clinical trials. In the second-line setting the combination 
chemotherapy with ACO did not show superiority to intravenous topotecan 
but was associated with a clinically relevant longer hospitalization time. 
Therefore, we recommend intravenous topotecan as preferred option for sec-
ond-line chemotherapy in patients with SCLC.
Disclosure: All authors have declared no conflicts of interest.
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SMALL CELL LUNG CANCER – THERAPEUTIC 
CHALLENGE. A LONG TIME SINGLE 
INSTITUTION EXPERIENCE
N. Chilingirova1, D. Damyanov1, G. Kurteva1, S. Tonev2, N. Dimitrova2 
1Medical Oncology Clinic, National Oncology Center, Sofia, BULGARIA, 
2Bulgarian National Cancer Registry, Bulgarian National Cancer Registry, 
Sofia, BULGARIA
Aim: Despite reported decrease in small cell lung cancer (SCLC) incidence, 
it still remains a considerable source of mortality. The aim of our study is to 
present a single institution experience on standard treatment of SCLC during 
the last 40 years, compare different treatment regiments and evaluate treat-
ment efficiency and survival rates.
Methods: A retrospective study of the medical records of patients with his-
tologically proven SCLC was performed for an interval of 40 years (1970–
2010) in the National Oncology Center, Sofia.
Results: To verify the reliability of therapeutic regiments and median survival 
rates we have studied retrospectively a group of 144 patients (23 women, 121 
men), median age by diagnosis – 57 years and median follow up time of 320 
months, divided by age into 3 groups – to 55, between 55–65, and over 65 
yo with median survival of 9,3 months and no statistically significant differ-
ence in survival by age, but statistically significant difference in the median 
overall survival (OS) by gender 8,9 months for males, and 12,6 for females. 
69 of the patients were with LD and 75 with ED SCLC, median survival rates 
of 10,6 and 9,3 months respectively. Patients were divided in groups based 
on the induction chemotherapy they had received: Group 1 - Vincristine, 
Cyclophosphamide, Methotrexate(VCM) followed by radiotherapy(RT), 
Group 2 – Cyclophosphamide (C) followed by RT, Group 3 – VCM, Group 
4 – C only, Group 5 – without treatment, Group 6 – Etoposide, Cisplatinum 
(EP) followed by RT, Group 7 – EP. Groups 1–4 include therapeutic regiments 
used before introducing EP as standard treatment for SCLC. According to 
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the subgroup analysis no statistically significant difference in OS rates was 
observed between groups 2-1, 2–4, 2–6, 2–7, 3–4, 4-1, 4–7, 6-1, 7-1 and 6–7, 
which gives no superiority of EP/RT and EP over VCM/RT and C/RT. Old 
therapeutic regiments showed no statistically significant difference between 
VCM/RT - C/RT and VCM - C, but pointed the role of RT for some improve-
ment in survival rates. Generall comparison between old and new regiments 
gives superiority to EP+/-RT.
Conclusions: Although there were some advances after introduction of 
new therapeutic regiments, changes in OS rates remain relative small, 
there is no dramatic change in outcomes and treatment of SCLC still 
remains a challenge, which makes it important to look for new therapeutic 
options.
Disclosure: All authors have declared no conflicts of interest.
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INVESTIGATING MOLECULAR BIOMARKERS  
IN SCLC
F. Abdelraouf1, D. Gonzalez de Castro2, A. Wotherspoon3, M. Maurya2, D. 
Mair2, J. Bhosle4, S. Popat4, M. O’Brien4 1Departments of Medicine and Clinical 
Pathology, The Royal Marsden NHS Foundation Trust and Cairo University, 
Surrey, UNITED KINGDOM, 2Department of Molecular Diagnostics, The 
Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, 
Surrey, UNITED KINGDOM, 3Department of Histopathology, The Royal 
Marsden Hospital NHS Foundation Trust, Surrey, UNITED KINGDOM, 
4Department of Medicine, The Royal Marsden Hospital NHS Foundation 
Trust, Surrey, UNITED KINGDOM
Aim: Small cell lung cancer (SCLC) is an aggressive cancer that relapses 
quickly after conventional treatment. Molecular biomarkers have been inves-
tigated in non-small cell lung cancer (NSCLC) and targeted treatments in 
advanced disease are established. Currently there are no established targeted 
therapies in SCLC and the aim of this study was to examine for the presence 
of known molecular targets in patients with SCLC.
Methods: A panel of histopathologically proven formalin fixed paraffin 
embedded (FFPE) specimens of SCLC diagnosed between 1990 and 2010 
were analysed for EGFR, KRAS, NRAS, BRAF mutations, ALK gene rear-
rangements and MET amplification. EGFR and KRAS testing were done 
using real time-polymerase chain reaction (RT-PCR cobas®), BRAF and 
NRAS using capillary electrophoresis-single strand conformation analy-
sis (CE-SSCA) and ALK and MET using fluorescent in situ hybridization 
(FISH). Any positive results were repeated for confirmation. Any inconsistent 
results were sequenced using the direct Sanger sequencing. .
Results: A hundred and five cases of SCLC were identified and 75 FFPE 
blocks retrieved. Sixty samples were suitable for molecular testing, with 25 
examined for all 6 molecular targets successfully. No mutations in EGFR 
were detected in 31 cases suitable for analysis. KRAS and NRAS muta-
tional analysis was successful in 35 and 37 cases respectively; all of which 
were wild type. Fifty-eight cases were assessed for ALK gene rearrange-
ments and 42 cases for MET gene amplifications; no rearrangements or 
amplifications were detected. Forty-seven samples were successfully ana-
lysed for BRAF gene mutation, with one V600E mutation detected (2.1% 
of cases). This patient was a 55 years old Caucasian male smoker who 
was diagnosed as SCLC, limited stage. He had a history of squamous cell 
carcinoma diagnosed 6 months prior to the SCLC diagnosis (treated by 
lobectomy). He responded well to his SCLC treatment (radical chemora-
diotherapy and prophylactic cranial irradiation). He died nine months after 
diagnosis.
Conclusions: EGFR, KRAS, NRAS, ALK and MET were not detected in 
the examined panel of SCLC patients. A BRAF mutation was identified 
in a single patient with a recent diagnosis of squamous cell carcinoma of 
the lung, suggesting a mixed pathology tumour rather than a biomarker 
in SCLC. This panel of biomarkers should no longer be explored in 
SCLC.
Disclosure: All authors have declared no conflicts of interest.
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OVERCOMING MACROPHAGE IMMUNOSUPPRESSION 
IN SMALL CELL LUNG CANCER WITH 
HIGH-AFFINITY SIRPA VARIANTS
K. Weiskopf1, P.J. Schnorr1, N. Jahchan1, A. Ring1, A. Volkmer1, J. Volkmer1, 
K.C. Garcia2, J. Sage1, I.L. Weissman1 1Institute for Stem Cell Biology and 
Regenerative Medicine, Stanford University School of Medicine, Stanford, 
CA, UNITED STATES OF AMERICA, 2Molecular and Cellular Physiology, 
Stanford University School of Medicine, Stanford, CA, UNITED STATES 
OF AMERICA
Aim: CD47 is a cell-surface molecule that allows cancer cells to evade the 
immune system by signaling through SIRPa, an inhibitory receptor on macro-
phages. Therapies that block CD47 stimulate macrophage phagocytosis and 
destruction of cancer cells. Here, we hypothesized that CD47-blocking thera-
pies could be used as effective treatments for small cell lung cancer (SCLC) 
in preclinical models. We aimed to identify new tumor antigens on SCLC 
cells and target them in combination with CD47-blocking therapies.
Methods: To examine CD47 expression levels and identify novel SCLC-
specific antigens, we screened SCLC samples by high-throughput flow cytom-
etry using LEGENDScreen comprehensive antibody arrays. We evaluated the 
ability of CD47-blocking therapies to stimulate phagocytosis using primary 
macrophages and SCLC cells. The therapeutic efficacy of CD47 blockade 
was evaluated in vivo using mouse xenotransplantation models of SCLC.
Results: We found all SCLC samples tested expressed high levels of CD47 on 
their surface. Moreover, we identified CD99, CD56, CD166, CD326, and CD164 
as antigens highly expressed on the surface of SCLC cells. Using purified mac-
rophages in vitro, we found that CD47-blocking therapies were able to induce 
macrophage phagocytosis of SCLC cell lines and primary patient samples, 
especially when combined with antibodies to the identified tumor antigens. In 
xenotransplantation models, CD47-blocking therapies were able to inhibit tumor 
growth and significantly prolong survival of mice engrafted with human SCLC.
Conclusions: We found that SCLC cells are susceptible to destruction by 
macrophages of the innate immune system upon CD47-blockade. Therefore, 
our study validates CD47 as a therapeutic target for SCLC and provides 
rationale for translation to the clinic. Comprehensive flow cytometry-based 
profiling proved valuable for identifying new tumor antigens. Combining 
SCLC-specific antibodies with CD47-blocking therapies is an optimal 
approach to maximizing macrophage mediated-destruction of SCLC.
Disclosure: All authors have declared no conflicts of interest.
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INVESTIGATING NEUROENDOCRINE MARKERS 
OF SMALL CELL LUNG CANCER
T. Layton Faculty of Life Sciences, University of Manchester, Oxford, 
UNITED KINGDOM
Aim: Small cell lung cancer (SCLC) is a widespread and devastating dis-
ease. SCLC tumours contain a neuroendocrine cell population that exhibit 
ectopic hormone production in a minority of patients. The aim of this study 
was to investigate a panel of neuroendocrine peptides as potential biomarkers 
fof SCLC, including pro-opiomelanocortin, neuron specific enolase, chro-
mogranin A and neural-cell adhesion molecule. This study validates further 
investigation into the neuroendocrine phenotype in SCLC, and POMC as a 
potential biomarker for the disease.
Methods: Immunohistochemistry methods were used to examine neuroen-
docrine peptides in five human lung cancer cell lines (CORL24, CORL47, 
DMS79, H526, A549) and a novel murine subcutaneous SCLC xenograft 
tumour. Liver, lung and brain samples were taken from xenograft mice to 
identify possible metastasis. ELISA measured POMC secretion and expres-
sion in cell lines during incubation and a Western Blot quantified chromo-
granin A levels in all cell lines and xenograft tumours.
Results: Results confirmed a significant neuroendocrine cell popula-
tion within SCLC xenograft tumours and cell lines.Results confirmed a 
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significant neuroendocrine cell population within SCLC xenograft tumours 
and cell lines. Additionally, POMC secretion proved to be a marker of 
SCLC growth in vitro in CORL24 and DMS79. H526, CORL47 and A549 
did not secrete POMC. Xenograft tumours appeared invasive with infiltra-
tion of surrounding connective tissue, but no metastases were present in 
liver, lung and brain samples.
Conclusions: This study validates further investigation into the neuroendo-
crine phenotype in SCLC, and POMC as a potential biomarker for the disease.
Disclosure: All authors have declared no conflicts of interest.
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WHEN IS A PATHOLOGICAL DIAGNOSIS 
PREFERRED BEFORE STEREOTACTIC 
ABLATIVE RADIOTHERAPY (SABR) FOR STAGE 
I LUNG CANCER? A DECISION ANALYSIS
A.V. Louie1, M.G. Hunink2, P. Patel3, B.S. Ferket2, F.J. Lagerwaard1, G.B. 
Rodrigues4, J.K. Salama3, C. Kelsey3, D.A. Palma4, S. Senan5 1Radiation 
Oncology, VU University Medical Center, Amsterdam, NETHERLANDS, 
2Department of Epidemiology, Center for Health Decision Sciences, Harvard 
School of Public Health, Boston, MA, UNITED STATES OF AMERICA, 
3Radiation Oncology, Duke University, Durham, NC, UNITED STATES 
OF AMERICA, 4Radiation Oncology, London Regional Cancer Program, 
London, CANADA, 5Radiation Oncology, Vrije University Medical Centre 
(VUMC), Amsterdam, NETHERLANDS
Aim: In unfit patients who are at increased risk for complications from a 
biopsy, SABR for a solitary pulmonary nodule (SPN) is acceptable after 
review by a multidisciplinary tumor board [ESMO recommendations 2013]. 
We performed a decision analysis that can be employed to inform the appro-
priate lung cancer prevalence threshold of when this strategy is warranted.
Methods: A decision tree and Markov model were constructed to evaluate 
the relative merits of 1) observation, 2) performing SABR without pathologic 
confirmation of malignancy, or 3) performing a transthoracic biopsy prior to 
SABR, when faced with a SPN at different lung cancer prevalences. Diagnostic 
test performance characteristics were extracted from the literature. Toxicity and 
recurrence rates, as well as health utilities (derived via mapping procedures) 
were abstracted from a prospectively collected database of 382 patients receiv-
ing SABR for confirmed or suspected stage I NSCLC. Deterministic and proba-
bilistic sensitivity analyses on all model inputs were performed to assess their 
effect on predicted prevalence thresholds between 3 treatment strategies. The 
model was constructed with a 5-year time horizon using a cycle length of one 
month; quality adjusted life years (QALYs) were discounted at a rate of 3%.
Results: The model was validated internally with source data and externally 
by predicting for results consistent with published recurrence and survival 
outcomes. In the base case analysis, the prevalence threshold between strate-
gies 1 (observation) and 2 (SABR without pathology) was 17.0%; and 85.0% 
between strategies 2 and 3 (performing transthoracic biopsy prior to SABR). 
The latter finding was confirmed on probabilistic sensitivity analysis (85.2%; 
95% confidence interval: 80.0% – 87.2%). The predicted prevalence thresh-
old of 85.0% was most sensitive to the variability in the diagnostic sensitivity 
of transthoracic biopsy (prevalence range: 77.2 – 94.0%).
Conclusions: SABR appears warranted for a SPN in the absence of pathologic 
confirmation if the prevalence of lung cancer is above 85%, a finding that is 
dependent on the diagnostic performance of biopsy within the area of practice.
Disclosure: A.V. Louie: Dr. Louie was the recipient of the 2013 Canadian 
Association of Radiation Oncologists’ Elekta Research Fellowship. The 
VUMC has a has a departmental master research agreement with Varian 
Medical Systems Inc. F.J. Lagerwaard: Dr. Lagerwaard has received speaker 
honorara from Varian Medical Systems Inc. The VUMC has a has a depart-
mental master research agreement with Varian Medical Systems Inc. D.A. 
Palma: Dr. Palma was the recipient of the 2009 Canadian Association of 
Radiation Oncologists’ Elekta Research Fellowship. S. Senan: Dr Senan has 
received research funding from Sanofi-Aventis and speaking honoraria from 
Varian Medical Systems Inc. The VUMC has a departmental master research 
agreement with Varian Medical Systems Inc. All other authors have declared 
no conflicts of interest.
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EFFICACY BY T CATEGORIES OF THE POSTOPERATIVE 
ADJUVANT IMMUNOTHERAPY WITH UBENIMEX 
(BESTATIN○R) ON SURVIVAL IN PATIENTS WITH STAGE 
L SQUAMOUS-CELL LUNG CANCER: AN EXPLORATORY 
ANALYSIS FROM A RANDOMIZED PHASE III STUDY
M. Tsuboi1, H. Kato2 1Thoracic Surgery & Oncology, Yokohama City 
University Medical Center, Yokohama, JAPAN, 2Thoracic Surgery & 
Oncology, Tokyo Medical University, Tokyo, JAPAN
Aim: The 7th Edition of the TNM Classification of Malignant Tumors in non-
small cell lung cancer (NSCLC) has demonstrated a more detailed classifica-
tion of primary tumor diameter. Stage IA T1 disease is subdivided into two 
groups: T1a disease (tumor diameter, < or = 2 cm) and T1b disease (tumor 
diameter, >2 to < or = 3 cm). Ubenimex (BestatinR), which is a competi-
tive protease inhibitor of aminopeptidase N (CD13) and aminopeptidase B, 
improves survival in patients with stage I squamous-cell lung cancer (JNCI 
2003; 98:605–610). However, whether it is effective in patients with each sub-
set of T categories, such as T1b and T2a, remains controversial. The objective 
of this study was to further explore the effectiveness of Ubenimex.
Methods: Data from a randomized double-blind placebo-controlled trial of 
Ubenimex in patients with resected stage I squamous-cell lung cancer were 
reanalyzed to evaluate the effectiveness of Ubenimex according to T1a, T1b 
and T2a tumors based on UICC7-TNM classification.
Results: Data from 398 patients were analyzed: 108 (27.1%) had T1a tumors, 
100 (25.1%) had T1b tumors, and 190 (47.8%) had T2a tumors. In the sur-
gery-alone group, overall survival rates (OS) at 5 years were 80.4% in patients 
with T1a tumors, 80.9% in those with T1b tumors, 68.0% in those with T2a 
tumors. On the other hand, in the adjuvant treatment group with Ubenimex, 
OS at 5 years were 88.2% in patients with T1a tumors, 79.2% in those with 
T1b tumors, and 77.9% in those with T2a tumors. In patients with T2a tumor, 
both the overall survival rate and the recurrence free survival were significantly 
higher in the Ubenimex group than in the surgery-alone group (hazard ratio = 
0.63 and 0.67, log-rank p = 0.026 and 0.025, respectively). The hazard ratio for 
death in the Ubenimex group when compared with the surgery-alone group 
was 0.75 for those with T1a-b disease (95% confidence interval, 0.42–1.34).
Conclusions: This exploratory analysis demonstrated that postoperative 
adjuvant therapy with Ubenimex significantly improved survival in patients 
with stage IB, T2aN0 NSCLC compared with surgery alone. The confirma-
tory adjuvant phase III study with Ubenimex for stage I squamous-cell lung 
cancer is warranted.
Disclosure: All authors have declared no conflicts of interest.
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ADJUVANT CHEMOTHERAPY IN RESECTED 
NSCLC: TREATMENT FACTORS THAT 
IMPACT SURVIVAL OUTCOMES
K. Ramsden, J. Laskin, C. Ho Medical Oncology, British Columbia Cancer 
Agency, Vancouver, BC, CANADA
Aim: Platinum-based adjuvant chemotherapy is the standard of care for 
resected stage II non-small cell lung cancer (NSCLC). In practice, the pro-
portion of patients who receive adjuvant treatment is limited and the dose 
delivered is often reduced compared to the clinical trials. The purpose of this 
population-based study was to identify factors that predict for receiving adju-
vant therapy and assess the impact of delayed administration and dose reduc-
tion on survival.
Methods: The British Columbia Cancer Agency (BCCA) provides cancer 
care to a population of 4.5 million. A retrospective review was conducted 
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on all patients diagnosed with stage II NSCLC who underwent resection and 
were referred to the BCCA between 2005 and 2010.
Results: Of 258 stage II NSCLC patients, 158 received adjuvant chemother-
apy (61%). No-adjuvant versus adjuvant population: M 52%/57%, median age 
67/62, ECOG <=1 55%/75%, Charlson comorbidity index <=1 61%/74%, pneu-
monectomy 11%/26% respectively. On multivariate analysis (MVA): younger 
age, better ECOG and pneumonectomy were predictive of adjuvant treatment. In 
patients who received chemotherapy: cisplatin/carboplatin 81%/19%, maximum 
cycles received 1/2/3/4 - 10%/9%/9%/72%, number of weeks from surgery to 
adjuvant chemotherapy <8/8–10/10–12/>12 - 11%/40%/25%/24%, percent of 
total planned dose received <50%, 50–75%, >75% - 12%/11%/77%. On MVA, 
patients who received less than 80% of their total planned platinum dose had 
poorer overall survival (HR 2.06, p=0.014). Time from surgery to adjuvant che-
motherapy did not have a significant effect on overall survival (all intervals NS).
Conclusions: Factors associated with better functional status (younger age, 
good ECOG) and pneumonectomy predicted for adjuvant chemotherapy. For 
patients who received adjuvant chemotherapy the total platinum dose admin-
istered impacted survival. The type of platinum and time from surgery, how-
ever, did not. We conclude that achieving a platinum dose delivery of 80% or 
greater is important in maintaining the efficacy of adjuvant chemotherapy for 
resected stage II NSCLC in this retrospective population-based study.
Disclosure: All authors have declared no conflicts of interest.
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ADJUVANT CHEMOTHERAPY IN RESECTED 
STAGE IB-III NON SMALL CELL LUNG CANCER
B. Zhang1, H-L. Wong1-2, D. Gunawardana2, P. Parente1, R. de Boer2, 
A. Barling3, P. Antippa4, R. Wong1 1Medical Oncology, Eastern Health, 
Box Hill, AUSTRALIA, 2Medical Oncology, Royal Melbourne Hospital, 
Parkville, AUSTRALIA, 3Cardiothoracic Surgery, Eastern Health, Box 
Hill, AUSTRALIA, 4Cardiothoracic Surgery, Royal Melbourne Hospital, 
Parkville, AUSTRALIA
Aim: A substantial proportion of patients (pts) with resected stage I, II or III non 
small cell lung cancer (NSCLC) recur and die. Adjuvant chemotherapy (CT) 
using platinum-based regimens is recommended for pts with stage II and III 
NSCLC, and may have a role in stage IB disease. The aim was to evaluate the 
role of adjuvant CT following complete resection of NSCLC in a real life setting.
Methods: A retrospective analysis was conducted on pts who underwent 
surgical resection of stage IB-III NSCLC at two tertiary institutions in 
Melbourne, Australia between 1 July 2006 and 30 June 2012. Follow up was 
to 30 September 2013. Pts who received neo-adjuvant CT or post-operative 
combined chemoradiation were excluded.
Results: 127 pts were identified with a median age of 68.9 years and a median 
follow up of 41 months. 45 pts (35%) received adjuvant CT. The proportion of 
pts receiving CT increased with higher tumour stage; Stage IB – 7%, Stage II 
– 38%, Stage III – 68%. The median time to commencing CT post-operatively 
was 6.4 weeks (range 3.4–17.1). The commonest regimens used were cisplatin-
vinorelbine, carboplatin-vinorelbine and carboplatin-paclitaxel. The median 
number of cycles was 4 (range 1–5). 84% of pts completed treatment. CT recipi-
ents had a longer median time to relapse (12.3 vs 10.4m). By stage, median time 
to relapse was 10.4 vs 7.4m (stage II) and 12.6 vs 4.3m (stage III) for pts receiv-
ing CT vs no CT. Overall survival (OS) was 59.3m (no CT) vs not reached (CT). 
When stratified by stage, CT was associated with significantly increased OS in 
stage II disease (not reached vs 48.5m, p=0.05) and a trend toward increased OS 
in stage III disease (not reached vs 30.1m). Median relapse free survival (RFS) 
and OS were worse for those who received <3 vs ≥3 cycles of CT: 12.6 vs 29.2m 
and 17.1m vs not reached, respectively. Choice of platinum backbone did not 
impact on RFS or OS. There was no significant difference in RFS or OS for those 
who commenced CT: ≤6 vs >6 wks, or ≤8 vs >8 wks post-operatively.
Conclusions: Overall survival was superior in patients with resected stage 
II-III NSCLC who received platinum-based adjuvant chemotherapy. Survival 
was influenced by the number of chemotherapy cycles received, but not by 
choice of platinum backbone, or time to starting chemotherapy.
Disclosure: All authors have declared no conflicts of interest.
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REPLICATION OF RESULTS OF A GENOME-
WIDE ASSOCIATION STUDY ON LUNG CANCER 
SURVIVAL IN A KOREAN POPULATION
M.J. Hong1, S.S. Yoo2, H. Jeon1, S.Y. Lee2, E. Lee3, J.Y. Park2 1Department 
of Biochemistry and Cell Biology, Kyungpook National University School 
of Medicine, Daegu, KOREA, 2Internal Medicine, Kyungpook National 
University School of Medicine, Daegu, KOREA, 3Department of Thoracic 
Surgery, Kyungpook National University School of Medicine, Daegu, 
KOREA
Aim: Recently, a genome-wide association study (GWAS) has identified sin-
gle nucleotide polymorphisms (SNPs) which may influence the prognosis of 
early-stage non-small cell lung cancer (NSCLC) in Caucasians. We attempted 
to replicate the impact of genetic variants identified in the GWAS for lung 
cancer survival in a Korean population.
Methods: Three hundred and sixty-three patients with surgically resected 
NSCLCs were enrolled. Twelve SNPs were genotyped by using SEQUENOM’s 
MassARRAY® iPLEX assay, TaqMan assay, or a polymerase chain reaction-
restriction fragment length polymorphism assay. The association between 
genotypes and overall survival (OS) was analyzed.
Results: Among the 12 SNPs, rs6034368T>C was associated with OS. Patients 
with the rs6034368C allele showed a better OS than the rs6034368T allele 
(adjusted hazard ratio = 0.72, confidence interval = 0.56–0.93, P = 0.01). The 
rs12446308A>G had an effect on OS, with marginal significance (under a 
codominant model, adjusted hazard ratio = 1.85, confidence interval = 0.98–
3.47, P = 0.06). The association of the rs6034368T>C with the survival outcome 
was further examined after categorizing the patients by clinicopathological fac-
tors such as age, gender, smoking status, pack-years, histologic type, pathologic 
stage, and adjuvant therapy. The effect of the rs6034368T>C on OS was not 
different according to these factors (P values for homogeneity test > 0.05).
Conclusions: In the present study, we attempted to replicate the association 
between the 12 genetic variants identified in the GWAS in Caucasians and 
survival of early-stage NSCLC in a Korean population. Among the 12 SNPs, 
rs6034368T>C was significantly associated with OS and the rs12446308A>G 
had an effect on OS, with marginal significance.
Disclosure: All authors have declared no conflicts of interest.
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ROLE OF EXPRESSION LEVELS OF FABP3, H19, 
TFPI2, ARK1B1 CYP3A5, SCGB3A2 GENES IN 
ADENOCARCINOMA STAGE I PATIENTS.
L. Crinò1, V. Ludovini1, A. Siggillino1, F. Bianconi2, F.R. Tofanetti1, L. Pistola1, 
G. Metro1, M. Ragusa3, A. Sidoni4, F. Puma3 1Medical Oncology Division, 
Ospedale S. Maria della Misericordia, Perugia, ITALY, 2Department of 
Electronic and Information Engineering, Perugia University, Perugia, ITALY, 
3Department of Thoracic Surgery, University of Perugia, Perugia, ITALY, 
4Institute of Pathological Anatomy and Histology, University of Perugia, 
Perugia, ITALY
Background: In a previous study, we compared gene expression profiling 
from adenocarcinoma (ADC) specimens and normal lung (NL) tissue with 
non relapse (NR) and early relapse (ER), and we selected 5 genes up-regu-
lated and 4 genes down-regulated were predictive for clustering patients (pts) 
(Siggillino et al. ECCO 2011). Here, we validate our results using an indepen-
dent cohort of patients with lung ADC stage I
Methods: We selected 58 frozen specimens of lung stage I ADC tissue with 
corresponding NL from tissue banking of 180 resected NSCLC. Quantification 
of mRNA expression levels of 9 genes (5 up-regulated:CLCA2, FABP3, H19, 
TFPI2, ARK1B1 and 4 down-regulated: CYP3A5, ALDH3A1, SCGB3A2, 
SCGB1A1, were analyzed by real-time one-step RT-PCR using QuantiFast 
technology.
Results: Fifty-eight ADC stage I pts were evaluable, 17% of which had an 
ER. Among all genes evaluated, the NR vs ER mean expression levels of two 
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genes down-regulated (CYP3A5, 1.09 vs 0.30; SCGB3A2, 2.28 vs 0.98) and 
two genes up-regulated (ARK1B1, 4.53 vs 34.20; FABP3 1.25 vs 1.55) were 
superimposable respect to the results of previous microarray analysis. The 
median disease free survival (DFS) and overall survival (OS) were 21 and 23 
months, respectively. In the logistic multivariate analysis the mean expression 
levels of all genes showed a tendency to predict the ER in the overall popula-
tion (p=0.07). Nevertheless considering only the expression levels of genes 
(FABP3, H19, TFPI2, ARK1B1 CYP3A5, SCGB3A2) identified as signifi-
cant with t-test, the covariates in multivariate analysis increased their capacity 
of ER prediction (p= 0.028).
Conclusions: Our results indicate that it is possible to define, through gene 
expression, a characteristic gene profiling of early relapse tumor patients with 
an increased risk of relapse disease. The contemporary expression levels of 
6 genes (FABP3, H19, TFPI2, ARK1B1 CYP3A5, SCGB3A2) predicted a 
worse DFS. Such features may have important implications for future targeted 
therapies. We thank Italian Association for Cancer Research (AIRC) for sup-
porting the study.
Disclosure: All authors have declared no conflicts of interest.
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DETERMINANTS OF SURVIVAL IN 7.214 PATIENTS 
WITH STAGE III NSCLC TREATED WITH 
CHEMORADIOTHERAPY IN THE NETHERLANDS
J. Belderbos1, J. Widder2, H. Groen3, R.A. Damhuis4 1Radiation Oncology, 
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 
Amsterdam, NETHERLANDS, 2Radiation Oncology, University Medical 
Center Groningen, Groningen, NETHERLANDS, 3Pulmonology, University 
Medical Center Groningen, Groningen, NETHERLANDS, 4Comprehensive 
Cancer Centre, Utrecht, NETHERLANDS
Aim: Chemoradiotherapy (CRT) for stage III non-small cell lung cancer 
(NSCLC) is a curative treatment that involves sequential or concurrent chemo-
therapy. The landmark meta-analysis by Auperin (2010) reported a five-year sur-
vival of 10.6% in sequential setting, as opposed to 15.1% in concurrent setting. 
However, that analysis comprised only 1205 patients and most of these had been 
treated before the year 2000. Since then, modern radiation techniques (IMRT, 
image guided RT) and staging examinations (FDG-PET and brain CTscan or 
MRI) were introduced. In the Netherlands, a national guideline was introduced 
in 2004, advocating concurrent CRT, but chemo- and radiotherapy regimes are 
known to differ between regions. The aim of our study was to assess time trends 
and regional differences in overall survival (OS) for patients receiving CRT.
Methods: Data from the Netherlands Cancer Registry were queried for patients 
diagnosed with stage III NSCLC from 2003 to 2011. Evaluation concerned age, 
gender, histopathology, TNM stage, year of treatment and treatment modality. 
Information regarding WHO performance score or CRT regimen (concurrent 
or sequential) was not available. Results were anonymously stratified by region 
(n=9) and radiotherapy department (n=21). Survival data were calculated from 
day of diagnosis and analysed using multivariable proportional hazards analysis.
Results: The total study group comprised 20.432 patients and 7.214 (35%) 
were treated with CRT. CRT use increased from 25% in 2003 to 46% in 2011. 
Median OS for patients treated with CRT was 19 months and five-year OS 
was 18%. Median OS improved from 16 months in 2003 to 21 months in 
2011. Five-year OS improved from 14% in 2003–2005 to 20% in 2006–2008 
(p<0.001). Multivariable analysis designated age, stage, gender and year of 
diagnosis as prognostic factors. Survival rates remained stationary after 2005. 
Histopathology type, region and radiotherapy department had no prognostic 
influence on OS.
Conclusions: Despite regional variation in treatment regimens for stage 
III NSCLC, the 5-year OS increased for all centers in the Netherlands and 
compares favorably with the recent meta-analysis. This improvement may be 
explained by better patient selection and the introduction of modern radio-
therapy techniques.
Disclosure: All authors have declared no conflicts of interest.
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POTENTIALLY FUNCTIONAL SINGLE 
NUCLEOTIDE POLYMORPHISMS IN CD133 
PREDICT LOCAL RECURRENCE AND DISTANT 
METASTASIS AFTER RADIOTHERAPY FOR 
NON-SMALL CELL LUNG CANCER
Q. Wang1, P. Li1, H. Liu2, H. Xiong2, J. Qian2, T. Xu3, Z. Liu2, Z. Liao3, Q. Wei2 
1Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou 
University, Henan Cancer Hospital, Zhengzhou, CHINA, 2Departments 
of Epidemiology, The University of Texas M. D. Anderson Cancer Center, 
Houston, TX, UNITED STATES OF AMERICA, 3Departments of Radiation 
Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, 
TX, UNITED STATES OF AMERICA
Aim: Cancer stem cells are believed to be involved in resistance to radio-
therapy and chemotherapy and responsible for local recurrence and distant 
metastasis. We hypothesized that genetic variations in CD133 (also called 
PROM1), an important marker gene of cancer stem cells, affect clinical out-
comes among patients with non-small cell lung cancer (NSCLC) treated with 
definitive radiotherapy.
Methods: We identified 393 patients with primary NSCLC who had received 
definitive radiotherapy at a single institution between March 1998 and 
February 2009. We genotyped four potentially functional single nucleo-
tide polymorphisms (SNPs) of CD133 (rs2240688A>C, rs10022537A>T, 
rs7686732G>C, and rs3130T>C) and estimated their associations with local 
recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), 
and overall survival (OS) by using Cox proportional hazards models.
Results: The rs2240688 SNP was found to be associated with LRFS and 
DMFS after adjustment for patient characteristics. Specifically, patients with 
the rs2240688C variant genotypes (AC/CC) had longer LRFS (log-rank 
P=0.048, adjusted hazard ratio [HR] =0.74, 95% CI 0.58–0.96, adjusted 
P=0.023) and DMFS (log-rank P =0.059, adjusted HR=0.76, 95% CI 0.59–
0.98, adjusted P=0.032) than did patients with the AA genotype. In stratified 
analysis, associations of the AC/CC variant genotypes with LRFS, DMFS, 
and OS were the strongest among patients with stage III-IV disease, or those 
who received <66 Gy in log-rank test and multivariable Cox models analysis.
Conclusions: Our findings suggest that rs2240688 SNP in CD133 may be 
marker for prognosis in patients with NSCLC, if confirmed in larger, prospec-
tive studies.
Disclosure: All authors have declared no conflicts of interest.
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EUROPEAN HARMONIZATION STUDY FOR THE 
IMMUNOHISTOCHEMICAL DETECTION OF ALK-
REARRANGED NSCLC (ON BEHALF OF ALL 16 
PARTICIPATING INSTITUTES ENROLLED IN THE STUDY)
M. von Laffert1, A. Warth2, R. Penzel2, P. Schirmacher2, D. Lenze1, M. 
Hummel1, M. Dietel1 1Institue of Pathology Charité, Charite Berlin Mitte, 
Berlin, GERMANY, 2Pathology, University Hospital, Heidelberg, GERMANY
Aim: The reliable identification of ALK-gene rearranged NSCLC is crucial for 
the treatment with ALK-inhibitors. Even though fluorescence in-situ hybrid-
ization (FISH) is regarded as the diagnostic gold standard, studies based on 
immunohistochemistry (IHC) seem promising. However, such an approach is 
only applicable if it is validated and standardized for multi-centre use.
Methods: To test the reliability of an ALK IHC assay in a multi-centre envi-
ronment (16 European institutes), two tissue microarrays (TMA) consisting 
of 15 NSCLC cases (3 cores/case; diameter: 1 mm/core) were independently 
tested for ALK-protein expression (binary interpretation: positive vs. nega-
tive) by each laboratory using the Ventana ALK (D5F3) Rabbit Monoclonal 
Primary Antibody combined with OptiView DAB IHC detection and 
OptiView Amplification kits. Included cases were unequivocal ALK break-
positive (6x), negative (7x) and ALK positive-“borderline” (2x) as demon-
strated by FISH. The latter show a low percentage of ALK break-positive 
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cells (around the cut-off of 15%) and are challenging for unequivocal FISH-
diagnosis. ALK breaks were confirmed by EML4-ALK-RT-PCR. To provide 
a uniform baseline interpretation, a webinar-based training was given to all 
observers.
Results: All 7 ALK FISH-negative cases were homogenously scored nega-
tive after ALK-IHC. All participants scored the 2 ALK positive-”borderline” 
cases as positive according to their ALK protein expression (RT-PCR: EML4-
ALK Variant 1 and 3a/b). Concordant IHC interpretation was also noticed 
in 4 of 6 unequivocal ALK positive cases. In the remaining 2 ALK-FISH 
positive cases, a weak and heterogeneous staining was described by some 
observers, which would have resulted in subsequent testing (FISH/ PCR) in 
their diagnostic setting.
Conclusions: After harmonization of the staining instruments and training of 
the observers, ALK IHC using the D5F3 clone in combination with OptiView 
detection can be regarded as a very reliable technique for the detection of 
ALK protein expression and is applicable for multi-centre use. So far, this 
ALK IHC assay might help as an alternative predictive test in cases with 
reduced FISH interpretability and could lead to broad use of ALK testing. 
However, further investigation is needed to implement this test as the stand-
alone pre-screening tool.
Disclosure: All authors have declared no conflicts of interest.
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SURGICAL RESULTS FOR T4 NSCLC 
INVADING MEDIASTINAL STRUCTURE
H.W. Lee1, M.C. Kang1, J.H. Park1, J.S. Koh2, H.J. Yoo3, C.H. Kim4, D.W. 
Choe5 1Thoracic Surgery, Korea Cancer Center Hospital, Seoul, KOREA, 
2Pathology, Korea Cancer Center Hospital, Seoul, KOREA, 3Radiation 
Oncology, Korea Cancer Center Hospital, Seoul, KOREA, 4Pulmonology, 
Korea Cancer Center Hospital, Seoul, KOREA, 5Radiology, Korea Cancer 
Center Hospital, Seoul, KOREA
Aim: Non-small cell lung cancer (NSCLC) with invasion of mediastinal 
structures is now classified as stage IIIA or IIIB according to N stages, and 
has been considered a surgically unfavorable category. However, in a selected 
group of these patients, better results have been reported after surgical resec-
tion compared with the non-surgical group. The aim of this study is to evalu-
ate the role of surgical resection in treatment of mediastinal T4 NSCLC and 
risk factors that need to be considered.
Methods: From 1999 to 2012, 407 patients received treatment for non-small 
cell lung cancer invading mediastinal structures. Among them, 108 patients 
(Group I) received initially surgery and 297 patients(Group II) received 
chemotherapy or chemoradiation therapy as initial treatment. Their medical 
records were reviewed and they were followed up completely until April 2013. 
We compared the clinilcal outcomes of both groups.
Results: Among group I patients, R0 resection was possible in 83 (77%) and 
their overall 5 year survival rate was 19%. Operative mortality was 8.4%, and 
80.7% was squamous cell carcinoma. Among group II patients, 31 (10.4%) 
patients underwent surgery after initial chemotherapy or chemoradiation 
therapy and their overall 5year survival rate was 17%. When nodal stage was 
N0 or N1, there was a significant survival difference between the two groups. 
(30.5% vs 19%, p=0.001) In group I, complete resection (p<0.0001) and 
adjuvant chemotherapy (p=0.013) were significant prognostic factors.
Conclusions: The operative risk of NSCLC invading mediastinal structures 
was high because of the high rate of pneumonectomy and wider range of 
resection, however it can be acceptable. Long-term outcome of the surgery 
group was better than the non-surgery group in selected patients (N0-1). 
When chemotherapy is executed as an initial therapeutic option, only 10.4% 
patients could receive complete resection. This study is not a randomized 
controlled trial study; however, our results imply that an aggressive surgical 
appraoch can be recommended in selected patients with good performance 
and N2(-) mediastinal T4 lesions.
Disclosure: All authors have declared no conflicts of interest.
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POSTOPERATIVE RADIOTHERAPY IN RESECTED 
STAGE III-N2 NON-SMALL CELL LUNG CANCER 
(NSCLC): CAN 3D-CONFORMAL RADIOTHERAPY 
IMPROVE THE 5-YEAR OVERALL SURVIVAL (OS) 
IN PATIENTS WITH PERSISTENT N2 DISEASE 
AFTER INDUCTION CHEMOTHERAPY?
C. Billiet1, Z. Gouw1, H. Decaluwé2, S. Peeters1, J. Vansteenkiste3, C. 
Dooms4, P. De Leyn2, D. De Ruysscher5 1Radiaton Oncology, University 
Hospitals Leuven, Leuven, BELGIUM, 2Thoracic Surgery and Leuven 
Lung Cancer Group, University Hospitals Leuven/ KU Leuven, Leuven, 
BELGIUM, 3Respiratory Oncology Unit (Pulmonology), University 
Hospitals Leuven - Campus Gasthuisberg, Leuven, BELGIUM, 
4Department of Pulmonology and Leuven Lung Cancer Group, University 
Hospitals Leuven - Campus Gasthuisberg, Leuven, BELGIUM, 5Radiation 
Oncology, University Hospitals Leuven - Campus Gasthuisberg, Leuven, 
BELGIUM
Aim: To investigate the effect on 5-year OS of modern postoperative radio-
therapy (PORT) in NSCLC patients with persistent N2 disease after induction 
chemotherapy.
Methods: Patients with pathologically proven N2 NSCLC who received 
induction chemotherapy followed by surgery were selected from a prospec-
tive database. In order to have at least 2 years of follow-up, we selected 
September 1999 to December 2010 as inclusion period. 103 patients with-
out progressive disease after chemotherapy underwent resection. 95% of 
patients were staged with FDG PET and 85% underwent brain imaging. In 
case of incomplete resection or persistent ypN2 status, patients received 
3D-PORT (n=53) to a dose of 50–66 Gy in 2 Gy QD fractions. Patients 
with a complete resection and nodal downstaging to ypN0 or ypN1 did not 
receive further therapy.
Results: Median follow up time was 46.3 months. For the entire operated 
group of (n=103), the 5-year outcome were: OS 31.3%, relapse free survival 
(RFS) 29.8%, 5-year cumulative local recurrence (LR) rate 51.0%. For the 
ypN2 or R1-2 resection (PORT) patients, the 5-year results were: OS 27.8 
%, RFS 28.0 %, LR 52.3%; for the ypN0-1 R0 group OS 35.7 %, RFS 32.0 
%, LR 49.3 % (table 1). None of these differences reached statistical signifi-
cance. In a multivariate analysis for OS, significant parameters for a better 
survival were PORT, downstaging after chemotherapy and completeness of 






ypN2 or R1 
resection (with 
PORT)
n 103 50 53
OS 31.3% 35.7% 27.8% (p=0.84)
RFS 29.8% 32.0% 28.0% (p=0.52)
LR 51.0% 49.3% 52.3% (p=0.51)
 PORT: post-operative radiotherapy; OS: overall survival; RFS: relapse free 
survival; LR: local recurrence;p: p-value PORT vs no PORT in univariate 
aynalysis.
Conclusions: Although patients having received PORT were a group with 
adverse prognostic factors, their LR and OS were similar to ypN0 or yPN1 
patients, suggesting that PORT may improve OS. As LR also remains high 
in the ypN0 and ypN1 groups, PORT is worth to be investigated (as in the 
ongoing EORTC Lung- ART trial) or considered in these patients, as well as 
optimizing local control in all groups.
Disclosure: All authors have declared no conflicts of interest.
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CONCURRENT CHEMO-RADIOTHERAPY IN PATIENTS 
WITH LOCALLY ADVANCED NSCLC: TOXICITY AND 
CLINICAL ASSESSMENT USING VMAT (RAPID ARC)
A.M. Ascolese1, F. De Rose1, P. Navarria1, M.C. Campisi1, E. Villa1, C. 
Iftode1, A. Stravato1, L. Cozzi2, S. Tomatis1, M. Scorsetti1 1Radiotherapy and 
Radiosurgery, Humanitas Research Hospital, Rozzano, ITALY, 2Physics, 
IOSI, Bellinzona, SWITZERLAND
Aim: In locally advanced NSCLC (stage IIIA-IIIB) concurrent chemo-radio-
therapy improves clinical outcomes compared with sequential treatments. 
However, patient selection and increased toxicity represent main limitation 
to the use of combined modalities. In this study we investigated toxicity and 
clinical outcomes in concurrent chemo-radiotherapy of advanced lung cancer 
using volumetric modulated arcs therapy (VMAT) by rapid arc (RA).
Methods: Patients with locally advanced NSCLC, age<70 years, good per-
formance status (PS 0-1) and minimal weight loss (< 10% within the 3 months 
prior to diagnosis) underwent to concurrent chemo-radiotherapy. Total body 
computed tomography (CT) scan, FDG positron emission tomography (PET) 
and pathological diagnosis were performed in each patient before treatment 
and every three months thereafter. Patients received five cycles cisplatin and 
etoposide (CDDP-VP16) every 21 days. The first cycle was completed prior 
to the radiotherapy. Total dose prescription was 60-70 Gy/30-35 fractions. 
Acute and late toxicity were evaluated by RTOG and CTCAE v. 4.0 score 
respectively. Evaluation of tumour response was defined according to the 
Response Evaluation Criteria in Solid Tumor (RECIST) v1.1.
Results: Between May 2009 and March 2013 44 patients were treated at our 
Institution. Patients characteristics: IIIA(N2)/IIIB 25/19; m/f 29/15; adeno/squa-
mous/NOS 29/10/5; age: median 62 (range 37-69). Acute Esophageal toxicity 
Grade 1- 2 occurred in all patients. No grade 3 toxicity occurred. Only one patient 
had a symptomatic pneumonia a month after the end of concurrent treatment requir-
ing hospitalization. The median follow up was 24 months (range 4-48). Four patients 
had only locoregional progression and eight patients had local and systemic disease 
progression. The overall survival at 1, 2, 3 years was 70%, 45%, 35% respectively.
Conclusions: Concurrent chemo-radiotherapy using VMAT proved to be a 
safe and advantageous treatment modality for locally advanced NSCLC with 
good toxicity profile. Clinical outcomes were satisfactory and comparable to 
the literature data.
Disclosure: All authors have declared no conflicts of interest.
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FEASIBILITY AND EFFICACY OF INDUCTION 
CHEMO OR CHEMORADIATION FOLLOWED BY 
CURATIVE RESECTION OR RADIOTHERAPY IN 
ELDERLY PATIENTS WITH LOCALLY ADVANCED 
NON-SMALL CELL LUNG CANCER
D. Marquez-Medina, A. Martin-Marco, A. Gasol-Cudos Medical Oncology, 
University Hospital Arnau de Vilanova, Lleida, SPAIN
Aim: Half of lung cancers are diagnosed as locally-advanced non-small cell 
lung cancer (LA_NSCLC) in patients older than 60 years. However, elderly 
patients are rarely included in multimodal programs of inductive chemother-
apy (CT) or chemo-radiation (CRT). We analyzed the feasibility and efficacy 
of induction CT or CRT followed by surgery or curative RT in elderly patients 
with LA-NSCLC.
Methods: We retrospectively reviewed the 108 ECOG-0-2 LA-NSCLC 
diagnosed in our center from October 2005 to June 2012. All of them were 
treated by combining induction CT or CRT plus surgery or RT. Feasibility, 
tolerability, and efficacy were compared between patients younger and older 
than 70 years.
Results: Mean age of the series was 66.7 years. Sixty-four patients were 
younger (59.2%) and 44 older than 70 years (40.7%). Female patients 
were 7.4% only. Elderly trended to present worse ECOG score (p= 0.088), 
but no differences in respiratory function were found. Proportion of 
squamous cell carcinomas, adenocarcinomas, and non-specified NSCLC 
was similar between age groups. Stage-IIIB NSCLC were more common 
among elderly patients (35.9% vs. 50%). Treatment was: 1) Induction 
CRT plus Surgery in 26.5% and 15.9% of younger and elderly patients, 
respectively; 2) induction CRT plus RT in 32.8% and 34%; 3) induc-
tion CT plus surgery in 26.5% and 31.8%, and; 4) induction CT plus 
RT in 14% and 18.1%. CT included platinum-doublets with vinorelbine, 
gemcitabine, and taxanes. Carboplatin- doublets were more commonly 
used in elderly patients. No differences were found in clinical and metha-
bolic responses by PET/SCAN (p= 0.723 and p= 0.323, respectively). 
Grade 3-4 toxicity was higher among younger patients (20.3 vs. 6.8%, 
p= 0.053). No grade 3-4 pneumonitis was detected. Resection was per-
formed in 50 patients: 1) Pneumonectomy in 31.4 vs. 23.5%, respectively; 
2) Lobectomy in 54.3 vs. 52.9%, respectively; 3) Sublobar-resections in 
8.6 vs. 23.5%, respectively. Medistinal dissection was performed in 90% 
of cases. Pathologic responses did not differ between age group. No dif-
ferences in disease free and overall survival were found (p= 0.959 and 
0.757, respectively).
Conclusions: Induction treatment including CT or CRT plus surgery or RT 
are feasible and tolerable in elderly patients. Their tolerance, response, and 
outcome is at least as well as that found in younger patients.
Disclosure: All authors have declared no conflicts of interest.
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THE COMPARATIVE EVALUATION OF RADIOTHERAPY 
WITH CONCURRENT WEEKLY CISPLATIN VERSUS 
CONCURRENT 3-WEEKLY CISPLATIN AND ETOPOSIDE 
IN PATIENTS WITH UNRESECTABLE LOCALLY 
ADVANCED NON SMALL CELL LUNG CANCER
P.K. Bagri1, P. Hirapara1, A. Kapoor1, M. Singhal1, D. Singh1, S.L. Jakhar1, 
S.K. Beniwal2, N. Sharma1, H. Kumar1, A. Sharma1 1Radiation Oncology, 
Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, 
INDIA, 2Medical Oncology, Acharya Tulsi Cancer Treatment and Research 
Institut, Bikaner, INDIA
Aim: In India, lung cancer is currently the fourth most common cancer 
and accounts for nearly 8% of all cancer related deaths. In our centre, 
lung cancer contributes approximately 8-10% of all newly diagnosed 
cases. This is a prospective comparison of weekly cisplatin to 3-weekly 
cisplatin and etoposide as concurrent chemotherapy with standard radio-
therapy (CCRT) for unresectable locally advanced non-small cell lung 
cancer (LA-NSCLC).
Methods: Between July 2011 and July 2013, 60 patients with histologically 
confirmed unresectable LA-NSCLC, Eastern Cooperative Oncology Group 
(ECOG) performance status 0-2, who met inclusion criteria were randomly 
assigned in two different groups of CCRT. In the first group, cisplatin (40 mg/
m2) was given intravenously (IV) on a weekly basis for a total of six cycles 
(n=30). In the second group, cisplatin (40 mg/m2 IV day 1-2) and etoposide 
(120 mg/m2 IV day 1-3) were repeated on a 3-weekly basis for a total of three 
cycles (n=30). The total dose of radiotherapy was 66 Gy. Dose schedule of 
radiotherapy was 2Gy per fraction and 5 fractions in a week. The primary end 
point was response rate at 6 weeks post-treatment. Patients were followed for 
15 months after completion of treatment for treatment response, toxicities and 
overall survival.
Results: 6 weeks after completion of treatment, complete response was 
seen in 13.8% and 10.3% patients (p=0.47); partial response in 17.2% and 
34.5% (p=0.016); stable disease in 41.4% and 31% (p=0.22); and pro-
gressive disease was seen in 27.6% and 24.1% patients (p=0.62) in first 
group and second group, respectively. Median overall survival was 8.5 
months and 10 months (p=0.72), and survival at 15 months was 30.7% and 
39.6% (p=0.4) in the first and second group, respectively. Of acute toxici-
ties, grade I & II haematological, renal toxicities, and pneumonitis were 
more common in second group; nausea, vomiting, and esophagitis were 
more common in first group. Of chronic toxicities, grade I & II renal and 
skin toxicities were more common in the second group, while grade I & II 
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esophagitis was common in the first group. Differences in toxicities were 
not statistically significant.
Conclusions: A better response rate was achieved with the 3-weekly cisplatin 
and etoposide regimen, and overall survival was also improved in 3-weekly 
cisplatin and etoposide regimen as compared with that seen with weekly cis-
platin for CCRT.
Disclosure: All authors have declared no conflicts of interest.
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COMPARATIVE EVALUATION OF NON-CONVENTIONAL 
RADIATION AND CHEMORADIATION IN LOCALLY 
ADVANCED NON-SMALL CELL LUNG CANCER
Y. Ragulin1, D. Gogolin2, Y. Mardynsky2, I. Gulidov2, I. Ivanova2, A. Zolotkov2 
1Thoracic, Medical Radiological Research Center, Obninsk, RUSSIAN 
FEDERATION, 2Radiology, Medical Radiological Research Center, Obninsk, 
RUSSIAN FEDERATION
Aim: Results of the treatment of inoperable locally advanced non-small cell 
lung cancer are unsatisfactory. To improve the results of treatment of patients 
there is a need for new treatment approaches. Non-traditional modes of radia-
tion therapy and the simultaneous use of chemotherapy can be an alternative 
to the traditional treatment methods. The aim of this study was to compare the 
efficiency of a radiotherapy and chemoradiotherapy in the mode accelerated 
hyperfractionation.
Methods: To improve the results of treatment of inoperable locally advanced 
non-small cell lung cancer (NSCLC) IIB-IIIB stage a methodology of accel-
erated hyperfractionated was developed with uneven crushing of the daily 
dose into two fractions (1 +1.5 Gy with an interval of 5-6 hours) to give a total 
focal dose of 60-70 Gy. In the period from 2005 to 2012, 123 patients with a 
verified diagnosis of NSCLC were treated by this method. The patients were 
divided into two groups. The study group included 55 patients who received 
concurrent chemoradiotherapy (2 courses with cisplatin and etoposide), and 
the control group consisted of 68 patients who received only a radical course 
of radiation therapy.
Results: The overall three-year survival rate in the study group was 37.5%, 
and in the control group 19%; complete regression of the tumor in the study 
group was 7.2%, compared with 4.4% in the control. Acute reactions of II-III 
degree esophagitis were seen in 32.6% in the intervention group and in 29.5% 
in the control group. Acute reactions from the blood were observed only in the 
study group and were as follows: grade 2 leukopenia 10.9%, grade 3 leukope-
nia 5.5%, anemia 7.2%, thrombocytopenia 3.6%.
Conclusions: Thus, we can conclude that simultaneous chemoradiotherapy 
conducted as described, using hyperfractionated accelerated with uneven 
crushing daily dose is satisfactorily tolerated and improves long-term 
outcomes.
Disclosure: All authors have declared no conflicts of interest.
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THE IMPACT OF EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATION ON CENTRAL 
NERVOUS SYSTEM (CNS) INVASION AND 
SURVIVAL IN PATIENTS WITH SURGICALLY 
RESECTED LUNG ADENOCARCINOMA
T. Akita, T. Etou, Y. Shishido, S. Morita, K. Asada, M. Hirose, S. Ota, M. 
Fujii, T. Shirai Pulumonary Division, Shizuoka-General-Hospital, Shizuoka, 
JAPAN
Aim: CNS invasion is common in patients with non-small cell lung cancer 
(NSCLC) and associated with a poor outcome. For patients who have devel-
oped CNS invasion, those with epidermal growth factor (EGFR) mutation 
derive clinical benefit from EGFR tyrosine kinase inhibitors (TKIs). The 
clinical manifestation of CNS invasion, the EGFR mutation, and progno-
sis are unclear in patients with resected stage I to III lung adenocarcinoma. 
The aim of this study is to analyze the impact of EGFR gene mutation on 
CNS-recurrence and prognosis in patients with surgically resected lung 
adenocarcinoma.
Methods: Between March 2002 and January 2012, 29 patients underwent the 
complete resection of stage I to III lung adenocarcinoma and developed CNS 
progression in their clinical course. Pathological records including EGFR muta-
tion testing were reviewed retrospectively. Basic patient demographics, EGFR 
mutation data, survival data and information on the first treatment for CNS pro-
gression were collected. Kaplan Meier curves were used for survival analysis.
Results: Twenty-nine patients were identified, with a median age of 63. The 
cumulative incidence of CNS progression was significantly higher in those 
with the EGFR mutation (69%) compared with the EGFR wild-type (38%). 
Tumor stages I, II, and III numbered 11, 8, and 10, respectively. The time from 
surgery to CNS invasion was 20 months for those with the EGFR mutation 
and 9 months for patients with the EGFR wild-type. MST from surgery was 
83 and 49 months, respectively. MST from CNS progression was 42 and 6 
months, respectively (P=0.002). The rate of the first treatment being gamma 
knife therapy for CNS lesions was 90% for patients with EGFR mutation and 
44% for patients with the EGFR wild-type.
Conclusions: Compared with EGFR wild-type, we observed the late occur-
rence of CNS invasion and significantly better survival in patients with EGFR 
mutation showing CNS invasion in their clinical course. The present findings 
suggest that we need to be aware of the occurrence of CNS invasion, and com-
bined modality treatment including EGFR-TKI and gamma knife therapy is 
important in CNS recurrence in patients with EGFR mutation with surgically 
resected lung adenocarcinoma.
Disclosure: All authors have declared no conflicts of interest.
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A MULTI-CENTER PHASE II RANDOMIZED STUDY OF 
CUSTOMIZED NEOADJUVANT THERAPY VS. STANDARD 
CHEMOTHERAPY (CT) IN NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS WITH RESECTABLE 
STAGE IIIA (N2) DISEASE (CONTEST TRIAL)
F. Grossi1, E. Rijavec1, G. Barletta1, C. Genova1, C. Sini1, M.G. Dal Bello1, G. 
Burrafato1, G.B. Ratto2, M. Truini3, D.F. Merlo4 1Lung Cancer Unit, IRCCS 
AOU San Martino IST - Istituto Nazionale per la Ricerca sul Cancro, Genova, 
ITALY, 2Department of Thoracic Surgery, IRCCS AOU San Martino IST - 
Istituto Nazionale per la Ricerca sul Cancro, Genova, ITALY, 3Department of 
Pathology, IRCCS AOU San Martino IST - Istituto Nazionale per la Ricerca 
sul Cancro, Genova, ITALY, 4Unit of Epidemiology And Biostatistics, IRCCS 
AOU San Martino IST - Istituto Nazionale per la Ricerca sul Cancro, Genova, 
ITALY
Background: The most powerful prognostic factor that has been identi-
fied in stage IIIA is clearance of mediastinal lymph nodes and pathologic 
complete response (pCR). A pCR is obtained in 5-15% of pts with a sig-
nificant survival prolongation. The identification of molecular biomarkers, 
such as excision repair cross-complementation 1 (ERCC1), ribonucleotide 
reductase subunit M1 (RRM1), and thymidylate synthase (TS), may predict 
response to CT. Similarly, EGFR mutations may predict response to EGFR 
inhibitors.
Trial design: CONTEST, a multicenter (19 Italian centers), randomized (2:1) 
2-arm phase II study, recruits pts with resectable stage IIIA (N2) NSCLC. 
Pts will be randomized to receive before resection either standard CT with 
Cisplatin (CDDP) + Docetaxel (Doc) or customized therapy using prede-
termined values for ERCC1, RRM1, TS, and EGFR mutations. Specimens 
are sent to Response Genetics (Los Angeles, CA, USA) for the evaluation of 
ERCC1, RRM1 and TS using RT-PCR and EGFR using Sanger sequencing. 
The choices of customized arms are as follows:
-EGFR+: Gefitinib.
-EGFR-/non-squamous (NS)/TS-/ERCC1-: CDDP + Pemetrexed.
-EGFR-/squamous (S) or NS TS+/ERCC1-/RRM1+: CDDP + Doc.
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-EGFR-/S or NS TS+/ERCC1-/RRM1-: CDDP + Gemcitabine (Gem).
-EGFR-/S or NS TS+/ERCC1+/RRM1+: Doc + Vinorelbine.
-EGFR-/S or NS TS+/ERCC1+/RRM1-: Doc + Gem.
The primary end point will be obtained by comparing the pCR in all random-
ized pts based on treatment arm. Because pCR is a surrogate endpoint and 
given the expected proportion of pCR’s in the control group pc= 5%, the mini-
mal clinically worthwhile effect of this customized treatment is an increase in 
this proportion to 20%. To detect such an effect at the 0.05 (1-sided) signifi-
cance level with 80% power, a total of 168 pts (112 in the investigational arm 
and 56 in the standard arm) will be enrolled. Secondary endpoints are: OS, 
DFS, OS at 1, 2 and 5 years, Overall Response, safety.
This study is open for accrual; further details can be found on ClinicalTrials.
gov (NCT01784549). Funded by the Italian Ministry of Health – RF 
2009-1530324.
Disclosure: All authors have declared no conflicts of interest.
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QUALITY OF LIFE (QOL) ANALYSIS FROM ENSURE, 
A PHASE 3, OPEN-LABEL STUDY OF FIRST-LINE 
ERLOTINIB VERSUS GEMCITABINE/CISPLATIN (GP) 
IN ASIAN PATIENTS WITH EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE 
(MUT+) NON-SMALL-CELL LUNG CANCER (NSCLC)
Y. Wu1, C. Zhou2, G. Wu3, X. Liu4, Z. Zhong5, S. Lu6, M.C.L. Fernando7, C. 
Liam8, M. Chen9, Y. Zuo10 1Guangdong Lung Cancer Institute, Guangdong 
General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, 
CHINA, 2Department of Oncology, Affiliated Shanghai Pulmonary Hospital 
of Tongji University, Shanghai, CHINA, 3Cancer Center, Union Hospital, 
Tongji Medical College, Huazhong University of Science and Technology, 
Wuhan, CHINA, 4Department of Lung Cancer, 307 Hospital of PLA, Beijing, 
CHINA, 5Cancer Centre, Research Institute of Surgery, Daping Hospital, 
Third Military Medical University, Chongqing, CHINA, 6Shanghai Lung 
Cancer Center, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong 
University, Shanghai, CHINA, 7Internal Medicine, Manila Doctors Hospital, 
Manila, PHILIPPINES, 8Department of Medicine, University of Malaya, 
Kuala Lumpur, MALAYSIA, 9Biostatistics, Roche Product Development 
in Asia Pacific, Shanghai, CHINA, 10Roche Product Development in Asia 
Pacific, Shanghai, CHINA
Aim: ENSURE, a randomised, phase 3 study, met its primary endpoint of 
improved progression-free survival (PFS) with erlotinib vs GP in Asian 
patients with EGFR mut+ NSCLC: interim analysis median PFS 11.0 vs 5.5 
months (HR 0.34, 95% CI 0.22–0.51; p<0.0001); updated analysis median 
PFS 11.0 vs 5.5 months (HR 0.33, 95% CI 0.23–0.47). QoL is important 
in assessing treatment benefit, as it examines the balance between efficacy 
and tolerability. Here we present QoL data from ENSURE (updated data 
cut-off).
Methods: Patients ≥18 years with histologically confirmed stage IIIB/IV 
EGFR mut+ NSCLC were randomised 1:1 to erlotinib (oral; 150mg qd until 
progression/unacceptable toxicity) or GP (G 1250mg/m2 iv d1 & 8 q3w; 
P 75mg/m2 iv d1 q3w; ≤4 cycles). QoL was assessed every 6 weeks until 
week 25, then every 12 weeks until progression. The Functional Assessment 
of Cancer Therapy-Lung (FACT-L) questionnaire was used, comprising sub-
scales on physical, emotional, social and functional well-being, as well as 
the lung cancer subscale (LCS). These were used to calculate time to symp-
tomatic progression (≥3-point decline in LCS score from baseline), time to 
deterioration in Trial Outcome Index (TOI; ≥6-point decline in LCS score 
plus physical and functional scores from baseline) and time to deterioration 
in QoL (≥6-point decline in TOI score plus social and emotional scores from 
baseline). Data cut-off was 19 November 2012.
Results: FACT-L completion rates were 99% for erlotinib and 98% for GP at 









E GP E GP E GP
Median, 
mo 13.8 5.5 11.4 4.2 8.2 2.8
HR 0.56 0.51 0.64
95% CI 0.36–0.87 0.34–0.76 0.44–0.93
p 0.0076 0.0006 0.0168
Conclusions: Erlotinib was associated with improved QoL (FACT-L) com-
pared with GP across all assessments, providing further support for the use of 
first-line erlotinib for Asian patients with EGFR mut+ NSCLC.
Disclosure: Y. Wu: Speaker fee from Roche, AstraZeneca, Eli Lilly, Sonofi, 
Pfizer M. Chen: M. Chen is an employee of Roche Product Development 
in Asia Pacific, China. Y. Zuo: Y. Zuo is an employee of Roche Product 
Development in Asia Pacific, China. All other authors have declared no con-
flicts of interest.
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TUMOR BURDEN AND TYROSINE KINASE 
INHIBITORS (TKI) BENEFIT IN ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC) PATIENTS 
WITH EGFR SENSITIZING MUTATIONS (EGFRM) 
AND ALK REARRANGEMENT (ALK+)
C. Leduc1, N. Moussa2, L. Faivre3, P. Biondani4, J. Pignon5, C. Caramella2, 
B. Besse4 1Pneumologie, Hopitaux Universitaires de Strasbourg, Strasbourg, 
FRANCE, 2Radiologie, Institut Gustave Roussy, Villejuif, FRANCE, 
3Biostastistique, Institut Gustave Roussy, Villejuif, FRANCE, 4Oncologie, 
Institut Gustave Roussy, Villejuif, FRANCE, 5Biostatistique, Institut de 
Cancérologie Gustave Roussy, Villejuif, FRANCE
Aim: EGFRm and ALK+ are eligible to TKI. Predictive factors of response 
to TKI are poorly known, in particular the impact of the initial tumor burden. 
The objective of this study is to define if the initial tumor volume impacts TKI 
benefit in advanced NSCLC with EGFRm or ALK+.
Methods: We retrospectively reviewed all consecutive patients with advanced 
NSCLC harboring EGFRm or ALK+ in a single center (Gustave Roussy). 
Baseline clinical characteristics were collected. CT images were centrally 
reviewed to assess initial tumor volume (volumetry software program lung 
VCAR, GE Healthcare), number, and type of metastatic lesions. EGFRm 
patients were treated with gefitinib or erlotinib, and ALK+ patients with 
crizotinib. Uni and multivariate Cox analyses were used to correlate with 
progression-free-survival (PFS) and overall survival (OS).
Results: Ninety-seven patients (80 EGFRm, 14 ALK+, 3 both) treated from 
june 2006 to november 2013 were included: median follow up was 31 months 
(m), median age 57 years, 70% of females. Median PFS and OS were 8.5 (95% 
CI: 7.3-11) and 25 (16.2 - 28.7) m. Patients were divided in 3 groups according 
to their volume (n=33, 31 and 33). A significant decrease in PFS with increasing 
tumor volume was found (<35 cm3: median 9.0 m 95% CI (5.7-21.2); 35-74 
cm3: 8.0 m (7.3-15.3); > 75 cm3: 7.3 m (4.3-10.1); p for trend=0.04). In multi-
variate analysis, results were similar when number of sites with metastasis and 
genomic alteration were included (<35 cm3: HR=1; 35-74 cm3: HR=1.54 95% 
CI [0.87-2.72]; > 75 cm3: HR=1.73 [1.01-2.96], p for trend=0. 04), but they 
were not significant when sex and presence of liver metastasis were included. 
Initial tumor volume was not associated to OS. Number of metastatic sites was 
associated with PFS and OS in multivariate analysis.
Conclusions: In patients with EGFRm and ALK+ advanced NSCLC treated 
by TKI, PFS, but not OS, decreases with increasing tumor volume. Number 
of metastatic sites is a stronger survival predictor. Those results suggest that 
TKI onset should not be delayed after diagnosis or begun after a cytoreductive 
treatment such as chemotherapy.
Disclosure: All authors have declared no conflicts of interest.
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FIRST-IN-HUMAN EVALUATION OF CO-1686, 
AN IRREVERSIBLE, HIGHLY SELECTIVE 
TYROSINE KINASE INHIBITOR OF MUTATIONS 
OF EGFR (ACTIVATING AND T790M)
H. Wakelee1, J. Soria2, R. Camidge3, S. Gadgeel4, J. Goldman5, A. Varga2, 
B. Solomon6, V. Papadimitrakopoulou7, P. Kaur8, L.V. Sequist9 1Thoracic 
Oncology, Stanford University, Stanford, CA, UNITED STATES OF 
AMERICA, 2Medical, Institut Gustave Roussy, Villejuif, FRANCE, 3Medical, 
University of Colorado, Denver, CO, UNITED STATES OF AMERICA, 
4Medical, Karmanos Cancer Institute, Detroit, MI, UNITED STATES OF 
AMERICA, 5Medical, UCLA, Santa Monica, CA, UNITED STATES OF 
AMERICA, 6Department of Medical Oncology, Peter MacCallum Cancer 
Centre, Melbourne, AUSTRALIA, 7Medical Oncology, MD Anderson 
Cancer Center, Houston, TX, UNITED STATES OF AMERICA, 8Clinical, 
Clovis Oncology, Boulder, CO, UNITED STATES OF AMERICA, 9Medical, 
Massachusetts General Hospital, Boston, MA, UNITED STATES OF 
AMERICA
Aim: Efficacy of existing EGFR tyrosine kinase inhibitors (TKIs) in 
NSCLC is limited by emergence of the T790M mutation in approxi-
mately 60% of patients, and significant skin rash and diarrhea, caused by 
wild-type (WT)-EGFR inhibition. CO-1686 is an oral, covalent TKI that 
targets common activating EGFR mutations and T790M, while sparing 
WT-EGFR.
Methods: This is an ongoing first-in-human dose finding study in patients 
with EGFR mutated recurrent, advanced NSCLC. All patients are previously 
treated with an EGFR TKI and must undergo tumor tissue biopsy within 28 
days before study drug dosing for central EGFR genotyping. Oral CO-1686 is 
administered continuously in 21-day cycles. Endpoints include safety, phar-
macokinetics (PK), and efficacy.
Results: As of 15th November 2013, 66 patients were treated with 
CO-1686; initially, 57 with CO-1686 free base, up to 900mg BID (N=19 
dose expansion at 900 mg BID); then, following formulation optimiza-
tion, 9 with CO-1686 HBr up to 750 mg BID). Dose escalation continues. 
70% of patients are T790M+,14% are T790M unknown/pending, median 
age is 60 years, 80% are female, 80% are white, and 75% are ECOG 
1. The median number of previous therapies was 3 (range: 1- 6); 45% 
had received > one line of EGFR TKI. Treatment-related AEs (all grades) 
occurring in ≥20% patients were: nausea (21%) and fatigue (20%). The 
majority of all events were mild or moderate. Events typical of EGFR 
WT inhibition, in particular rash combined with diarrhea, have not been 
observed. Nine T790M+ patients treated with 900 mg BID (free base) 
were evaluable for response; 6 (67%) achieved PRs, 2 (22%) achieved 
SD. One patient at a lower dose also achieved a PR. Eight of the 9 patients 
had progressed on an EGFR TKI immediately before initiating CO-1686. 
Data for the cohorts receiving the optimized formulation are maturing and 
current data will be presented at the meeting.
Conclusions: CO-1686 has demonstrated good tolerability and promis-
ing efficacy against proven T790M+ EGFR mutant NSCLC. Dose-related 
WT-driven diarrhea and rash has not been seen. Dose escalation is con-
tinuing with CO-1686 HBr which has improved exposure and reduced PK 
variability.
Disclosure: H. Wakelee: Research funding from Clovis Oncology to 
Stanford University. R. Camidge: Advisory board member for Clovis 
Oncology. S. Gadgeel: Research funding from Clovis to Karmanos. J. 
Goldman: Advisory board member and research funding from Clovis 
Oncology. B. Solomon: Advisory board member for Clovis Oncology. P. 
Kaur: Employee and stock owner of Clovis Oncology Ltd L.V. Sequist: 
Advisory board member for Clovis Oncology. Research funding from 
Clovis Oncology to Mass General. All other authors have declared no con-
flicts of interest.
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LUNG ADENOCARCINOMA WITH RET 
FUSION: EARLY EXPERIENCE WITH 
DIAGNOSIS AND TARGETED THERAPY
O. Gautschi1, G. Pall2, A. Schultheis3, F. Aebersold Keller4, M. Gardizi3, J. 
Heuckmann5, S. Merkelbach-Bruse3, J. Diebold4, J. Wolf6, L. Heukamp3 1Klinik für 
Onkologie, Luzerner Kantonsspital, Luzern, SWITZERLAND, 2Innere Medizin, 
Universitätskliniken Innsbruck, Innsbruck, AUSTRIA, 3Institut für Pathologie, 
Universitätsklinikum Köln, Köln, GERMANY, 4Institut für Pathologie, Luzerner 
Kantonsspital, Luzern, SWITZERLAND, 5Blackfield AG, Köln, GERMANY, 
6Innere Medizin, Universitätsklinikum Köln, Köln, GERMANY
Aim: Lung adenocarcinoma with RET fusion is a new diagnostic entity with 
potential clinical implications. Experience with diagnosis and targeted ther-
apy is limited.
Methods: In November 2012, we integrated RET break-apart fluorescence in-
situ hybridization (FISH) into our diagnostic test algorithms for primary lung 
adenocarcinoma. Positive cases were recorded in our databases, and clinical 
outcomes were collected from patients who received RET inhibitors on an indi-
vidual compassionate use or off-label use basis. Next generation sequencing 
and PCR were performed on selected diagnostic and repeat biopsy samples, to 
identify RET kinase mutations and fusion partners. All patients with targeted 
therapy consented to treatment, translational research and publication.
Results: By November 2013, 529 consecutive tumor samples were analysed by 
RET-FISH in our diagnostic laboratories. Twelve (2.3%) samples were positive, and 
none carried a secondary mutation in EGFR, HER2, KRAS, BRAF, ALK, or ROS1. 
So far, 4 pts with RET fusion and previous chemotherapy received one or more lines 
of targeted therapy. One pt received sunitinib and had prolonged disease stabiliza-
tion. Three pts received vandetanib as first targeted therapy and 2 had a response. 
The same 3 pts received cabozantinib as second targeted therapy after progression 
on vandetanib. Two pts had a response to cabozantinib and one pt started with pona-
tinib recently. Three pts had tumor rebiopsy after targeted therapy. Molecular analy-
ses are ongoing and updated results will be presented at the meeting.
Conclusions: The incidence of RET fusion was higher than expected, and 
preliminary activity of targeted therapy was confirmed. Of note, we observed 
preliminary activity of cabozantinib in pretreated tumors with primary and 
secondary resistance to vandetanib. Activation of a global phase II trial with 
cabozantinib in RET fusion positive lung cancer is planned. Clinicians should 
be aware of it, and refer eligible patients to participating centers.
Disclosure: J. Heuckmann: Co-founder, shareholder and full time employee 
of Blackfield AG, Cologne, Germany All other authors have declared no con-
flicts of interest.
95PD
MOLECULAR HETEROGENEITY AND 
RESPONSE TO GEFITINIB OF EGFR MUTANT 
ADVANCED LUNG ADENOCARCINOMA
E. Bria1, S. Pilotto1, E. Amato2, M. Fassan2, S. Novello3, T. Vavalà3, L. Righi3, 
I. Sperduti4, A. Scarpa5, G. Tortora1 1Medical Oncology, Azienda Ospedaliera 
Universitaria Integrata Verona-“Borgo Roma”, Verona, ITALY, 2Applied 
Research on Cancer Center, ARC-NET, Verona, ITALY, 3Medical Oncology, 
Azienda Ospedaliero-Universitaria ASOU San Luigi Gonzaga, Orbassano, 
Turin, ITALY, 4Biostatistics, Regina Elena National Cancer Institute, Roma, 
ITALY, 5Pathology and Diagnostics, University of Verona, Verona, ITALY
Aim: Among EGFR mutant advanced lung adenocarcinoma (ALA) patients 
treated with Gefitinib, 40% benefit for >12 months, while 1/3 rapidly progress. 
Assessment of molecular heterogeneity may help identify these clinically rel-
evant subgroups.
Methods: Eighteen EGFR mutant ALA treated with gefitinib in first line were 
analyzed for mutations in 22 genes using paraffin embedded tissues and next-
generation sequencing (NGS) technology (Ion Lung and Colon Cancer Panel, 
Life Technologies), which also permits the assessment of the Rate of Mutated 
Cells (RMC). Patients were grouped according to the time to progression: 
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poor responders (progression at first disease assessment); intermediate and 
good responders (within or after 12 months).
Results: Patients features: m/f 6/12, and had median age 72 yrs (range 37-83), 
PS 0/1: 14/4, EGFR deletion-19/L858R: 13/5, progressions/deaths: 13/7. At 
gefitinib therapy, 6 (33%) were poor, 5 (28%) intermediate, and 7 (39%) good 
responders. Median progression-free-survival (PFS) was 1.7 (95% CI 0.1-3.2), 
6.1 (95% CI 3.0-9.2), and 17.9 months (8.9-25.7) for poor, intermediate and 
good responders, respectively (p<0.0001). Median RMC for EGFR was 33.5%, 
46% and 64% for poor, intermediate and good responders, respectively. A trend 
towards significance was found between pts with a EGFR-RMC cut-off of 30% 
(p[Tarone-Ware]=0.17). Mutated genes in addition to EGFR were: TP53 in 7 
cases; KRAS and CTNNB1 in 2 cases each; PIK3CA, SMAD4 and MET in 1 
patient each, respectively. TP53 mutations with a median RMC of 45% occurred 
exclusively among poor and intermediate responders (poor/intermediate vs 
good responders, 66.7% vs 0%, p[Fisher]=0.01). A significant difference in PFS 
between patients with more than 1 mutation and an EGFR-RMC <30% (10 pts, 
median PFS 12.3 [95% CI 5.9-18.7]) and those with EGFR mutation alone with 
a RMC >30% (6 pts, median PFS 3.0 [95% CI 0.1-5.9]), p[Tarone-Ware]=0.05.
Conclusions: Our pilot study shows that NGS technology may reveal of help 
to characterize EGFR mutant ALA patients into clinically significant prognos-
tic and/or predictive subgroups, according to the proportion of EGFR mutated 
cells and of the associated molecular lesions. The study is ongoing to a larger 
series to assess its validity in accurately predicting the individual patient risk
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL ACTIVITY, SAFETY AND SUBPOPULATION 
RESPONSE ANALYSIS OF NIVOLUMAB (ANTI-PD-1; 
BMS-936558; ONO-4538) IN PATIENTS (PT) WITH 
NON-SMALL CELL LUNG CANCER (NSCLC)
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Institute, Tampa, UNITED STATES OF AMERICA, 4Hematology/oncology, 
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, UNITED 
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Hospital, Boston, MA, UNITED STATES OF AMERICA, 6Bristol-Myers 
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Aim: Treatment with nivolumab, a fully human IgG4, PD-1 immune check-
point inhibitor antibody resulted in durable objective responses (ORs) 
and prolonged stable disease in pts with advanced NSCLC in a phase 1 
study (CA209-003; NCT00730639) (Topalian S, et al. N Engl J Med. 
2012;366:2443-54). We report long-term safety, efficacy, updated survival 
outcomes and clinical activity in subpopulations of the NSCLC cohort.
Methods: NSCLC pts received nivolumab 1, 3, and 10 mg/kg IV Q2Wk with 
tumor assessment (RECIST 1.0) after each 4-dose cycle. Clinical activity by 
select pt characteristics (age, gender, ECOG PS, histology, number of prior 
therapies, prior TKI therapy, EGFR and KRAS status) was also assessed.
Results: 129 pretreated NSCLC pts (non-squamous [n=74], squamous [n=54], 
unknown histology [n=1]) were treated as of September 2013. Durable OR 
occurred in 22 pts (17%); estimated median duration, 74.0 wk (6.1+, 133.9+); 
with responses ongoing in 45% (10/22) of pts. Responses were rapid; 50% of 
pts (11/22) demonstrated response at first tumor assessment (8 wk) and in some 
pts continued following treatment discontinuation. Across doses, 1- and 2-year 
OS rates were 42% and 24%. Across histologies, median OS was 9.9 months 
across doses and 14.9 months at 3 mg/kg. Any grade drug-related select adverse 
events occurred in 41% (53/129) of pts (grade 3/4, 5% [6/129]); most common 
were skin (16%), gastrointestinal (12%), and pulmonary (7%). Any grade drug-
related pneumonitis occurred in 6% (8/129) of pts (grade 3/4, 2% [3/129]), 
resulting in 2 deaths early in the trial and leading to increased emphasis on man-
agement algorithms. Responses were observed across a broad range of NSCLC 
pt populations regardless of histology, including pts with >3 prior therapies, pts 
>70 years old and pts with/without tumors driven by KRAS or EFGR mutations.
Conclusions: In advanced NSCLC pts, nivolumab produced durable responses 
and survival benefit with a long-term safety profile acceptable for the outpatient 
setting. Responses were observed in a wide array of NSCLC pt populations. 
These findings support the ongoing development of nivolumab in phase 3 trials.
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NINTEDANIB (BIBF 1120) + DOCETAXEL AS 2ND-
LINE THERAPY IN PATIENTS WITH STAGE IIIB/IV 
OR RECURRENT NSCLC: RESULTS OF THE PHASE 
III, RANDOMISED, DOUBLE-BLIND LUME-LUNG 1 
TRIAL. (FOR THE LUME-LUNG 1 STUDY GROUP)
M. Reck1, A. Mellemgaard2, J. Douillard3, S. Orlov4, M. Krzakowski5, 
J. von Pawel6, M. Gottfried7, B. Gaschler-Markefski8, R. Kaiser8, S. 
Novello9 1Thoracic Oncology, Lung Clinic Grosshansdorf, Grosshansdorf, 
GERMANY, 2Oncology, Herlev University Hospital, Herlev, DENMARK, 
3Medical Oncology, Centre René Gauducheau, Nantes, FRANCE, 4Thoracic 
Oncology, St. Petersburg State Medical University, Petersburg, RUSSIAN 
FEDERATION, 5Oncology, The Maria Sklodowska-Curie Institute of 
Oncology, Warsaw, POLAND, 6Oncology, Pneumology Clinic, Asklepios 
Fachkliniken, Gauting, GERMANY, 7Lung Cancer Unit, Meir Medical Center, 
Kfar Saba, ISRAEL, 8Oncology, Boehringer Ingelheim Pharma GmbH & Co. 
KG, Biberach, GERMANY, 9Oncology, University of Turin, Turin, ITALY
Background: Nintedanib (N) inhibits VEGFRs, PDGFRs and FGFRs. LUME-
Lung 1 was a placebo (P) controlled Phase III trial of N + docetaxel (D) in patients 
with locally-advanced/metastatic NSCLC progressing after 1st line therapy.
Methods: Stage IIIB/IV or recurrent NSCLC patients (stratified by histology, 
ECOG PS, prior bevacizumab and brain metastases) were randomised to N 
200mg bid + D 75mg/m2 q21d (n=655) or P+D (n=659). The primary endpoint 
was centrally reviewed PFS after 713 events. The key secondary endpoint, OS, 
was analysed hierarchically after 1121 events (1. adenocarcinoma patients <9mo 
since start of 1st line therapy, 2. all adenocarcinoma patients, 3. all patients). 
Predefined sensitivity analyses added sum of longest diameters of target lesions 
(SLD) to stratification factors in the Cox model. Patient-reported quality of life 
(QoL) was recorded at regular intervals using standard QoL questionnaires.
Results: Patient characteristics were balanced between the arms. N+D prolonged 
PFS v P+D (HR 0.79; CI 0.68–0.92; p=0.0019; median 3.4 v 2.7mo) regard-
less of histology (squamous HR 0.77, p=0.0200; adenocarcinoma HR 0.77, 
p=0.0193). OS was significantly prolonged in adenocarcinoma patients (HR 0.83; 
p=0.0359; median 12.6 v 10.3mo) and in T<9mo adenocarcinoma patients (HR 
0.75; p=0.0073; median 10.9 v 7.9mo). A trend for improved OS was seen for the 
overall patient population (HR 0.94; p=0.2720; median 10.1 v 9.1mo). Adjusted 
for SLD, OS benefit was seen in all patients (HR 0.88; CI 0.78–0.99; p=0.0365). 
Patients with squamous cell histology with a high tumour burden showed a trend 
towards improved OS (SLD ≥7.5cm; HR 0.82; p=0.0995; median OS 7.7 v 
6.1mo). Survival benefits were achieved without substantial alterations in patient-
reported QoL. The most common AEs were diarrhoea (any: 42.3 v 21.8%; Gr ≥3: 
6.6 v 2.6%) and ALT elevations (any: 28.5 v 8.4%; Gr ≥3: 7.8 v 0.9%).
Conclusions: N+D significantly improved PFS independent of histology, and 
prolonged OS for adenocarcinoma patients. AEs were generally manageable 
with dose reductions and symptomatic treatment.
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Abstracts Journal of Thoracic Oncology ®  •  Volume 9, Number 4, Supplement 1, April 2014
Disclosure: M. Reck: 1. Compensated Member of Advisory Board: 
Hoffmann-La Roche, Lilly, BMS, AstraZeneca, Daiichi-Sankyo, Pfizer 2. 
Honoraria for lectures: Hoffmann-La Roche, Lilly, BMS, AstraZeneca, 
Daiichi-Sankyo, Pfizer J. Douillard: Consultant/Advisory: Boehringer 
Ingelheim J. von Pawel: Consultant or advisory: Boehringer Ingelheim B. 
Gaschler-Markefski: Employment: Boehringer Ingelheim Pharma GmbH & 
Co. KG R. Kaiser: Employment: Boehringer Ingelheim Pharma GmbH & Co. 
KG All other authors have declared no conflicts of interest.
98PD
EXON 20 MUTATIONS OF THE EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) IN LUNG 
ADENOCARCINOMAS: CLINICOPATHOLOGIC 
FACTORS AND RESPONSE TO THERAPY
J. Naidoo1, C.S. Sima2, M.D. Hellmann1, M.E. Arcila3, N.A. Rizvi1, H.A. 
Yu1 1Thoracic Oncology, Memorial Sloan-Kettering Cancer Center, New 
York, NY, UNITED STATES OF AMERICA, 2Department of Epidemiology 
and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, 
UNITED STATES OF AMERICA, 3Department of Pathology, Memorial 
Sloan-Kettering Cancer Center, New York, UNITED STATES OF AMERICA
Aim: EGFR exon 20 insertions or point mutations in EGFR S768 or R776 
represent 10-15% of mutations in EGFR. It is unclear whether their presence 
predicts response to EGFR tyrosine kinase inhibitors (TKI).
Methods: Patients with EGFR exon 20 insertions (Ex20ins) or point mutations 
were identified through molecular pathology testing including a PCR-based 
fragment length analysis, mass spectrometry-based genotyping (Sequenom) 
and Sanger sequencing. Age, gender, performance status (PS), smoking history, 
mutation position and size as well as concurrent mutations were noted. Treatment 
data including progression free survival (PFS) on cytotoxic chemotherapy and 
EGFR TKI was collected for patients with stage IV disease. Overall survival 
(OS) of these patients was compared to a cohort of patients with either sensitiz-
ing EGFR mutations (Exon 19 del or L858R) or EGFR/KRAS wild-type (WT).
Results: From 2009-2013, 77 patients were identified, 55 (71%) had Ex20ins, 
18 (23%) had S768I, and 4 (5%) had R776H. Nineteen patients (24%) had 
concurrent mutations in EGFR (74%, n=14), KRAS (16%, n=3) or PI3K 
(11%, n=2). Among the patients with Ex20ins 66% were female, 57% were 
never smokers and the median age was 69 years. 61% (n=34) had a 9bp inser-
tion (range 3-26 bp). Compared to patients with sensitizing EGFR mutations, 
patients with Ex20ins were older (p=0.04) and more likely to have PS≥80 
(p<0.001). There was no difference in OS between patients with Ex20ins and 
those with sensitizing EGFR mutations (1yr OS 86% vs 90%, p=0.45). Both 
groups had better OS compared to stage-matched EGFR/KRAS WT patients 
(Ex20ins vs WT, p=0.028). Twelve patients received erlotinib: 8 Ex20ins, 3 
S768I and 1 R776H. The best radiologic response was a partial response, with 
a median PFS of 3 months on erlotinib (range <1 mo to 8 years).
Conclusions: OS in stage IV patients with EGFR Ex20ins is similar to those 
with classically sensitizing mutations, and superior to EGFR/KRAS WT patients. 
Patients with EGFR Ex20ins and point mutations exhibited a range of responses 
to EGFR TKI, suggesting that the decision to treat with EGFR TKI should be 
individualized based on the specific genetic alterations within EGFR exon 20.
Disclosure: All authors have declared no conflicts of interest.
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HIGH PROPORTION OF COMPLETE RADIOLOGIC 
AND METABOLIC RESPONSE AND PROLONGED 
PROGRESSION-FREE SURVIVAL AFTER INTERCALATED 
CHEMOTHERAPY AND ERLOTINIB FOR ADVANCED 
NSCLC WITH ACTIVATING EGFR MUTATIONS
M. Zwitter, V. Kovac Department of Radiotherapy, Institute of Oncology, 
Ljubljana, SLOVENIA
Aim: NSCLC with activating EGFR mutations is a tumor sensitive to both 
tyrosine kinase inhibitors (TKIs) and to cytotoxic drugs. To avoid their mutual 
antagonistic effect and still derive benefit from the combination, pharmaco-
dynamic separation of the two classes of drugs has been proposed. Here we 
present experience from a Phase 2 trial on patients with advanced NSCLC with-
out prior systemic treatment and with confirmed activating EGFR mutations.
Methods: Eligible patients had stage IIIB or IV NSCLC with activating EGFR 
mutations; had not received any prior systemic therapy; fulfilled the standard 
criteria for platin-based chemotherapy; and provided written informed con-
sent. Patients received gemcitabine (1250 mg/m2 on days 1 and 4), cisplatin 
(75 mg/m2 on day 2) and erlotinib (150 mg on days 5 to 15) every 3 weeks for 
4 – 6 cycles, followed by uninterrupted erlotinib maintenance. The primary 
objective was progression-free survival (PFS); secondary objectives were tox-
icity, response to treatment, metabolic response and overall survival (OS).
Results: Among 35 patients (19 female; mean age 61 years), 34 had stage IV 
disease, 8 were in performance status (PS) 2-3 and 13 had brain metastases (1 
untreated and 12 after whole-brain radiotherapy). Grade 4 toxicity included 1 
case of neutropenia and 4 thrombo-embolic events. Among 31 patients with 
measurable disease, complete response (CR) or partial response (PR) accord-
ing to RECIST was seen in 13 (41.9%) and 13 (41.9%) patients, respectively, 
for an overall response rate of 83.9%. PET-CT scanning was performed in 
27 patients and confirmed CR and PR in 13 (48.1%) and 11 (40.7%) cases, 
respectively (objective metabolic response 88.9%). Median PFS was 24.3 
months (95% CI 17.7 – 30.8). Median OS was 32.5 months (25.5 – 39.5). 
After median follow-up of 29 months, 20 patients are alive, of whom 9 con-
tinue the treatment and are still in CR.
Conclusions: High response rate and long PFS obtained in our trial of inter-
calated therapy are most promising, especially after considering a relatively 
unfavourable population of patients. A randomized trial with comparison to 
monotherapy with TKI is clearly warranted.
Disclosure: All authors have declared no conflicts of interest.
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PGG β-GLUCAN WITH CARBOPLATIN, PACLITAXEL 
AND CETUXIMAB FOR CHEMOIMMUNOTHERAPY OF 
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
F. Schneller1, M. Thomas2, P. Sadjadian3, J. Kollmeier4, N. Bose5, M. 
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GERMANY, 4Lung Clinic Heckeshorn, Helios Clinic von Behring, 
Berlin, GERMANY, 5Immunology R&D, Biothera, Inc., Eagan, UNITED 
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STATES OF AMERICA
Aim: PGG β-glucan (Imprime PGG®, Imprime) primes innate immune cells 
to kill monoclonal antibody-targeted cancer cells via complement receptor 3 
(CR3). In humans, naturally occurring anti-beta glucan antibodies (ABA) are 
required for binding of Imprime to CR3. Subjects with ABA levels conducive 
to binding are considered “biomarker positive” (BM+).
Methods: In a Phase 2 study, stage IIIb/IV NSCLC subjects received cetux-
imab (CET) 250 mg/m2 following initial 400 mg/m2 loading dose) without 
(Control, N=30) or with Imprime 4mg/kg (Imprime, N=60) on Days 1, 8 
and 15 of each 3-week treatment cycle of carboplatin (AUC 6) + paclitaxel 
(200 mg/m2) on Day 2 for the first 4 to 6 cycles. After completion, subjects 
achieving radiographic stable disease or tumor response (RECIST 1.0) 
received CET or CET/Imprime maintenance treatment.
Results: Among all RECIST-evaluable treated subjects, median overall sur-
vival (mOS) was 11.2 mo in the control group (N=26), 10.2 mo in the entire 
Imprime group (N=46) (HR 1.06, p=0.85 vs. control), 16.5 mo in the BM+ 
Imprime group (N=15) (HR 0.63, p=0.26) and 9.1 mo in the BM- Imprime 
group (N=31) (HR 1.35, p=0.35). Three-year survival was 0% in the control 
group, 7% in the entire Imprime group, 17% in the BM+ Imprime group 
and 0% in the BM- Imprime group. The objective response rate (ORR, 
S41Copyright © 2014 by the European Lung Cancer Conference organisers, ESMO, and IASLC.
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primary endpoint for the study) was 23% in the control group, 48% in the 
entire Imprime group (p= 0.048 vs. control), 67% in the BM+ Imprime group 
(p=0.009) and 39% in the BM- Imprime group (p=0.26). Among subjects 
with squamous cell histology (SqCC), 6 of 6 BM+ Imprime subjects had 
responses compared with 3 of 10 control subjects (p=0.01). In SqCC sub-
jects, mOS was 15.6 vs. 12.2 mo in BM+ Imprime subjects (N=6) vs. control 
(N=10), respectively (HR 0.62, p=0.47). Demographic factors of age, gender 
and ECOG performance status were balanced across analysis populations. 
Adverse events were consistent with toxicities attributable to the cytotoxic 
drugs or CET.
Conclusions: In summary, the addition of Imprime PGG to the chemoimmu-
notherapy regimen of carboplatin, paclitaxel and CET resulted in improved 
outcomes in BM+ subjects with respect to increased ORR and extended sur-
vival compared to control subjects and had a good safety profile.
Disclosure: N. Bose: Employee of Biothera, Inc. M. Antonysamy: Employee 
of Biothera, Inc. M. Patchen: Employee of Biothera, Inc. J. Lowe: Employee 
of Biothera, Inc. P. Mattson: Employee of Biothera, Inc. All other authors 
have declared no conflicts of interest.
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THYMIDYLATE SYNTHETASE (TYMS) EXPRESSION 
IS NOT PREDICTIVE IN PATIENTS WITH METASTATIC 
NSCLC TREATED WITH PEMETREXED, CISPLATIN 
AND BEVACIZUMAB IN THE SAKK19/09 TRIAL
O. Gautschi1, S. Rothschild2, Q. Li3, S. Savic4, L. Bubendorf4, M. Brutsche5, 
L. Stalder3, N. Mach6, A. Ochsenbein7, R. Jaggi8 1Klinik für Onkologie, 
Luzerner Kantonsspital, Luzern, SWITZERLAND, 2Medical Oncology, 
University Hospital Basel, Basel, SWITZERLAND, 3Coordinating Center, 
SAKK, Bern, SWITZERLAND, 4Pathology, University Hospital Basel, 
Basel, SWITZERLAND, 5Pulmonology, Kantonsspital St. Gallen, St. 
Gallen, SWITZERLAND, 6Oncology, Geneva University Hospital, Geneva, 
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SWITZERLAND, 8Department of Clinical Research, Bern University, Bern, 
SWITZERLAND
Aim: Retrospective data suggest thymidylate synthetase (TYMS) expression 
as a predictive marker for pemetrexed activity in patients (pts) with advanced 
nonsquamous NSCLC. We prospectively measured TYMS by quantitative 
PCR (qPCR) in the phase II trial SAKK19/09 (NCT01116219).
Methods: The clinical results of SAKK19/09 were reported recently 
(Gautschi et al, WCLC 2013). This trial enrolled 77 pts with advanced 
nonsquamous NSCLC and EGFR wild type. Pts received 4 cycles of cis-
platin (or carboplatin), pemetrexed and bevacizumab, followed by peme-
trexed and bevacizumab maintenance. All tumor samples were tested for 
KRAS mutations. RNA isolation and qPCR for TYMS were performed 
from tissue sections or core biopsies (AmpTec, Hamburg, Germany). Two 
independent sets of control genes were used for normalization, one internal 
set (GAPDH, RPLP0, TFRC, UBB) and one external set (GUSB, HMBS, 
SDHA, TOP1) published recently (Nicholson et al, JTO 2013). TYMS 
expression was calculated using TYMS quantification cycle (Cq) value 
minus mean Cq value of control genes. The exact Wilcoxon Mann-Whitney 
rank sum test was used to assess the association between progression free 
survival (PFS) at 6 months/objective response (OR) and TYMS expression, 
while Cox regression was used to assess the association between PFS/over-
all survival (OS) and TYMS expression.
Results: Sufficient high-quality RNA was available for qPCR in 57 out of 77 
pts (74%). Large variation was observed for normalized TYMS expression 
(range 1.8-37.6). We found no statistically significant associations between 
TYMS expression based on the internal control set with PFS at 6 months 
(primary endpoint, P=0.56), PFS (P=0.97), OS (P=0.68), or OR (P=0.47). 
Using the external control set, all results stayed insignificant. KRAS mutation 
associated with poor OS (P=0.03), but not with TYMS expression (P=0.8).
Conclusions: This study showed significant intertumor heterogeneity and no 
predictive value for TYMS expression in pts with NSCLC and pemetrexed 
therapy. Until the results of other prospective trials are available, we do not 
recommend the use of TYMS expression for clinical decision-making outside 
of a controlled trial.
Disclosure: All authors have declared no conflicts of interest.
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CHARACTERIZATION OF PD-L1 EXPRESSION 
AND ASSESSMENT OF ASSOCIATION WITH 
TUMOR HISTOLOGY AND GENE EXPRESSION 
STATUS IN PRETREATMENT NON-SMALL CELL 
LUNG CANCER (NSCLC) TUMOR SPECIMENS
C.T. Harbison, J.F. Kurland, C.E. Horak, J.P. Cogswell, H.D. Inzunza, X. Hu, 
X. Han, J.F. Novotny, J.S. Simon, M.N. Jure-Kunkel Oncology, Bristol-Myers 
Squibb, Princeton, UNITED STATES OF AMERICA
Aim: Immunohistochemistry (IHC) analysis suggested an association 
between pretreatment tumor programmed death ligand 1 (PD-L1) expression 
and response to the human IgG4 PD-1 immune checkpoint inhibitor antibody 
nivolumab (Nivo) (Grosso ASCO 2013 abstract 3016). Associating PD-L1 
expression with gene profiles, mutational status, or patient (pt) characteristics 
may inform which pts may be more likely to benefit from Nivo therapy.
Methods: 60 NSCLC tumor samples (Asterand) were analyzed. PD-L1 
expression was evaluated by IHC using an automated assay with the sensitive 
and specific PD-L1 monoclonal antibody clone 28-8. PD-L1 positivity (PD-
L1+) was defined as ≥5% tumor cell membrane staining at any intensity. DNA 
mutations were analyzed on the AmpliSeq™ cancer panel. Gene expression 
was conducted on the Affymetrix platform and association with PD-L1 status 
analyzed by ANOVA.
Results: 25/59 (42%) tumor samples were PD-L1+. No association between 
PD-L1 protein expression and NSCLC histology was apparent: 38% squa-
mous and 47% non-squamous tumors were PD-L1+. PD-L1+ tumors showed 
higher expression of several immune-related genes (eg, interferon-gamma) 
and other genes involved in immune-cell regulation. The PD-L1 gene was 
differentially expressed in PD-L1+ and PD-L1-negative samples, with no 
continuous relationship noted. Genes for tumor progression and signaling 
pathways (eg, proto-oncogene tyrosine kinase [MET]) were over-expressed 
in PD-L1+ tumors. PD-L1 positivity was observed amongst KRAS mutation 
positive (8/10) and wild-type tumors (15/43). PD-L1 positivity was not asso-
ciated with PTEN or EGFR protein expression.
Conclusions: PD-L1 expression on NSCLC tumors may associate with fac-
tors, including expression of immune genes, tumor progression markers, and 
driver mutations. Ongoing analyses of this tumor panel and ongoing Phase 
III studies are exploring putative associations of PD-L1 expression with pt 
characteristics and outcomes to help define other factors that may influence 
the likelihood of response to Nivo.
Disclosure: C.T. Harbison, J.F. Kurland, C.E. Horak, J.P. Cogswell, X. Hu, X. 
Han, J.F. Novotny, J.S. Simon, and M.N. Jure-Kunkel: Employed by and has 
stock ownership in Bristol-Myers Squibb. All other authors have declared no 
conflicts of interest.
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COMPARATIVE ANALYSIS OF INCIDENCE AND 
TREND OF NON-HEMATOLOGIC TOXICITIES IN 
ADVANCED NON-SMALL-CELL LUNG CANCER 
PATIENTS TREATED WITH EGFR TKIS
A. Passaro, E. Del Signore, F. de Marinis Division of Thoracic Oncology, 
European Institute of Oncology, Milan, ITALY
Aim: Rash and diarrhoea are frequently observed in patients receiv-
ing epidermal growth factor receptor (EGFR) tyrosine kinase inhibi-
tor (TKI) therapy in advanced non-small-cell lung cancer (NSCLC). 
Nowadays, three different EGFR TKIs are approved for the treatment of 
patients harbouring EGFR mutations, though these drugs showed dif-
ferent safety profile. Among patients treated with afatinib, erlotinib and 
S42 Copyright © 2014 by the European Lung Cancer Conference organisers, ESMO, and IASLC.
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gefitinib, we performed a retrospective comparative analysis evaluating 
the incidence and trend of rash and diarrhoea, before and after correct 
management.
Methods: Patients and methods: From 2010 to 2013, we evaluated 158 
patients with advanced NSCLC treated in first-, second- or third-line with the 
EGFR TKIs: afatinib, erlotinib or gefitinib. We assessed the incidence of rash 
and diarrhoea by grade (G) at initial assessment (< 30 days) compared to last 
assessment after correct management.
Results: The incidence of toxicities (rash, diarrhoea) classified by grade at the 
initial assessment, and the re-evaluation after management demonstrated an 
approximate reduction of 95% from the starting toxicity grade for diarrhoea 
and approximately 65% for cutaneous rashes. The time course for skin rash 
appearance from the time of starting TKIs was 7 days (95% CI: 5 to 12 days) 
for afatinib, 9 days (95% CI: 7 to 18 days) for erlotinib, and 14 days (95% 
CI: 9 to 19 days) for gefitinib. The time course for diarrhoea onset was 13 
days (95% CI: 7-18 days) for erlotinib, 18 days (95% CI: 10 to 19 days) for 
gefitinib 5 days (95% CI: 4 to 11 days) for patients receiving afatinib. About 
82% of all AE were grade 1/2 in severity and 10% were grade ≥3. However, 
the results collected after reparative management were similar and did not 
demonstrate any significant differences among the three different drug. Most 
patients had lower grades of AEs at their last assessment compared with their 
initial assessment. The last evaluation for the toxicity profile was similar for 
the three EGFR TKIs used.
Conclusions: This analysis suggests that immediate therapeutic approaches 
and continuous management are required to ensure patient treatments with-
out severe adverse events (SAEs) that could adversely affect survival and the 
quality of life (QoL). No significant differences were detected among the 
three different drug, when evaluated after management.
Disclosure: All authors have declared no conflicts of interest.
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SURGICAL MANAGEMENT IN OLIGOMETASTATIC 
NON–SMALL CELL LUNG CANCER: A 
CRITICAL ANALYSIS FROM A SINGLE 
CENTER MULTIDISCIPLINARY TEAM
L. Bertolaccini1, A. Viti1, M. Merlano2, I. Colantonio2, E. Russi3, A. Terzi1 
1Division of Thoracic Surgery, Azienda Ospedaliera St. Croce e Carle, Cuneo, 
ITALY, 2Division of Medical Oncology, Azienda Ospedaliera St. Croce e 
Carle, Cuneo, ITALY, 3Division of Radiation Oncology, Azienda Ospedaliera 
St. Croce e Carle, Cuneo, ITALY
Aim: Does oligometastatic (OMTS) state in NSCLC justify aggressive 
approach? Clinical study: radical surgery in OMTS NSCLC.
Methods: Observational study on prospectively collected data. Minimum 
follow-up >12 months. We defined surgically resectable OMTS NSCLC, 
primary tumor with 1 eradicable MTS in patients aged <75 years fit for 
surgery. Data of 27 OMTS NSCLC were collected. Survivals were calcu-
lated by Kaplan-Meier. Univariate (Wilcoxon and Log–Rank) and multi-
variate (Cox) analysis identified independent prognostic factors.
Results: Characteristics and postoperative features were reported in Table. 
MTS sites were brain (18), adrenal gland (6), and vertebrae (3). For brain 
MTS, 11 patients underwent surgical radical excision, and 7 radiosur-
gery. Adrenal MTS underwent surgery, vertebral MTS radiation therapy. 
Therapeutic sequences were MTS treatment/neoadjuvant therapy/lung sur-
gery in 6 (22.2%); MTS treatment/lung surgery in 9 (33.3%); neoadjuvant 
therapy/lung surgery/MTS treatment in 7 (25.9%); and lung surgery/MTS 
treatment in 5 (18.6%). Lung resection was complete in all cases. There was 
no 30-day mortality. Major complications occurred in 3 (11.1%): 1 pneumo-
nia, and 2 bleeding with reoperation. Minor complications occurred in 14 
(51.9%): 5 arrhythmias, 8 persistent air leak, 1 atelectasia. Adjuvant therapy 
was administered in 8 (29.6%). Median follow-up was 53 months (minimum: 
12 months). At last follow-up, 10 (37.1%) had died of disease, 5 (18.5%) alive 
with disease, and 12 (44.4%) alive with no evidence of disease. At multivari-
ate analysis, pN was correlated with overall survival (p = 0.005). Mediastinal 
involvement influenced control of disease (p = 0.017). Control of MTS 
(surgery or radiation therapy) has seem to impact on disease-free survival 
(p < 0.001). Disease-free survival was 38 months.
Age 61 (56 – 74)
ECOG - 0 - 1 21 6
Stage cTN - IA - IB - IIA - IIB 16 11
Histology - Adenocarcinoma - Squamous 20 7
Lung surgery - Lobectomies - Bilobectomies - 
Pneumonectomies
24 1 2
Stage pTN - IA - IB - IIA - IIB - IIIA 9 14 4
First recurrence - Local - Distant 5 1 4
Conclusions: Surgery in selected OMTS NSCLC represents feasible and 
effective option. Completeness of resection and pN0 status emerged as pre-
dictive factors for long-term survival. Further prospective investigations are 
needed for this highly debated cohort of patients.
Disclosure: All authors have declared no conflicts of interest.
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A LITERATURE-BASED META-ANALYSIS ABOUT 
THE COMPARISON BETWEEN PLATINUM-
BASED DOUBLET AND SINGLE AGENT 
CHEMOTHERAPY IN PS 2 NSCLC PATIENTS
C.D. Rolfo1, F. Passiglia1, G. Bronte2, S. Rizzo2, I. Gil Bazo3, E. Fiorentino4, 
J.P. Van Meerbeeck5, A. Russo2 1Phase I- Early Clinical Trials Unit, Antwerp 
University Hospital, Edegem, BELGIUM, 22. Department of Surgical, 
Oncological and Oral Sciences, Section of Medical Oncology, Palermo 
University, Palermo, ITALY, 3Medical Oncology, Clinica Universidad de 
Navarra, Pamplorna, SPAIN, 4Department of Surgical, Oncological and Oral 
Sciences, Section of Surgical Oncology, Palermo University, Palermo, ITALY, 
5Thoracic Oncology, Multidisciplinary Oncology Center Antwerp (MOCA), 
Antwerp University Hospital, Edegem, BELGIUM
Background: Platinum-based doublet chemotherapy is still the stan-
dard 1st-line treatment for most EGFR wild-type NSCLC patients with 
performance status (PS) 0-1. However the treatment of PS2 patients is 
still controversial. Single-agent treatment with third-generation agents is 
recommended as the best option. Recently new prospective, randomized- 
phase III trials showed very interesting updates regarding the treatment 
of PS2 population. This meta-analysis aims to review all randomized tri-
als comparing platinum-based doublets and single-agents in NSCLC PS2 
patients.
Methods: Data from all published randomized trials, that compared efficacy 
and safety of platinum-based doublets to single agents in untreated NSCLC 
patients either wholly or partially dedicated to PS2, were collected by search-
ing in PubMed and Cochrane Library. Pooled ORs were calculated for the 
1-Year Survival-Rate (1-Y-SR), Overall Response Rate (ORR), and grade 3-4 
(G3-4) hematologic toxicities.
Results: Five eligible trials (620 NSCLC PS2 patients) were selected among 
1367 studies. Pooled analysis showed a significant improvement in ORR 
(OR: 3,243; 95% CI: 1,883-5,583) and 1-Y-SR (OR: 1,906; 95% CI: 1,281-
2,836) in favor of platinum doublet chemotherapy. Hematologic toxicity data 
were obtained from 4 out of these 5 trials. G3-4 anemia (OR: 2,743; 95% CI: 
1,359-5,536), neutropenia (OR: 7,956; 95% CI: 3,999-15,828) and throm-
bocytopenia (OR: 12,882; 95% CI: 4,901-33,857) were observed more fre-
quently in patients receiving platinum.
Conclusions: This meta-analysis suggests that platinum-based combina-
tion regimens are superior to single-agent chemotherapy both in terms of 
ORR and survival-rate with increase of severe hematological toxicities. 
Carboplatin-based combination appears a feasible treatment option in first-
line therapy of wild-type NSCLC PS2 patients. However we need to bet-
ter understand which factors induce a worse PS, i.e. comorbidities or tumor 
S43Copyright © 2014 by the European Lung Cancer Conference organisers, ESMO, and IASLC.
Journal of Thoracic Oncology ®  •  Volume 9, Number 4, Supplement 1, April 2014 Abstracts
burden, to select a favorable subgroup of patients who could better tolerate 
platinum-based doublet chemotherapy.
Disclosure: All authors have declared no conflicts of interest.
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EFFICACY AND SAFETY OF BEVACIZUMAB IN ELDERLY 
PATIENTS WITH LUNG CANCER ADENOCARCINOMA
K.N. Syrigos, D. Vassos, M. Panagiotarakou, G. Tsoukalas, G. Athanasiadis, 
E. Sepsas, I. Gkiozos Oncology Unit GPP, Sotiria General Hospital, Athens 
School of Medicine, Athens, GREECE
Aim: Bevacizumab is a novel anti-angiogenic agent used in many advanced 
solid tumours, including non-squamous NSCLC. In contrast to clinical stud-
ies where enrolled patients are fit, many elderly NSCLC patients suffer from 
co-morbidities and often have history of a Cardiovascular Disease.
Methods: Medical records of 2672 patients diagnosed with NSCLC between 
2001-2012 were screened. We identified and examined patients ≥75 years old 
treated with bevacizumab, for their demographics, clinical data and treatment 
details. We focused on those elderly patients with stable pre-existing cardio-
vascular disease.
Results: 356/2672 NSCLC patients received Bevacizumab at any treat-
ment line. 33/382 (8,6%) were ≥75 years old. Of those, 29 had various 
co-morbidities including 19 patients with stable cardiovascular disease 
on medical treatment. In the 19 patients with Cardiovascular disease the 
male: female ratio was 17:2 and mean age 77 years (range 75-86). 8/19 
patients had impaired renal function. All patients were of Performance 
Status ECOG 0/1. Median number of Bevacizumab cycles was 5 (range 
2-11). 17/19 patients experienced ≥1 side effects (11 epistaxis and hae-
moptysis, 5 proteinuria, 4 hypertension) which led to treatment discon-
tinuation in 5 patients. No major/fatal adverse events were noted. 8/19 
patients (42%) showed radiological partial response and 5 (19%) stable 
disease (total disease control rate 61%). Median survival from initiation 
of Bevacizumab till death/last follow up was 7 months (range 2-28, 95% 
CI 5.14-12.55).
Conclusions: Treatment with Bevacizumab seems to be safe and effective in 
elderly NSCLC patients with controlled pre-existing cardiovascular disease 
and good performance status. These patients might benefit from participation 
in clinical trials similarly to younger NSCLC patients.
Disclosure: All authors have declared no conflicts of interest.
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EFFICACY AND SAFETY OF ERLOTINIB IN ELDERLY 
PATIENTS WITH LUNG CANCER ADENOCARCINOMA
K.N. Syrigos, P. Boura, D. Vassos, A. Vassias, A. Bastas, A. Boufas, I. Gkiozos 
Oncology Unit GPP, Sotiria General Hospital, Athens School of Medicine, 
Athens, GREECE
Aim: Besides chemotherapy, Erlotinib is another option in NSCLC patients 
especially in those with EGFR mutations. Elderly patients enrolled in tri-
als are fit without co-morbidities, but in clinical practice most suffer from 
co-morbidities.
Methods: Medical records of 1221 patients diagnosed with NSCLC between 
2008-2012 were screened. We examined patients ≥75 years for demographics, 
clinical data and Treatment details.
Results: 233/1221 NSCLC patients received erlotinib at any line. 53/233 
(23%) were ≥75 years old. Male:female ratio was 34:19 and median 
age 79 years (range 75-88). NSCLC subtypes included 31 adenoca, 8 
squamous cell, 9 NOS and 5 others. 50/53 patients had co-morbidities 
(≥2 in 46 patients, 1 in 4 patients). Main co-morbidities were cardiovas-
cular disease (n=41), COPD (n=14), other cancer (n=10) and diabetes 
(n=8). 8 patients were tested for EGFR mutations (5 negative, 3 positive). 
Performance Status was satisfactory (ECOG 0-1) in 8 patients and poor 
(2-3) in 45 patients. 8 patients were treated with erlotinib 100mg and 
45 patients with erlotinib 150mg (12 patients needed dose reduction). 
Complete follow up data were found in 46 patients. Mean duration of 
treatment was 79 days (range 9-662). 35/46 patients experienced side 
effects [rash n=29, diarrhea n=17] which led to treatment discontinua-
tion in 12 patients. Patients with abnormal creatinine clearance (n=13) 
were more likely to stop treatment due to side effects (6/13 versus 6/33). 
17/46 patients (37%) achieved disease control (5 PR –partial response, 
12 SD- stable disease) and a time to progression (TTP) of 157 days (range 
106-662, 95% CI 132.79-270,74) while 22/46 patients had PD as best 
response (TTP 49days, range 19-88, CI 44,67-64,97). 7patients were not 
evaluable (stopped Treatment due to side effects). All EGFR positive 
patients had disease control (2PR, 1SD).
Conclusions: Erlotinib is a valuable option in elderly NSCLC patients with 
co-morbidities, especially if they harbor EGFR mutations. Impaired renal 
function might be associated with propensity to side effects and early treat-
ment discontinuation.
Disclosure: All authors have declared no conflicts of interest.
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TREATMENT COMPLIANCE, TOLERANCE AND 
EFFICACY IN ELDERLY PATIENTS WITH ADVANCED 
NON-SMALL CELL LUNG CANCER RECEIVING  
FIRST LINE CHEMOTHERAPY: A COMPARATIVE  
STUDY
G. Mountzios1, M. Bakogeorgos2, E. Mpournakis2, P. Economopoulou1, N. 
Kentepozidis1, M.A. Dimopoulos2 1Medical Oncology, 251 Airforce General 
Hopsital, Athens, GREECE, 2Medical Oncology, University of Athens School 
of Medicine, Athens, GREECE
Aim: Elderly patients with advanced non-small cell lung cancer (NSCLC) 
tend to receive suboptimal treatment mainly due to fears of poor compliance 
and excessive toxicity.
Methods: Using the age of 70 years as the cut-off, we identified all elderly 
patients with advanced NSCLC who received first line chemotherapy 
between 2007 and 2012 in two tertiary cancer centers and compared them 
with their younger counterparts in terms of: i) adherence to treatment, 
including dose intensity (DI) and relative dose intensity (RDI), ii) toxic-
ity and tolerance and iii) efficacy outcomes, including progression-free 
survival (PFS) and overall survival (OS). We evaluated the association 
between treatment schedule, age group and clinical outcome using logistic 
regression models.
Results: Among 292 eligible patients, complete data were available for 
245, of whom 107 (43.7%) belonged to the elderly group. This group was 
associated with the presence of comorbidities (p<0.0001), non-smoking 
status (p<0.001), diagnosis based on cytology instead of biopsy or surgery 
(p=0.047) and with performance status of 2 or more (p=0.012). As com-
pared to the younger, older patients were more likely to receive single-agent 
therapy (29.2% vs 8.0%, p<0.001), less likely to receive platinum-based 
combination chemotherapy (57.9% vs 80.3%, p<0.001), received fewer 
treatment cycles (median: 4 vs 5, p=0.073) and necessitated more days of 
hospitalization (median: 9 vs 6 days, p=0.033). Younger patients were more 
likely to receive cytotoxic drugs with optimal dosing, using the threshold of 
RDI >0.8 (49.6% vs 33%, p=0.012) and the threshold of RDI>0.9 (29.6% vs 
16%, p=0.015). Substantial (Grade 3-4) toxicity was similar in both groups 
(p=0.487). There were no significant differences in efficacy outcomes 
between the two groups.
Conclusions: Although type, intensity and duration of first-line chemother-
apy differ between elderly and younger patients with advanced NSCLC, this 
was not translated in significant differences in treatment efficacy or toxicity. 
These data further support the use of optimal treatment regimens in elderly 
patients with NSCLC
Disclosure: All authors have declared no conflicts of interest.
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EPIDERMAL GROWTH FACTORS TYROSINE-KINASE 
INHIBITORS (EGFR-TKI) EFFICACY IN NSCLC 
PATIENTS WITH HIGH POLYSOMY OF CHROMOSOME 
7 AND EGFR/KRAS WILD TYPE TUMORS
F. Toffalorio1, F. Conforti1, G. Spitaleri1, C. Catania1, C. Noberasco1, C. 
Lazzari1, M. Barberis2, F. de Marinis1, T. De Pas1 1Medical Oncology, European 
Institute of Oncology, Milan, ITALY, 2Pathology Division, European Institute 
of Oncology, Milan, ITALY
Background: More than even before, the efficacy of epidermal growth factors 
tyrosine-kinase inhibitors (EGFR-TKI) in NSCLC patients carrying EGFR 
wild-type tumors has been under investigation. EGFR wild-type patients rep-
resent a large and heterogeneous group of patients. In this setting, the role 
played by high polysomy of chromosome 7 still remains controversial. Indeed, 
previous reports did not discriminate between chromosome 7 high polysomy 
and EGFR amplification and/or did not investigate the simultaneous presence 
of EGFR and KRas mutations.
Methods: We retrospectively collected data from 163 patients analyzed for 
EGFR status (mutation, amplification, chromosome 7 trysomy and poly-
somy), in addition to KRas mutation, between 2000 and 2010 in our Institute. 
EGFR-TKI was administered to 72 of them. All of them had previously 
received at least one line of chemotherapy. Objective responses and time to 
progression to EGFR-TKI were evaluated.
Results: Among the 163 samples analysed, 25 (15.3%) displayed high poly-
somy of chromosome 7, in presence of EGFR wild-type, absence of KRas 
mutation and EGFR amplification. Twelve patients, out of the 25 with high 
polysomy, received EGFR-TKI. The treatment led to a disease control in 10 
of them (80%). One patient was lost to follow-up. In terms of overall response 
rate, we observed 2 PD, 4 PR and 5 SD. The mean time to progression was 
8.9 months.
Conclusions: High polysomy of chromosome 7 characterizes 15% of tumors 
without EGFR mutations. Among the EGFR wild-type population, the evalu-
ation of high polysomy of chromosome 7 could be a helpful tool to predict for 
benefit from EGFR-TKI.
Disclosure: All authors have declared no conflicts of interest.
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UNCOMMON EPIDERMAL GROWTH FACTOR 
RECEPTOR MUTATIONS IN PATIENTS WITH 
NON-SMALL CELL LUNG CANCER
M. Oyaert1, I. Demedts2, E. Boone1, J. Van Dorpe3, E. De Laere1, J. Breyne1 
1Molecular Diagnostics, AZ Delta Roeselare Menen, Roeselare, BELGIUM, 
2Pneumology, AZ Delta Roeselare Menen, Roeselare, BELGIUM, 3Pathology, 
AZ Delta Roeselare Menen, Roeselare, BELGIUM
Aim: Classic activating mutations in the EGFR tyrosine kinase domain, such 
as L858R and deletions in exon 19, have been strongly associated with sen-
sitivity to tyrosine kinase inhibitors (TKIs) in patients with Non-Small Cell 
Lung Cancer (NSCLC). Other mutations, e.g. T790M, show drug resistance. 
Detection of EGFR mutations has become an important issue for therapeutic 
decision-making in NSCLC. The clinical significance of uncommon EGFR 
mutations, however, remains poorly understood. The present study describes 
clinical outcomes of 6 patients with uncommon EGFR mutations, receiving TKI.
Methods: Three hundred and thirty patients with NSCLC (106 females aged 
62.5 ± 1.1 years; 224 males aged 68.0 ± 0.6 years) were enrolled in the study 
from February 2011 until April 2013. FFPE tissue samples were screened for 
mutations using a High Resolution Melting technique, followed by Sanger 
sequencing of exons 18-21 of the EGFR gene. Mutation status was also tested 
using the Cobas® EGFR mutation test (Roche). Mutations found with HRM/
sequencing but not with the Cobas® test and/or complex mutations, were 
considered as novel.
Results: EGFR mutations were found in 31/330 (9.4%) samples (18 female, 13 
male). Nine mutations were considered as novel, not yet described mutations. 
Four mutations were singlet mutations (G735 (ex 19); V843L (ex 21); P699S 
(ex 18) and an ex 20 insertion), four were doublets (G719S + E709A (ex 18); 
G719S + E709K (ex 18); L858R + V689L (ex 18) and G719S + ex 20 inser-
tion) and one patient had a triplet mutation (L858R + T790M + L730F). Six 
of them received TKIs. Two patients with singlet mutations receiving TKI, did 
not respond to their treatment. Patients with a G719S mutation in combina-
tion with an E709A or E709K mutation, showed stable disease upon TKI. 
Finally, two patients with complex mutations containing the activating L858R 
mutation in exon 21, showed partial response to treatment.
Conclusions: Novel singlet mutations showed a lack of response to TKIs. 
Complex mutations, harbouring a novel and a known mutation, showed the 
same response as described for the known mutation alone. This shows that 
using the commercial test for EGFR mutation analysis would have led to the 
same clinical outcome. The clinical significance of novel mutations remains 
unclear and poorly described and should be reported to support the decision 
making process in these patients.
Disclosure: All authors have declared no conflicts of interest.
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EGFR MUTATIONS AMONG LUNG ADENOCARCINOMA 
PATIENTS IN SERBIA – EGFR MUTATION 
INCIDENCE AND ITS CORRELATION WITH 
PATIENT DEMOGRAPHIC CHARACTERISTICS
B. Zaric1, B. Perin1, V. Kovcin2, M. Cekic3, D. Jovanovic4, D. Radosavljevic5, 
Z. Murtezani6, M. Rancic7, R. Jankovic8, N. Vukobradovic-Djoric9 1Clinic 
for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina, 
Sremska Kamenica, SERBIA, 2Outpatient Chemotherapy Department, 
Clinical Hospital Center Bezanijska Kosa, Belgrade, SERBIA, 3Pulmolology, 
Clinic of Lung Diseases and TB, Knez Selo, SERBIA, 4Institute of Lung 
Diseases, Clinical Center of Serbia, Belgrade, SERBIA, 5Oncology, Institute 
of Oncology and Radiology of Serbia, Belgrade, SERBIA, 6Oncology, 
Clinical Hospital Center Bezanijska Kosa, Belgrade, SERBIA, 7Clinic of 
Lung Diseases and TB, Knez Selo, SERBIA, 8Department of Experimental 
Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, SERBIA, 
9Roche, Serbia, Belgrade, SERBIA
Aim: The detection of EGFR mutations in tumor tissues nowdays is guiding 
the treatment for advanced NSCLC. It is known that patients with lung adeno-
carcinoma have more frequent mutations, especially in population of women, 
non-smokers. The mutation L858R in exon 21 and the deletions in exon 19 
account for >85% of all clinically important mutations.
Methods: The purpose of EGFR testing conducted in Serbia, is to assess 
the EGFR mutation rate among lung adenocarcinoma patients in Serbia in 
order to select group of patients suitable for treatment with erlotinib. Genomic 
DNA used for EGFR mutation analysis was isolated from FFPE tumor sam-
ples from 214 patients with NSCLC. For detection of EGFR mutations in 
exons 18-21 therascreen® EGFR PCR Kit and Cobas® EGFR Mutation Test 
were used.
Results: All tested patients had NSCLC, adenocarcinoma subtype, stage IIIb 
and IV. 214 patients were tested for EGFR mutations, male to female ratio 
140(65%):74(35%), median age 63 years (range 36-83). EGFR mutations 
were detected in 30 patients (14,02% overall positivity rate). In tested male 
population, EGFR mutation rate is less than 10%, hence in tested female pop-
ulation, mutation rate is 23.6%. EGFR positivity rate varied between centers, 
with lowest EGFR mutation rate in southern Serbia(11.4%), folowing central 
Serbia(13.97%) and highest in northern Serbia(16,67%). Male to female ratio 
among EGFR positive patients was 13(41.4%):17(58,6%). Types of muta-
tions detected were deletions in exon 19 in 18(60%) patients and L858R point 
mutation in exon 21 in 11(36.7%) patients, respectively. Insertion on exon 20 
was detected in 1 patient.
Conclusions: EGFR mutation rate in Serbia among lung adenocarcinoma 
patient is 14,02%. Overall EGFR mutation rate in Serbia is in concordance 
with literature data, but lower in some parts of the country, which leads to 
conclusion that there is a need for better patient selection. Reason for lower 
mutation rate can lie in unknown smoking status of tested patients, and larger 
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proportion of male patients tested. Regarding characteristics of EGFR posi-
tive patients, we can conclude that EGFR mutations in Serbia are more fre-
quent in female patients. Regarding type of mutations, more frequent type of 
mutation are deletions in exon 19.
Disclosure: N. Vukobradovic Djoric is a full time employee of Roche. All 
other authors have declared no conflicts of interest.
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ROLE OF EGFR MUTATIONAL STATUS IN RESPONSE 
TO FIRST-LINE CLASSICAL CHEMOTHERAPY IN 
PATIENTS WITH NON-SMALL-CELL LUNG CANCER
I. Franco1, A. Antunes1, S. Campainha1, S. Conde1, A.M. Barroso2 
1Pulmonology, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de 
Gaia, PORTUGAL, 2Unidade de Pneumologia Oncológica, Centro Hospitalar 
de Vila Nova de Gaia/Espinho (CHVNG/E), Porto, PORTUGAL
Aim: Several studies showed that EGFR mutation is a predictor of 
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-
TKI) treatment response in patients with non-small-cell lung cancer 
(NSCLC). However, to what extent EGFR mutation status may influ-
ence the response to first-line chemotherapy regimens other than EGFR-
TKI is not known. First-line treatment with EGFR-TKI was approved in 
Portugal in 2012. In our center, EGFR mutation analysis is performed to 
all NSCLC patients since 2006. The aim of this study was to evaluate the 
response to first-line classical chemotherapy – disease control, progres-
sion free survival (PFS) and overall survival (OS) – according to EGFR 
mutational status.
Methods: We retrospectively reviewed the medical records of 120 NSCLC 
patients – 6th ed. TNM stages IIIa (no radiotherapy), IIIb and IV - diagnosed 
and treated with first-line classical chemotherapy since 01.01.06 through 
31.12.11. All patients underwent EGFR mutation analysis by direct DNA 
sequencing and were followed up until 31.10.13. Effect of EGFR mutations 
on PFS and OS was evaluated by Kaplan-Meier curves and disease control 
was evaluated by Odds Ratio.
Results: One hundred and twenty patients were included in the study: 72 
(60%) men, 62.63+12.24 (mean+SD) years-old, 76 (63.5%) smokers or for-
mer smokers. EGFR mutations were detected in 17 (14.2%) patients. Median 
PFS after first-line chemotherapy was 12 months in EGFR mutated group 
versus 5 months wild-type group (p = 0.021). Median OS was 23 months in 
the EGFR mutated group versus 19 months in wild-type group (p = 0.152). 
Disease control was obtained in 82 patients (68%); EGFR mutation was asso-
ciated to disease control - 2.402 (95% CI, 0.646-8.919).
Conclusions: In conclusion, EGFR mutation status seems to be a predictor of 
good response, not only to EGFR-TKI targeted therapy, but also to first-line 
classical chemotherapy, with a significant effect on PFS of NSCLCs patients. 
Nevertheless OS was not significantly different between both groups: dete-
rioration of performance status or further changes of EGFR mutational status 
could explain these results.
Disclosure: All authors have declared no conflicts of interest.
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PALLIATIVE RADIATION DURING PEMETREXED  
PLUS CISPLATIN FIRST-LINE TREATMENT 
FOR ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): PATIENT SAFETY IN 
THE JMDB AND PARAMOUNT TRIALS
G.V. Scagliotti1, C. Gridelli2, F. de Marinis3, B. Biesma4, M. Reck5, B. San 
Antonio6, A.H. Zimmermann7, C. Visseren-Grul8, N. Chouaki9, L. Paz-
Ares10 1Clinical and Biological Sciences, University of Torino, Torino, 
ITALY, 2Dept Oncology / Hematology, San Giuseppe Moscati Hospital, 
Avellino, ITALY, 3First Oncological Pulmonary Unit, San Camillo 
Forlanini Hospital, Rome, ITALY, 4Dept Pulmonary Diseases, Jeroen Bosch 
Hospital, Hertogenbosch, NETHERLANDS, 5Thoracic Oncology, Hospital 
Grosshansdorf, Grosshansdorf, GERMANY, 6Oncology, Eli Lilly and 
Company, Madrid, SPAIN, 7Oncology, Eli Lilly and Company, Indianapolis, 
UNITED STATES OF AMERICA, 8Oncology - Thoracic, Eli Lilly and 
Company, Houten, NETHERLANDS, 9Oncology - Thoracic, Eli Lilly 
and Company, Paris, FRANCE, 10Oncology, Seville University Hospital, 
Seville, SPAIN
Aim: The safety of palliative radiation (XRT) during first-line treatment 
with pemetrexed (Pem) plus cisplatin (Cis) was studied in a subset of pts 
in the JMDB (DB) and PARAMOUNT (PM) Phase 3 trials. Pts with stage 
IIIB/IV nonsquamous (NS) NSCLC (DB, n=618; PM, n=939) received 
up to 6 cycles and up to 4 cycles of induction therapy with Pem/Cis, 
respectively.
Methods: In both trials Pem (500 mg/m2) + Cis (75 mg/m2) were admin-
istered every 21 days. A subset of pts (DB, n=20; PM, n=45) also received 
palliative XRT. Safety was assessed via the incidence of adverse events (AEs) 
(CTCAE). All patients received oral folic acid, vitamin B
12
 and dexametha-
sone, consistent with the Pem label.
Results: Of pts who received palliative XRT during induction treatment, 
90% of DB pts were male with an ECOG PS of 1 (90%) and a median age 
of 55 years; 58% of PM pts were male with an ECOG PS of 1 (69%) and a 
median age of 61 years. All patients except 1 in DB had stage IV disease. 
Bone was irradiated in 12/20 DB pts and 34/45 PM pts. Other locations 
(DB;PM) were: lymph node (0;2), mediastinum (3;2), chest wall (3;2), adre-
nal gland (0;1), intraocular (0;1), lung (1;1), brain (4;1), spinal cord (1;0) 
and abdomen (0;1). Total doses of XRT ranged from 8-50 Gy in both trials. 
The time between day 1 of last chemotherapy cycle and the start of pallia-
tive XRT ranged from 0-31 days in DB and 0-28 days in PM. Of 65 total 
pts, 12 (2:10) had ≥1 AE during XRT considered possibly related to Pem/
Cis and/or XRT. Gr 2 anemia was the most common AE. Three pts had Gr 
3/4 anemia. Five pts had Gr 1/2 nonhematologic toxicities. AEs during pal-
liative XRT or within 2 weeks after the end of the last fraction in JMDB / 
PARAMOUNT (n=65).
*JMDB - 1 Gr 2 anemia; 1 Gr 2 radiation dermatitis
Toxicity Gr 1, n (%) Gr 2, n (%) Gr 3-4, n (%)
Anemia 1 (1.5) *4 (6.1) 3 (4.6)
Leukocytes 0 2 (3.1) 0
Platelets 0 1 (1.5) 0
Rash/dermatitis 1 (1.5) 1 (1.5) 0
Rash/
desquamation
1 (1.5) 1 (1.5) 0
Radiation 
dermatitis
0 *1 (1.5) 0
Conclusions: In DB and PM, few pts with advanced NS NSCLC experienced 
AEs when treated with palliative XRT during Pem+Cis first line chemother-
apy, and most events were Gr 1 / 2.
Disclosure: G.V. Scagliotti: Dr. Scagliotti receives honoraria from Eli 
Lilly and Company, Roche, Astrazeneca and Pfizer. C. Gridelli: Dr. 
Gridelli receives honoraria for serving as an advisory board and speaker\’s 
bureau member for Eli Lilly and Company and Roche. M. Reck: Dr. Reck 
receives honoraria for lectures and is a compensated member of an advi-
sory board for Eli Lilly and Company. B. San Antonio: Belen San Antonio 
is a full time employee of Eli Lilly and Company. A.H. Zimmermann: 
Dr. Zimmermann is a full time employee of Eli Lilly and Company and 
also owns some Eli Lilly and Company stock. C. Visseren-Grul: Carla 
Visseren-Grul is an employee of Eli Lilly and Company and owns some 
Eli Lilly and Company stock. N. Chouaki: Nadia Chouaki is a full time 
employee of Eli Lilly and Company and owns some Eli Lilly and Company 
stock. L. Paz-Ares: Dr. Paz-Ares receives compensation from Eli Lilly and 
Company for scientific advice. All other authors have declared no conflicts 
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PEMETREXED MAINTENANCE THERAPY 
(PEM-MT) IN PATIENTS WITH ADVANCED NON-
SQUAMOUS NON-SMALL CELL LUNG CANCER 
(NSQ-NSCLC): A PRACTICE PATTERN ANALYSIS
V. Adam, L. Peeters, C. Dooms, K. Nackaerts, S. Lepers, C. Oyen, J. 
Vansteenkiste Respiratory Oncology Unit (Pulmonology), University 
Hospitals Leuven - Campus Gasthuisberg, Leuven, BELGIUM
Aim: The PARAMOUNT trial showed a significant improvement in over-
all survival (OS) with pem-MT in NSQ-NSCLC. After our pilot study (JTO 
7:1291-5, 2012) on patients’ perceptions on MT in a hypothetical context (i.e. 
before reimbursement of pem-MT in Q2, 2012), we now analysed the stan-
dard practice patterns (with reimbursed general implementation).
Methods: Retrospective database analysis of all consecutive pts with EGFR-
wild-type NSQ-NSCLC who started cisplatin-pem from Jan 2012 till June 
2013. Patients were stage IV at diagnosis or had a systemic relapse at least 
1 year after initial (neo)adjuvant chemotherapy. RECIST assessment during 
MT was based on CT scan after 2 and after 4 cycles, and every 4 cycles 
thereafter. Endpoints of this analysis: uptake of pem-MT, tolerance, number 
of cycles, reason for discontinuation.
Results: We included 71 patients (93% stage IV; 86% adenocarcinoma). Thirty-
seven pts (52%) did not receive MT. The main reasons were progressive disease 
(PD) during/after 1st line (n=21), toxicity (n= 7), worsening of performance status 
during/after 1st line (n=7, of whom 3 died), others (1 lost to follow-up, 1 switch to 
consolidating radiotherapy). 34 pts received MT, of whom 9 are still on treatment. 
Stop of MT was due to PD (n=16); adverse events (AEs, n=9): deterioration of renal 
function (n=4), haematological intolerance (n=3), oedema (n=1); patient request 
(n=1). The median and mean (range) number of MT cycles is 4 and 7 (1-26).
Conclusions: About 50% of 1st line cisplatin-pem pts continued with MT. Overall 
subjective tolerance of pem-MT was good, 7 of the 9 AEs leading to treatment dis-
continuation were lab toxicities, one main problem being cumulative renal toxicity 
(probably also related to repeated contrast-enhanced CT-scans to evaluate disease).
Disclosure: All authors have declared no conflicts of interest.
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MAINTENANCE LOW-DOSE GEMCITABINE 
VERSUS BEST SUPPORTIVE CARE IN ADVANCED 
AND METASTATIC NON-SMALL CELL LUNG 
CANCER: RANDOMIZED PHASE III TRIAL
A. Nagy, E. Fouad, K. Nasr, H. El-Ghazaly, A. Adel Clinical Oncology and 
Nuclear Medicine, Ain Shams University Faculty of Medicine, Cairo, EGYPT
Aim: To evaluate efficacy (defined in terms of prolongation of Time to 
Progression and Overall survival) and safety (as regard grade 3 and 4 tox-
icity)of low-dose gemcitabine as maintenance chemotherapy after first line 
gemcitabine/cisplatin in advanced and metastatic NSCLC.
Methods: This prospective phase III study included 120 patients with advanced 
and metastatic NSCLC (70.8% aging less than 60 years, 75.5% males, 59.2% 
with performance status 2, 75% with nonsquamous histology and 79.2% pre-
sented with stage IV 79.2%), who presented to Clinical Oncology and Nuclear 
Medicine Department, Ain Shams University Hospitals during the period 
from January 2010 to June 2012. All eligible patients started induction with 
gemcitabine/cisplatin. Patients who finished 4 cycles and showed response 
(CR-PR-SD) were randomized into two arms, Arm I (received gemcitabine 
250 mg/m2 over 6 hours on days 1 & 8 every 3 weeks) and Arm II (received 
supportive care). Response was assessed by Revised RECIST guidelines every 
2 cycles and toxicity by NCI criteria for common toxicities every cycle.
Results: The median TTP was 6.1 months (CI 5.3-6.6, p = 0.454) in Arm 
I and 5.8 months (CI 5.2-6.4, p = 0.454) in Arm II. The median OS were 9 
months (CI 7.9-10.0. p = 0.994) and 8 months (CI 8.5-9.4, p = 0.994) in Arms 
I and II respectively. This trial showed that maintenance therapy with low dose 
gemcitabine was well tolerated with no grade 3 or 4 toxicity.The only signifi-
cant toxicity was grade 2 anaemia in 8 patients (22.9%) in maintenance arm.
Conclusions: This trial did not show any statistical significance as regard 
TTP or OS between the 2 arms. The cause to this could be due to the smaller 
sample size or the use of low dose gemcitabine instead of conventional dose, 
the predominance of non-squamous histology and the predominance of PS 2.
Disclosure: All authors have declared no conflicts of interest.
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GEMCITABINE IN BRIEF STANDARD DOSE 
VERSUS PROLONGED LOW-DOSE INFUSION, 
BOTH COMBINED WITH CISPLATIN FOR 
ADVANCED NON-SMALL CELL LUNG CANCER
S.K. Beniwal1, S.L. Jakhar2, P.K. Bagri2, N. Sharma2, H. Kumar2, A. Sharma2, 
M. Singhal2, D. Singh2, G. Singh2, A. Kapoor2 1Medical Oncology, Acharya 
Tulsi Cancer Treatment and Research Institut, Bikaner, INDIA, 2Radiation 
Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, 
Bikaner, INDIA
Aim: Gemcitabine in low-dose prolonged infusion is a treatment with docu-
mented activity against a variety of tumors.The present study was conducted to 
evaluate the efficacy and safety of the combination of gemcitabine at a low-dose 
prolonged infusion in comparison with standard dose gemcitabine with cispla-
tin in chemonaive patients with advanced non-small cell lung cancer (NSCLC).
Methods: Eligible patients had non-small cell lung cancer in stage IIIB or IV, 
Eastern Cooperative Oncology Group(ECOG) 0-2, measurable disease, were 
chemonaïve and fulfilled the standard criteria for chemotherapy. Patients were 
randomly assigned 1:1 to receive 350mg/m2 gemcitabine in a 6-h infusion on 
days 1 and 8 and cisplatin at 80 mg/m(2) divided in 2 days on day 1and 2 (Arm 
I) versus gemcitabine 1000mg/m2 in 30 minutes on days 1 and 8 and cisplatin 
same schedule as Arm I (Arm II) (3-week cycle both). A total of 92 patients 
(65 men and 27 women, median age 54.5 years) were included and the two 
groups were balanced for prognostic factors.
Results: Histology was predominantly adenocarcinoma (55% of the patients).
Patients had overall response rate (ORR) 41.3% and 36.9%(P-0.738), stable 
disease 32.6% and 34.8% (P-0.857) and progressive disease 26.1% and 
28.3% (P-0.844) in standard arm and low-dose infusional arm respectively. 
Median progression-free survival was 5.5 months and 5.4 months, median 
overall survival was 10.2 months and 10.8 months, and 1-year survival was 40 
% and 35.6% in standard arm and low-dose infusion arm respectively. Grade 
3/4 toxicities were rare in both arm.
Conclusions: In NSCLC, gemcitabine low-dose prolonged infusion with 
cisplatin has low toxicity, especially thrombocytopenia, and has an activity 
comparable with gemcitabine given in higher dose in standard infusion. Low-
dose gemcitabine may be preferred for incurable cancer among patients with 
poor economic status.
Disclosure: All authors have declared no conflicts of interest.
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WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT 
TEMOZOLOMIDE FOR BRAIN METASTASIS IN 
NON-SMALL CELL LUNG CANCER: A SINGLE 
INSTITUTION, OPEN LABELED RANDOMIZED 
CLINICAL STUDY FROM SOUTH INDIA
S.S. Vadakke Puthiyottil, B.S. Mathew, P.G. Jayaprakash, C.D. Sivanandan, K. 
Ratheesan Radiation Oncology, Regional Cancer Centre Thiruvananthapuram, 
Trivandrum, INDIA
Aim: The mainstay of treatment for multiple Brain metastases (BM) is 
fractionated whole brain radiotherapy (WBRT). Concurrent Temozolomide 
(TMZ) with WBRT has been reported to improve response rates with non-
significant prolongation of median survival. This study was intended to assess 
the efficacy of WBRT + TMZ in improving neurological progression free sur-
vival (PFS) for newly diagnosed patients with BM from Lung cancer.
S47Copyright © 2014 by the European Lung Cancer Conference organisers, ESMO, and IASLC.
Journal of Thoracic Oncology ®  •  Volume 9, Number 4, Supplement 1, April 2014 Abstracts
Methods: Patients with radiologically proven multiple BM from Non Small Lung 
cancer (NSCLC) were included this study. Patients were randomly assigned to 
receive either WBRT of 20 Gy in 5 fractions with or without concurrent TMZ 
(75 mg/m2/d) for the 5 days. The primary end point was neurological PFS assessed 
clinically at 3 and 6 months after treatment. Survival curves were obtained by 
using the Kaplan-Meier method and were compared with the log-rank test.
Results: Between December 2011 and August 2013, 82 patients with NSCLC 
were enrolled. The mean age was 54.5years. There were 55 males and 27 
females. 23 patients belonged to RTOG Recursive partitioning analysis (RPA) 
Class I and 59 to Class II. The PFS at 3 and 6 months were 38.46% and 23.77% 
for WBRT alone vs. 90.70% and 76.43% for WBRT with TMZ (p=0.00001). 
Subset analyses showed significantly better PFS for RTOG RPA Class-II 
(p-value 0.0143) receiving WBRT+TMZ.
Conclusions: The treatment of BM should be directed not only at improving 
survival but also improving the quality of life. While significant advances 
have been made for patients with solitary or limited (< four) BM with sur-
gery and radio surgery, the outcome for patients with more advanced disease 
remains poor. This study demonstrated a significantly improved neurological 
PFS with the addition TMZ in patients with NSCLC with BM. Larger studies 
addressing this issue would be worthwhile considering the increasing inci-
dence of BM owing to advances in systemic therapies, leading to prolonged 
survival for patients with lung cancer.
Disclosure: All authors have declared no conflicts of interest.
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INTRAPLEURAL HYPERTHERMIC CHEMOTHERAPY 
(IPHC) MAY ENHANCE SURVIVAL IN 
MALIGNANT PLEURAL DISSEMINATION
S. Sung1, D.S. Noh2, E. Yi2, S.J. Park2, H.C. Yang2, S.C. Cho2, K. Kim2, 
C.L. Lim2, S. Jheon2 1Department of Thoracic and Cardiovascular Surgery, 
Seoul St Mary’s Hospital, Seoul, KOREA, 2Department of Thoracic and 
Cardiovascular Surgery, SNU Bundang Hospital, Seongnam, KOREA
Aim: Malignant pleural effusion or dissemination of lung cancer is detected 
in advanced cancer patients, and is generally associated with poor prognosis 
and poor survival. Palliative chemotherapy and or radiotherapy is not good 
enough to improve survival. Intrapleural perfusion hyperthermic chemo-
therapy (IPHC) provides direct effects to cancer tissue. The present study 
attempted to evaluate the efficacy and safety of IPHC.
Methods: From 2003 to 2012, 40 patients received IHPC for malignant pleural 
effusion or malignant pleural dissemination of lung cancer in a single institute. 
We excluded small cell lung cancer, multiple organ metastasis, N3 lymph node 
metastasis and additional procedure such as partial rib resection, decortication 
and other repeated surgery. A high dose cisplatin (150-200 mg/m2 BSA) with 
saline was pooled into circuit and heated up to 43 degree Celsius. The cisplatin 
fluid filled the thoracic cavity nearly completely and was circulated with pump 
machine for 1 hour 30 minutes trying to maintain the temperature. Renal pro-
tective agents were adminstered perioperatively. We compared results with a 
chemotherapy-only group in terms of short-term survival and others.
Results: There were 40 patients in the IPHC and 36 in the chemotherapy-only 
groups.The mean age was 63.6 ± 10.3 year (from 33 to 82). There was no statisti-
cal difference between two groups except age. The 2-year survival rate and 5-year 
survival rate of IPHC and the chemotherapy-only group were 65.0% and 12.5% 
versus 41.7% and 8.3%, respectively. We analysed prognostic factors and found 
SUV
max
 of post IPHC pleura of the patients who lived more than 2 years was less 
than that of the patients who lived less than 2 years (p-value=0.031). However 
preIPHC lung mass, preIPHC pleura SUV value, age, sex, chemotherapy, turmor 
size and nodela status did not have any influence on survival. Post IHPC compli-
cations were four acute renal failures(9.76%), two air-leaks (4.88%), two cardiac 
rhythm changes (bradycardia, atrial fibrillation, 4.88%) and gastrointestinal prob-
lem (2.44%). 16 patients received chemotherapy post procedure.
Conclusions: IPHC provides better survival compared with conventional 
chemotherapy. We suggest that IPHC is safe and effective for treatment of 
malignant pleural effusion or dissemination.
Disclosure: All authors have declared no conflicts of interest.
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THE EFFICACY AND TOXICITY OF CHEMOTHERAPY 
WITH BEVACIZUMAB FOR PREVIOUSLY 
TREATED PATIENTS WITH ADVANCED NON-
SQUAMOUS NON-SMALL CELL LUNG CANCER
R. Itotani, T. Kitajima, D. Inoue, K. Takamatsu, M. Ishitoko, S. Marumo, 
M. Sakuramoto, M. Fukui Respiratory Disease Center, The Tazuke Kofukai 
Medical Research Institute Kitano Hospital, Osaka City, JAPAN
Aim: Bevacizumab (Bev) including chemotherapy is recommended as first 
line chemotherapy for patients with advanced non-squamous non-small cell 
lung cancer (non-Sq NSCLC). However there are few reports on the efficacy 
and toxicity of chemotherapy including Bev for previously treated patients 
with advanced non-Sq NSCLC. We conducted a retrospective cohort study to 
evaluate the efficacy and toxicity of chemotherapy including Bev for previ-
ously treated patients with advanced non-Sq NSCLC.
Methods: We examined advanced non-Sq NSCLC patients who were treated 
with chemotherapies including Bev as second or more lines at The Tazuke 
Kofukai Medical Research Institute Kitano Hospital between April 2010 and 
November 2013 in this study. The objective response rate (ORR), disease 
control rate (DCR), progression free survival (PFS) and adverse effects (AE) 
were investigated.
Results: A total of 41 patients received 60 chemotherapy regimens including 
Bev (median age 67 years old; gender male/female 22/19; clinical stage IIIA/
IIIB/IV 3/4/34; Eastern Cooperative Oncology Group Performance Status 
(ECOG-PS) 0-1/2 58/2 regimens; lines of treatment 2nd line/3rd line/above 
4th line 17/17/26 regimens; median number of cycles 4). The ORR and DCR 
were 14.8% and 80.4%, respectively. The median PFS time was 6.0 months. 
Toxicities of each regimens beyond Grade 3 in Common Terminology Criteria 
for Adverse events version 4.0 were as follows; neutropenia 30 (50%), 
thrombocytopenia 5 (8.3%), anemia 4 (6.7%), febrile neutropenia 2 (3.3%), 
anorexia 1 (1.7%), hypertension 7 (11.7%), proteinuria 2 (3.3%), skin disor-
der 3 (5.0%), pneumothorax 1 (1.7%) and bronchopulmonary hemorrhage 
1 (1.7%, Grade 5). Most of these toxicities were acceptable except for one 
patient who had a fatal hemoptysis, and could be managed by some medica-
tions or only observation. During the treatment period, the patients’ ECOG-PS 
didn’t deteriorate except in 5 cases.
Conclusions: Chemotherapy including Bev seems to be mostly feasible and 
may provide favorable efficacy for previously treated patients with advanced 
non-Sq NSCLC. Further investigation is necessary to confirm this.
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL RESULT OF IL-2 PLUS MELATONIN 
AND EPIGALLOCATECHIN GALLATE (EGCG) 
IN THE TREATMENT OF PATIENTS WITH NOT 
PREVIOUSLY TREATED ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC)
A.A. Tavartkiladze, Clinical Oncology, Georgian Cancer Research Center, 
Tbilisi, GEORGIA
Aim: The aim of our research is to study the efficiency of interleukin 2 
(IL-2) plus melatonin and epigallocatechin gallate (EGCG) in the treatment 
of patients with not previously treated advanced non-small-cell lung cancer 
(NSCLC). Melatonin is a phylogenetically well-preserved molecule with 
diverse physiological functions. In addition to its well-known regulatory 
control of the sleep/wake cycle, as well as circadian rhythms generally, mel-
atonin is involved in immunomodulation, hematopoiesis, and antioxidative 
processes. Recent human and animal studies have shown that melatonin also 
has important oncostatic properties. EGCG is a major catechin compound 
in tea extract and is also the most active form among the tea catechins in a 
variety of biological activities. For instance, EGCG has anticancerogenic, 
antioxidant, as well antimicrobal activities. Biological therapies are treat-
ments that use natural body substances, or drugs that block them, to treat 
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cancer.  IL-2 is a type of biological therapy for the treatment kidney cancer. 
It is also being evaluated in clinical trials for some other types of cancer 
including for NSCLC.
Methods: We have studied 34 patients with advanced  not previously 
treated NSCLC. Each patient was administrated melatonin 40 mg/day 
orally (continually) in the evening, EGCG 1500 mg twice (750X2) 
daily (continually) and IL-2 intravenous 600,000 IU/kg day, over 5 days 
(repeated every 14 days). After one year we have studied using the FISH 
method the genetic profile (Genes: AKT1, ALK, BRAF, DDR2, EGFR, 
FGFR1, HER2, KRAS, MEK1, MET, NRAS, PIK3CA, PTEN, RET, 
ROS1) for the 34 patients.
Results: After one year from start of treatment 7 patients (20,58%) had sur-
vived (3 had partial response and 4 had stable disease). The genetic research 
showed the 7 surviving patients had amplification of the FGFR1 gene, while 
the other patients did not show genetic changes in the FGFR1 gene.
Conclusions: This research has very interesting implications for the develop-
ment of the treatment of NSCLC showing FGFR1 amplification.
Disclosure: All authors have declared no conflicts of interest.
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NON-SMALL CELL LUNG CANCER (NSCLC) 
AMONG YOUNG ADULTS - SINGLE INSTITUTIONAL 
ANALYSIS OF DIAGNOSIS AND PROGNOSIS
M. Wollner1, M. Moskovitz2, D. Levy Faber3, A. Agbarya1 1Department 
of Oncology, Rambam Health Care Center, Haifa, ISRAEL, 2Oncology, 
Rambam Health Caare Campus, Haifa, ISRAEL, 3General Thoracic Surgery, 
Rambam Health Care Center, Haifa, ISRAEL
Aim: The median age of newly diagnosed patients with NSCLC is 
70, only 1.7% of patients are diagnosed at age younger than 45. Data 
regarding the characteristic and prognosis of this group is scant and 
contradictive.
Methods: Retrospective analysis of medical records of patients with NSCLC, 
45 year old and younger at diagnosis, treated at Rambam Health Care Campus.
Results: One hundred and sixteen patients under the age of 45 were treated 
for NSCLC between 2000-2013, third (36.6%) were non-smokers, 36% of 
arabic origin, 39% jewish of east-european origin. Relevant comorbidities 
had 16%. Histology: Adenocarcinoma represented 61%, and squamous cell 
carcinoma 16.4%. At diagnosis: locally advanced (25%) or metastatic (56%) 
disease. Median duration of symptoms was 9 weeks. Majority (76%) were in 
good performance status (PS ECOG 0-1), and only 25.9% had weight loss. 
The overall response rate to all lines of treatment was 44%. Response rate to 
first line chemotherapy was 41.3%. Median overall survival was 13.8 months, 
17.4 months among non-smokers and 11.8 months among smokers. Survival 
was worse among patients with poor PS (18 vs. 4.8 months, p<0.0001), 
weight loss (16.8 vs. 7.2 months, p=0.029). Survival was significantly lower 
for patients presented at diagnosis with anemia, thrombocytosis, leukocytosis, 
hypoalbuminemia, elevated liver enzymes and elevated lactate dehydrogenase 
(LDH) levels. In multivariate analysis, leucocytosis and hypoalbuminemia at 
diagnosis predicted survival. Thirteen patients performed molecular analysis 
of tumor, 4 patients had EGFR mutation, 2 patients had ALK-EML rearrange-
ment, 1 KRAS mutation, 1 RET mutation. Overall 7/13 patients had gene 
mutation predictive to treatment, and were treated with molecular targeted 
therapy accordingly.
Conclusions: This cohort of younger lung cancer patients had higher 
rates of advanced disease at diagnosis, adenocarcinoma histology, 
response to therapy, and lower rates of smoking than general population 
of patients with NSCLC, but no difference in survival. Prognostic factors 
significant for survival were PS and weight loss, anemia, thrombocyto-
sis, leucocytosis, hypoalbuminemia, elevated liver enzymes and LDH 
at diagnosis. The rate of tumor gene mutations predictive to treatment 
was high, genetic tumor profiling is of particular importance among this 
group of patients.
Disclosure: All authors have declared no conflicts of interest.
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DIFFERENT EFFICACY BETWEEN TWO 
ERYTHROPOIESIS-STIMULATING AGENTS 
(ESAS) FOR CHEMOTHERAPY-INDUCED 
ANAEMIA (CIA) TREATMENT IN PATIENTS 
WITH NON-SMALL CELL LUNG CANCER 
(NSCLC): A SINGLE CENTER EXPERIENCE
A. Rodriguez Garzotto1, S. Cortijo2, C. Pernaut1, I. Otero1, G. Ruiz Ares1, 
L. Parrilla1, M. Blazquez Arroyo1, J. Zugazagoitia1, S. Ponce Aix1 1Servicio 
de Oncologia Medica, University Hospital 12 de Octubre Medical Oncology, 
Madrid, SPAIN, 2Servicio Farmacia, University Hospital 12 de Octubre 
Medical Oncology, Madrid, SPAIN
Aim: There are limited data on the relative effectiveness of biosimilar ESAs 
and other available ESAs for the treatment of CIA. In addition, it is unclear 
whether the most recent recommendations for more conservative use of ESAs 
to treat CIA are reflected in real-world clinical practice.
Methods: We analyzed 73 patients with NSCLC who were included in a ret-
rospective audit of CIA treatment with ESAs in a large oncology centre in 
Spain, with patients treated by multiple physicians. The patients were treated 
for CIA with Binocrit® 40,000 IU QW (n=12), Binocrit® 30,000 IU QW 
(n=6), darbepoetin alfa 500 μg Q3W (n=36) or darbepoetin alfa 150 μg QW 
(n=19). In addition to overall haemoglobin (Hb) outcomes, comparisons were 
performed according to the different ESA treatments given. Results: The 
mean overall haemoglobin (Hb) at start of ESA treatment was 9.4 g/dL; the 
mean overall Hb level at the end of treatment was 10.6 g/dL. 36/73 patients 
(49%) achieved a Hb increase of at least 1 g/dL. There were no significant dif-
ferences (p>0.05) between the groups in terms of Hb levels at the start of ESA 
treatment. At the end of treatment, however, the mean Hb level in the group 
treated with darbepoetin alfa 500 μg Q3W was significantly lower than that in 




Mean Hb at start 
of treatmen(g/dl)
Mean Hb at  








Binocrit 30,000 IU 3.50 9.4 11.1
Binocrit 40,000 IU 3.67 9.5 10.7
Conclusions: Our data indicate that Hb outcomes in a real-world clinical 
practice setting are similar for the ESA treatments used with the exception of 
Darbepoetin 500 μg Q3W, which achieved a significantly lower Hb at the end 
of treatment. We consider the use of ESAs in our centre to be conservative and 
safe, and to reflect the most recent change in ESA prescribing information and 
recommendations for more moderated use in patients with CIA (that is, use the 
lowest possible dose and duration of treatment necessary to avoid transfusions)
Disclosure: All authors have declared no conflicts of interest.
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STUDY 20070782: RANDOMIZED PHASE 3 
TRIAL OF THE LONG-TERM SAFETY OF 
DARBEPOETIN ALFA IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER (NSCLC) WITH 
CHEMOTHERAPY-INDUCED ANEMIA (CIA)
P. Gascon1, C.H. Barrios2, D. Gordon3, V. Hirsh4, S. Orlov5, K. 
Syrigos6, C. Volovat7, L. Zhang8, C. Bohac9 1Division of Medical 
Oncology, Hematology-oncology Department, Hospital Clinic, 
Barcelona University, Barcelona, SPAIN, 2Department of Medicine, 
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PUCRS School of Medicine, Porto Alegre RS, BRAZIL, 3Oncology, 
Cancer Care Centers of South Texas, San Antonio, UNITED STATES 
OF AMERICA, 4Oncology, McGill University, Quebec, CANADA, 
5University N.a.academic I.p.pavlov of Moh and Sd of Rf, SBEI of HPE 
Saint Petersburg State Medical, St Petersburg, RUSSIAN FEDERATION, 
6Sotiria General Hospital, Athens School of Medicine, Athens, GREECE, 
7Oncology, Center of Medical Oncology, IASI, ROMANIA, 8Medical 
Oncology, Sun Yat-Sun University Cancer Center, Guangzhou, CHINA, 
9Clinical Development, Amgen Inc., Thousand Oaks, UNITED STATES 
OF AMERICA
Background: Controlled trials have shown erythropoiesis-stimulat-
ing agents (ESAs) raise hemoglobin (Hb) and reduce transfusions in 
patients with CIA. While some suggestions of increased mortality and/
or tumor progression have been raised in a few trials, most studies to 
date have not associated the use of ESAs with worse outcomes. As 
CIA often develops in lung cancer, studying ESA safety in NSCLC is 
warranted.
Trial design: Study 20070782 (NCT00858364) is a randomized, dou-
ble-blind, non-inferiority trial comparing darbepoetin alfa with placebo 
currently enrolling patients with Stage IV NSCLC with CIA. Overall 
survival (primary endpoint) and progression-free survival (secondary 
endpoint) will be analyzed when approximately 2700 deaths occur. Other 
safety endpoints include tumor response and thromboembolic event rate. 
Superiority of darbepoetin alfa to placebo with respect to transfusion 
rates will be tested if non-inferiority is achieved for overall survival and 
progression-free survival. Patients (approximately 3000) from up to 500 
world-wide sites will be randomized 2:1 to darbepoetin alfa (500 mcg) 
or placebo once-every-three-weeks until progression or end of chemo-
therapy. Eligibility criteria include ≥ 18 years, ECOG status ≤ 1, stage 
IV NSCLC, no prior adjuvant/neoadjuvant NSCLC therapy, ≥ 2 cycles 
first-line chemotherapy planned (≥ 6 weeks total), and screening Hb ≤ 
11 g/dL. At Hb > 12 g/dL, study drug will be withheld until Hb ≤ 12 g/
dL. Transfusions are allowed when medically indicated. As of October 31, 
2013, active sites in the US, Europe, Latin America, and the Asia-Pacific 
region have enrolled 1234 patients. To date, an independent data monitor-
ing committee has conducted 6 reviews of unblinded data (including a 
planned formal interim analysis to test for harm at 20% of the planned 
total number of 2700 deaths) and has recommended trial continuation 
without changes. Study 20070782 is the largest NSCLC clinical trial con-
ducted and will provide comprehensive data on the benefit:risk profile of 
darbepoetin alfa in patients with CIA. We acknowledge the contributions 
of Jesús Cárdenas, David Henry, Jin-Hyoung Kang, Shona Nag, Martin 
Šmakal, H. Tilman Steinmetz, Gary Thomas, and Alex Fleishman. This is 
an Amgen Inc. sponsored study.
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by AMGEM. D. Gordon: I own more than $50,000 in stock in Amgen 
ad receive paymnet for uties associated with the Steering Committee for 
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and Roche Other substantive relationships: No L. Zhang: Stock owner-
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STEREOTACTIC ABLATIVE BODY RADIOTHERAPY 
(SABR) WITH FLATTENING FILTER FREE 
(FFF) MODE FOR NSCLC OLIGOMETASTATIC 
PATIENTS: FEASIBILITY AND OUTCOMES
P. Navarria1, F. De Rose1, A.M. Ascolese1, E. Clerici1, A. Tozzi1, A. Fogliata2, 
P. Mancosu1, A. Gaudino1, L. Cozzi2, M. Scorsetti1 1Radiotherapy and 
Radiosurgery, Humanitas Research Hospital, Rozzano, ITALY, 2Physics, 
IOSI, Bellinzona, SWITZERLAND
Aim: Data in the literature suggest the existence of oligometastatic disease, 
a state in which metastases are limited in number and site. Different kinds 
of local therapies have been used for the treatment of limited metastases and 
in the recent years reports on the use of Stereotactic Ablative radiotherapy 
(SABR) are emerging and the early results on local control are promising. 
The aim of this study is the evaluation of local control, toxicity and overall 
survival in NSCLC oligometastatic patients underwent SABR
Methods: Between October 2010 and May 2013, 36 NSCLC patients for 58 lung 
lesions were treated at our Institution. SABR was performed in case of controlled 
primary tumor, long interval time from the first diagnoses (greater than 6-12 
months), exclusion of surgery, and number of metastatic sites ≤ 5. The total dose 
prescribed varied according to tumor site and maximum diameter. Dose prescrip-
tion was 48 Gy in 4 fractions for peripheral lesions, 60 Gy in 8 fractions for cen-
tral lesions and 60 Gy in 3 fractions for peripheral lesions with diameter ≤ 2 cm.
Results: Radiological response was obtained in the vast majority of patients. 
The local control at 1, 2 and 3 years was 100%, 95% and 95% respectively. No 
pulmonary toxicity G3-G4, chest pain or rib fracture occurred. The median 
follow up was 38 months (range 6-57 months). Overall Survival (OS) at 1, 2 
and 3 years was 90%,84% and 82% respectively.
Conclusions: SABR is feasible with limited morbidity. We believe that the 
discussion within a multidisciplinary team is of pivotal importance to select 
patients with better prognosis.
Disclosure: All authors have declared no conflicts of interest.
125P
BEVACIZUMAB SAFETY WHEN COMBINED WITH 
WHOLE-BRAIN RADIATION THERAPY (WBRT)
J. Arrondeau1, C. Le Pechoux2, S. Le Moulec3, F. Barlesi4, P. Lesueur5, B. 
Besse1 1Department of Medicine, Institut Gustave Roussy, Villejuif, FRANCE, 
2Department of Radiotherapy, Institut de Cancérologie Gustave Roussy, 
Villejuif, FRANCE, 3Medical and Radiation Therapy, Hopital d’Instruction 
des Armées du Val-de-Grâce, Paris, FRANCE, 4Multidisciplinary Oncology 
and Therapeutic Innovations Department, Assistance Publique Hôpitaux de 
Marseille, Marseille, FRANCE, 5Oncology, Centre François Baclesse, Caen, 
FRANCE
Aim: Bevacizumab (bev.) based chemotherapy was approved for treatment of 
patients with metastatic non squamous non small lung carcinoma (NSCLC). 
In case of cerebral progression, whole-brain radiation therapy (WBRT) is 
offered. Because of its long half-life, bev. could increase with WBRT’s toxic-
ity. We reviewed toxicity and efficacy of WBRT when offered within 6 months 
after the last infusion of bev.
Methods: We report a retrospective, multicenter study of bev. followed by WBRT 
for NSCLC pts with inoperable brain metastasis. We collected data of pts, treated 
between 2009 and 2013 with BCT before WBRT, with a delay ≤ 6 months. 
Evaluation of neurologic symptoms was reported and toxicities were scored 
according to the version 4 common terminology criteria for adverse events.
Results: 28 pts were eligible. Median age was 45. Sex ratio was 1:1 (14 males, 
14 females). 9 pts (32.1%) were never smokers. Median delay between brain 
metastasis and NSCLC diagnosis was 6.35 months (0-65 months). Median 
Graded Prognosis Assessment was 1,5 (0,5-3). 20 pts (71.4%) had neuro-
logic symptoms before WBRT; mostly sensorimotor deficit (12 pts, 42.9%). 
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Bev. was in median used after 2,5 other treatments (1-8). The median dose 
of bev. was 15mg/kg and the median duration of treatment was 5.1 months 
(0.7-35 months). The median delay between brain metastasis diagnosis and 
WBRT was 6 months (0.1-25 months) and between BCT and WBRT was 12 
days (0-143 days). Neurologic symptoms were stable during WBRT in 10 pts 
(35.7%), while the others had improvement or degradation of symptoms (8 
pts, 28.6% each); one patient is dead during WBRT because of disease pro-
gression. Most common reported side-effects were intracranial hypertension 
symptoms (n=6 pts), grade 2 (n=1) or 3 (n=5), grade 2 seizure (n=2), grade 3 
vertigo (n=1), grade 3 dizziness (n=1), and grade 2 intracranial bleeding (n=2). 
Radiologic brain metastasis assessment showed 1 complete response (3.6%), 7 
partial responses, (25%) 9 stable diseases (32.1%), and 7 progressive diseases 
(25%). Then 10 pats had brain progression with median delay of 3.5 months 
(0.5-13 months). Median survival from WBRT was 3.15 months (0.1-36.8).
Conclusions: The combinaison of BCT and WBRT was not associated with 
increase toxicity, except in 2 patients with intracranial bleeding. Because of 
the limited number of pts, these results must be confirmed prospectively.
Disclosure: All authors have declared no conflicts of interest.
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SERUM MARKERS OF BONE REMODELING IN 
PATIENTS WITH ADVANCED NON-SMALL CELL 
LUNG CANCER AND BONE METASTASES
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Aim: Lung cancer is the most common cause of cancer death worldwide. In 
the USA, there were estimated to be 246,000 new cases and 164,000 deaths in 
2013. Approximately, 80 % of lung cancers are carcinomas that are classified 
histologically as non-small cell lung cancer (NSCLC). The efficacy control for 
the treatment of bone metastases in NSLCLC is difficult and usually initiated 
later and with longer time between treatment cycles than the restaging of vis-
ceral or soft tissue metastases. The aim of this study was to evaluate the useful-
ness of bone formation serum markers bone alkaline phosphatase (bALP) and 
osteoprotegerin (OPG), and bone resorption serum markers tartrate-resistant 
acid phosphatase isoform-5b (TRACP 5b), carboxy terminal cross-linked telo-
peptide of type I collagen (CTX), and receptor activator of nuclear factor-κ 
ligand (RANKL) in patients with NSCLC and bone metastases.
Methods: Twenty-six patients with advanced NSCLC (21 men, 5 women, 
median age 74 years, range 57-79 years) scheduled for palliative chemother-
apy were enrolled in the study. All patients underwent whole body (18)F-FDG 
PET/CT that showed the presence of bone metastases in 12 (cases). Controls 
(N=14) were patients with negative (18)F-FDG PET. The pre-treatment panel 
of serum markers was obtained in the entire study population. The results 
were expressed as positive or negative when they did not result within the 
reference range of each serum marker. The two-tailed Fisher exact probability 
test was used for testing results.
Results: TRAC5b (OR=0.09, 95%CI 0.01-0.56, p=0.016), RANKL 
(OR=0.13, 95%CI 0.02-0.78, p=0.044), and OPG (OR=0.13, 95%CI 0.02-
0.76, p=0.047) exhibited a good sensitivity, whilst CTX (OR=0.20, 95%CI 
0.04-1.06, p=0.11) and bALP (0.54, 95%CI 0.11-2.55, p=0.69) were not sen-
sitive enough (cases vs. controls).
Conclusions: In patients with NSCLC and bone metastases the measure-
ment of serum TRAC55, RANKL, and OPG could be useful in diagnos-
ing advanced disease early. References Pollmann D, Siepmann S, Geppert 
R, Wernecke KD, Possinger K, Lüftner D. The amino-terminal propeptide 
(PINP) of type I collagen is a clinically valid indicator of bone turnover and 
extent of metastatic spread in osseous metastatic breast cancer. Anticancer 
Res. 2007; 27: 1853-1862.
Disclosure: All authors have declared no conflicts of interest.
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PROGRAMMED CELL DEATH 1 LIGAND 
1 EXPRESSION AND ASSOCIATION WITH 
SURVIVAL IN MESOTHELIOMA
A.S. Mansfield1, T. Peikert2, A. Roden3, C. Krco4, S. Harrington5, H. Dong5, E. 
Kwon5 1Medical Oncology, Mayo Clinic, Rochester, MN, UNITED STATES 
OF AMERICA, 2Pulmonology, Mayo Clinic, Rochester, MN, UNITED 
STATES OF AMERICA, 3Laboratory Medicine and Pathology, Mayo Clinic, 
Rochester, MN, UNITED STATES OF AMERICA, 4Immunology, Mayo 
Clinic, Rochester, MN, UNITED STATES OF AMERICA, 5Urology, Mayo 
Clinic, Rochester, MN, UNITED STATES OF AMERICA
Aim: Due to the role Programmed Cell Death 1 Ligand 1 (PD-L1, aka B7-H1) has 
in establishing immune tolerance, its associations with worse survival in patients 
with many human malignancies, and the availability of agents to target PD-1:PD-L1 
interactions, we decided to investigate the expression of PD-L1 in mesothelioma 
with the goal of exploring whether it might serve as a therapeutic target.
Methods: We evaluated 224 cases of malignant pleural mesothelioma (MPM) 
diagnosed between the years of 1986 and 2003 for the expression of PD-L1 
using immunohistochemistry. These tissue samples were obtained during diag-
nostic surgical pleural biopsies or therapeutic resections from patients with 
clinically diagnosed MPM. All cases were diagnosed as MPM by a pathologist. 
The mouse monoclonal anti-human B7-H1 (clone 5H1-A3) antibody was used 
at a dilution of 1:300. The location and percent of PD-L1 expression was scored 
for each sample by a pathologist. Cases with less than 5% expression were con-
sidered negative. Survival between groups was compared with Kaplan-Meier 
curves and the log-rank test. The associations of PD-L1 expression with out-
come were assessed with Cox proportional hazards regression models.
Results: Eighty-nine of 224 samples (40%) expressed PD-L1. The median 
percent expression was 40% (10-70% interquartile range [IQR]). There were 
no significant differences in gender, age, decade of diagnosis, or lymphocytic 
infiltration between PD-L1 positive and negative patients; however, patients with 
PD-L1 positive tumors were less likely to be offered a therapeutic surgery due 
to greater extent of disease at presentation (p=0.001). Survival was significantly 
worse for patients with PD-L1 expression (6 months median, 4-9 mo. IQR) 
compared to those without PD-L1 expression (14 mo. median, 11-16 mo. IQR; 
p<0.0001). PD-L1 expression remained significantly associated with worse sur-
vival after adjusting for age, gender, lymphocytic infiltration, and therapeutic sur-
gical intervention (risk ratio 1.73, 95% confidence interval 1.3-2.3; p=0.0002).
Conclusions: PD-L1 is expressed in a substantial proportion of MPMs and is 
associated with poor survival. PD-L1 expression may have important implica-
tions for the management of patients with MPM.
Disclosure: C. Krco: CK has patents pending in regard to B7-H1 as a prog-
nostic marker. S. Harrington: SH has patents pending in regard to B7-H1 as 
a prognostic marker. H. Dong: HD has patents pending in regard to B7-H1 
as a prognostic marker. E. Kwon: Both E. Kwon and the Mayo Clinic have 
received royalties greater from the licensing related to B7-H1. EK has patents 
pending in regard to B7-H1 as a prognostic marker. All other authors have 
declared no conflicts of interest.
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IDENTIFICATION OF A PROGNOSTIC MICRORNA 
SIGNATURE FOR PATIENTS WITH MALIGNANT 
PLEURAL MESOTHELIOMA UNDERGOING 
EXTRAPLEURAL PNEUMONECTOMY
M.B. Kirschner1, Y.Y. Cheng1, S.C. Kao1, N.J. Armstrong2, B.C. McCaughan3, 
N. van Zandwijk1, G. Reid1 1Asbestos Diseases Research Institute, University 
of Sydney, Sydney, AUSTRALIA, 2School of Mathematics and Statistics, 
University of Sydney, Sydney, AUSTRALIA, 3Cardiothoracic Surgical Unit, 
Royal Prince Alfred Hospital, Sydney, AUSTRALIA
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Aim: So far, clinical factors have not been able to reliably predict which 
patient with malignant pleural mesothelioma may benefit from radical treat-
ment approaches. We have investigated the possibility of using a microRNA 
expression signature as prognostic/predictive marker for patients undergoing 
extrapleural pneumonectomy (EPP).
Methods: Levels of 20 candidate microRNAs previously identified through 
microarray profiling of tumours from ‘long and short survivors’ after EPP 
were assessed by TaqMan assay-based RT-qPCR in RNA from 48 formalin-
fixed paraffin embedded tumour tissue samples from patients following EPP. 
Multivariate Cox proportional hazard model selection was carried out using 
all available samples with likelihood ratio tests being used to determine 
improved fit. The performance of this best fit model was then compared to 
that of a model consisting of clinical factors (age, gender, histological sub-
type and stage) to evaluate the gain in predictive accuracy achieved by using 
microRNA levels (method of Schemper and Henderson).
Results: We identified 6 microRNAs: miR-221, -23a, -21, -31, -662 and -625-
3p with prognostic potential. These microRNAs were significantly associated 
with prognosis (p-value <0.05). When applying a univariate log-rank model, 
higher tumour expression of miR-662 and lower tumour expression of the 
remaining microRNAs were associated with a survival benefit. The compari-
son of a model containing these microRNAs with a model of (only) clini-
cal prognostic factors revealed a lower predictive inaccuracy (0.403 ± 0.031 
vs 0.473 ± 0.031) for the microRNAs model. Combining clinical factors and 
microRNAs resulted in a gain of 0.076 further reducing the predictive inac-
curacy to 0.397 ± 0.033, suggesting that the predictive inaccuracy can be 
decreased by using microRNA information.
Conclusions: This study has identified six microRNAs that seem to act as a 
prognostic signature with the potential to assist in better selection of MPM 
patients considered for EPP. Further validation of this model is essential.
Disclosure: All authors have declared no conflicts of interest.
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GAS5 LONG NON CODING RNA IN MALIGNANT 
PLEURAL MESOTHELIOMA
A. Renganathan1, J. Kresoja1, N. Echeverry1, G. Ziltener1, B. Vrugt2, I. 
Opitz3, R.A. Stahel4, E. Felley-Bosco1 1Laboratory of Molecular Oncology, 
University Hospital of Zurich, Zurich, SWITZERLAND, 2Institute of 
Surgical Pathology, University Hospital of Zurich, Zurich, SWITZERLAND, 
3Division of Thoracic Surgery, University Hospital of Zurich, Zurich, 
SWITZERLAND, 4Clinik and Policlinic of Oncology, Universitätsspital 
Zürich, Zurich, SWITZERLAND
Aim: Malignant pleural mesothelioma (MPM) is an aggressive cancer with 
short overall survival. Long noncoding RNAs (lncRNA) are a class of RNAs 
more than 200 nucleotides that do not code for protein and are part of the 
90% of the human genome that is transcribed yet less well characterized. 
Earlier experimental studies showed GAS5 (growth arrest specific transcript 
5) lncRNA deletion in asbestos driven mesothelioma. The function of GAS5 
is not well known, but it has been shown to act as glucocorticoid receptor 
decoy and microRNA “sponge”. Thus our aim is to investigate the possible 
role of the GAS5 in the growth of MPM.
Methods: Primary MPM cultures grown in serum-free condition in 3% oxygen 
or MPM cell lines grown in serum medium were used. Doxycycline induc-
ible shGas5 clones were generated from ZL55SPT cells. Gene expression was 
quantified by qPCR. To investigate GAS5 promoter, 1kb sequence was inserted 
into pGL3 reporter plasmid and reporter activity was determined after transfec-
tion into MPM cells. Cell cycle length was determined by EdU incorporation 
assay. Localization of GAS5 lncRNA was identified by in situ hybridization. 
Expression of podoplanin and ki67 was identified by immunohistochemistry.
Results: GAS5 expression was lower in MPM cell lines compared to normal 
mesothelial cells. GAS5 was upregulated upon growth arrest induced by inhi-
bition of Hedgehog or PI3K/mTOR signaling in in vitro MPM models. The 
increase in mRNA was accompanied by increased promoter activity. Silencing 
GAS5 increased the expression of glucocorticoid responsive genes GILZ and 
SGK1 and shortened the length of the cell cycle. Drug induced growth arrest 
was associated with GAS5 accumulation in the nuclei. Surprisingly, GAS5 was 
expressed at higher level in tumor tissue compared to non-tumoral tissue, was 
abundant in tumor quiescent cells and it was correlated to podoplanin expression.
Conclusions: Drug induced growth arrest increases Gas5 expression and 
decreasing levels of GAS5 shortens cell cycle in vitro. The higher GAS5 expres-
sion in MPM tissue compared to non-tumoral tissue is associated with cell qui-
escence and podoplanin expression. Because podoplanin and GAS5 mRNA 
sequence contain the same microRNA targets, this supports GAS5 lncRNA hav-
ing an important role in growth-arrest and microRNA-“sponge” in MPM.
Disclosure: All authors have declared no conflicts of interest.
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POSITRON EMISSION TOMOGRAPHY (PET) 
AS A PROGNOSTIC FACTOR IN MALIGNANT 
PLEURAL MESOTHELIOMA (MPM)
S. Cedres1, S. Ponce2, J. Zugazagoitia2, A. Navarro3, A. Martinez1, P. 
Martinez1, F. Salva3, C. Muñoz2, G. Ruiz Ares2, E. Felip4 1Medical Oncology, 
Vall d´Hebron University Hospital. Universidad Autonoma de Barcelona, 
Barcelona, SPAIN, 2Medical Oncology, Hospital 12 Octubre. Universidad 
Complutense, Madrid, SPAIN, 3Medical Oncology, Vall d´Hebron University 
Hospital, Barcelona, SPAIN, 4Oncologia Médica, Vall d`Hebron University 
Hospital Institut d’Oncologia, Barcelona, SPAIN
Aim: Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to 
asbestos exposure and a marked increase in the incidence is predicted over the 
next decades in Europe and developing nations. We investigated the overall sur-
vival (OS) and variables affecting survival in patients (p) diagnosed of MPM.
Methods: Ninety-two patients diagnosed of MPM in Vall d´Hebron 
University Hospital and 12 Octubre University Hospital between November 
2002 and September 2013 were retrospectively reviewed. Baseline factors 
analyzed were age, gender, performance status (PS), histology, stage, standard 
uptake value (SUV) and chemotherapy (CT). Survival data were calculated by 
the Kaplan-Meier method.
Results: Patient’s characteristics: median age 68 years (31-88years), males 
71.7%, PS 1:59.8%, asbestos exposure 57.6%, chest pain 73.9%, dyspnea 
75%, clinical stage III 45% and IV 39%, epithelial subtype 69.6%. All 
patients were considered initially unresectable and 79.3% received CT in 1st 
line and 42.4 % in 2nd. PET study was performed to 31 patients with no previ-
ous talc pleurodesis. Median SUV was 7.2 and patients with epithelial histol-
ogy presented lower SUV than no-epithelial group (11.9 vs 6.6, p=0.002). 
After a median follow up of 13 months the median OS was 13.3 months. 
We found significant increase in OS in patients with epithelial subtype (19.7 
vs 5.0 months in no-epithelial, p<0.001), patients without chest pain (23.3 v 
12.4, p=0.012), PS1 (13.3 vs 2.5 months in PS 2, p=0.011) and patients who 
received 2nd line CT (25.5 vs 9.6 months, p=0.003). In the group of patients 
underwent PET, SUV<7.2 was predictor of better survival regardless of his-
tology (24.7 vs 7.6 months, for patients SUV<7.2, p=0.025) Although no sig-
nificant, age, tumor stage, and response to CT were associated with better OS.
Conclusions: In our study with 92 MPM patients, epithelial subtype, chest 
pain, PS, and treatment with second line therapy are prognostic factors for 
survival. We demonstrated PET provides prognostic information indepen-
dently of histology in advanced MPM.
Disclosure: All authors have declared no conflicts of interest.
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ANTAGONIST IN A RAT BIOLUMINESCENT 
MODEL OF MESOTHELIOMA RECURRENCE
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Aim: Tumor recurrence remains a challenge after complete resection of 
malignant pleural mesothelioma (MPM). Stem cell activation by the hedge-
hog pathway was detected in MPM, thus we hypothesized that the local appli-
cation of a hedgehog antagonist could suppress the growth of MPM after 
resection. Here, we aim to use an immuno-competent rat bioluminescent 
MPM model to test the efficacy of local intracavitary treatment with the FDA 
approved hedgehog antagonist in the prevention of MPM recurrence.
Methods: Cytotoxicity and colony formation assays were applied to determine 
sensitivity of rat MPM cells expressing luciferase (IL-45-luc) to the hedgehog 
antagonist in vitro. These cells were sub-pleurally inoculated to immune-com-
petent rats. Tumor nodule was resected six day later and pneumonectomy was 
performed. The hedgehog antagonist was intra-cavitary administered using fibrin 
as a carrier (n=3) and compared to a control group receiving fibrin alone (n=2). 
Tumor growth was monitored daily after the treatment using an in vivo biolumi-
nescent imager. The gene expression was analyzed by quantitative real time PCR.
Results: IL-45-luc cells express key molecules of hedgehog pathway. The 
hedgehog antagonist suppressed the growth of these cells in a dose dependent 
manner and inhibited the expression of hedgehog target genes in vitro. The 
expression of a hedgehog ligand was increased in vivo compared to in vitro 
condition. In vitro assay showed that the hedgehog antagonist was gradually 
released from fibrin over 7 days, however, in vivo only a trend in tumor growth 
suppression was observed at day 4 after treatment.
Conclusions: Compared to in vitro condition, in vivo environment induced 
increased expression of hedgehog ligand suggesting a role of the hedgehog 
pathway in this rat MPM model. Tumor recurrence was not significantly 
reduced after intrapleural administration of the hedgehog antagonist com-
pared to control, however the number of animals was limited. Systemic treat-
ment will be carried out to further investigate the efficacy of this drug in the 
immuno-competent rat MPM model.
Disclosure: All authors have declared no conflicts of interest.
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ENHANCING RISK STRATIFICATION IN PRIMARY 
MEDIASTINAL NONSEMINOMATOUS GERM CELL 
TUMORS (PMNSGCT): A 27-YEAR EXPERIENCE 
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Aim: Mediastinal GCTs and PMNSGCTs poorly benefit from CT and half of 
patients (pts) still die for disease. Enhancing the risk stratification may result 
in tailoring a personalized treatment strategy since diagnosis.
Methods: Between 1985 and 2012, 87 pts with PM-GCT were treated at our 
center. Of them, pure seminomatous histology was excluded. Cox propor-
tional hazards regression analysis was conducted to examine the prognostic 
impact of these candidate factors on overall survival (OS): type of 1st-line 
CT (high [HDCT] vs conventional dose [CDCT]), post-CT surgery, type of 
baseline elevated serum tumor marker (STM), presence of lung or liver-bone-
brain metastases (LBB), STM response (still elevated vs normal or normal-
ized), and histology (viable cancer [VC] vs necrosis/teratoma [NT]). OS 
curves were compared by Kaplan Meier method with the log-rank test.
Results: The study included 68 cases with PMNSGCT. Median age was 28.5 
yrs (IQR: 23-35). 12 pts (17.7%) presented with mediastinal syndrome, 23 
(33.8%) had lung and 7 (10.3%) LBB metastases. 12 pts received upfront 
HDCT and 45 pts (66.2%) underwent post-CT surgery. The final model of 
poor prognostic factors included no surgery (HR: 8.74, 95%CI, 1.77-43.01), 
surgery + VC (HR: 6.97, 95%CI, 1.46-33.30), and lung metastases (HR: 
2.92, 95%CI, 0.99-8.64). The model demonstrated moderate discrimina-
tory ability for OS (c-statistic=0.68). A risk stratification model based on 
the combination of these factors and accounting for a 50% five-year survival 
cutoff identified 2 groups (poor prognosis, N=28 vs good prognosis, N=26) 
with distinct overall survival curves (p<0.001). Pre-operative STM and final 
histology were not associated (p=0.574 at Chi squared test). 5-yr OS after 
receiving 2nd line CT (n=25) was 18.7% (95%CI, 7.9-44.5). Results are lim-
ited by small numbers.
Conclusions: Pts with PMNSGCT classified as having a good prognosis in 
this model had a fairly high survival estimate, while a strategy of consolida-
tion CT for pts with poorest risk features warrants investigation, once the 
model is confirmed. The effect of surgery on survival was independent of 
post-CT STM, which also poorly predicted final histology.
Disclosure: All authors have declared no conflicts of interest.
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PLEURA:SURGICAL TREATMENT ANALYSIS OUR 
CASES FROM SEPTEMBER 1999 TO DECEMBER 2013.
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Aim: Solitary fibrous tumours (SFT) of the pleura are rare tumours, originated 
from the mesenchimal tissue. This tumours present unpredictable clinical 
course, probably related to their histological and morphological characteris-
tics.We present our experiency in surgical treatment of our cases with solitary 
fibrous tumour of the pleura, from September 1999 to December 2013.
Methods: Twenty-five (25) patients affected by SFT of the pleura were 
referred to us for surgical resection in our clinic in SU”Shefqet Ndroqi” from 
September 1999 to December 2013. All the patients had chest radiographs, 
computerized tomogrphy, lung function tests and ECG, and biochemical study. 
All patients underwent a bronchoscopy prior surgery. The diagnosis was esta-
bilish by Fine needle aspiration biopsy, VATS biopsy or open biopsy. Immuno-
histochemical reactions positive for CD34 did not perform in all patients.
Results: Surgical excision required 18 posterolateral thoracotomies, five 
anterior lateral thoracotomies and no one video-assisted thoracoscopy. 
Average tumor diameter was 8.5 cm range from (4-28 cm) and weight was 
130 g,range from(20-1650 gram). In all our patients resections were com-
plete. No intraoperative or perioperative medical or surgical complications 
occurred. Median hospital stay was 5 days while perioperative mortality 
rate was 0. Median follow-up was 70 months. Only one patient experienced 
tumour recurrence.
Conclusions: Surgical resection of benign solitary fibrous tumours is usually 
curative. Malignant solitary fibrous tumours generally have a poor prognosis. 
Clinical follow-up and radiological follow-up are indicated for both benign 
and malignant solitary fibrous tumours.
Disclosure: All authors have declared no conflicts of interest. 
